



## Clinical trial results:

### A Phase 2, Randomized, Open-label, Multicenter Study to Evaluate Efficacy,

### Pharmacokinetics, Safety, and Tolerability of Treatment With JNJ-73763989, Pegylated

### Interferon Alpha-2a, Nucleos(t)ide Analog With or Without JNJ-56136379 in Treatment-naïve

### Patients With HBeAg Positive Chronic Hepatitis B Virus Infection

## Summary

|                          |                  |
|--------------------------|------------------|
| EudraCT number           | 2019-004978-26   |
| Trial protocol           | GB FR DE         |
| Global end of trial date | 12 February 2024 |

## Results information

|                                |               |
|--------------------------------|---------------|
| Result version number          | v1 (current)  |
| This version publication date  | 17 April 2025 |
| First version publication date | 17 April 2025 |

## Trial information

### Trial identification

|                       |                   |
|-----------------------|-------------------|
| Sponsor protocol code | 73763989PAHPB2005 |
|-----------------------|-------------------|

### Additional study identifiers

|                                    |             |
|------------------------------------|-------------|
| ISRCTN number                      | -           |
| ClinicalTrials.gov id (NCT number) | NCT04439539 |
| WHO universal trial number (UTN)   | -           |

Notes:

## Sponsors

|                              |  |
|------------------------------|--|
| Sponsor organisation name    | Janssen Research & Development, LLC  |
| Sponsor organisation address | 920 Route 202, Raritan, United States, 08869   |
| Public contact               | Clinical Registry Group, Janssen Research & Development, LLC, ClinicalTrialsEU@its.jnj.com |
| Scientific contact           | Clinical Registry Group, Janssen Research & Development, LLC, ClinicalTrialsEU@its.jnj.com |

Notes:

## Paediatric regulatory details

|  |    |
|--|----|
| Is trial part of an agreed paediatric investigation plan (PIP)       | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

## Results analysis stage

|  |                  |
|--|------------------|
| Analysis stage                                       | Final            |
| Date of interim/final analysis                       | 12 February 2024 |
| Is this the analysis of the primary completion data? | No               |

|                                  |                  |
|----------------------------------|------------------|
| Global end of trial reached?     | Yes              |
| Global end of trial date         | 12 February 2024 |
| Was the trial ended prematurely? | No               |

Notes:

## General information about the trial

Main objective of the trial:

The main objective of the study was to assess the efficacy of a treatment regimen of JNJ-73763989 (JNJ-3989) plus pegylated interferon alpha-2a (PegIFN-alpha-2a) plus nucleos(t)ide analog (NA: tenofovir disoproxil [TDF]/tenofovir alafenamide [TAF]).

Protection of trial subjects:

This study was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and that are consistent with Good Clinical Practices and applicable regulatory requirements.

Background therapy: -

Evidence for comparator: -

|   |                 |
|---|-----------------|
| Actual start date of recruitment                          | 15 October 2020 |
| Long term follow-up planned                               | No              |
| Independent data monitoring committee (IDMC) involvement? | No              |

Notes:

## Population of trial subjects

### Subjects enrolled per country

|                                      |                        |
|--------------------------------------|------------------------|
| Country: Number of subjects enrolled | Canada: 7              |
| Country: Number of subjects enrolled | Germany: 2             |
| Country: Number of subjects enrolled | Spain: 8               |
| Country: Number of subjects enrolled | France: 6              |
| Country: Number of subjects enrolled | United Kingdom: 5      |
| Country: Number of subjects enrolled | Japan: 4               |
| Country: Number of subjects enrolled | Russian Federation: 10 |
| Country: Number of subjects enrolled | Türkiye: 9             |
| Country: Number of subjects enrolled | Taiwan: 2              |
| Country: Number of subjects enrolled | United States: 1       |
| Worldwide total number of subjects   | 54                     |
| EEA total number of subjects         | 16                     |

Notes:

### Subjects enrolled per age group

|  |   |
|--|---|
| In utero                               | 0 |
| Preterm newborn - gestational age < 37 | 0 |

|  |    |
|--|----|
| wk                                       |    |
| Newborns (0-27 days)                     | 0  |
| Infants and toddlers (28 days-23 months) | 0  |
| Children (2-11 years)                    | 0  |
| Adolescents (12-17 years)                | 0  |
| Adults (18-64 years)                     | 54 |
| From 65 to 84 years                      | 0  |
| 85 years and over                        | 0  |

## Subject disposition

### Recruitment

Recruitment details:

The Study consisted of 3 phases: induction phase (IP), consolidation phase (CP) and follow-up (FU) phase. Response-guided treatment (RGT): hepatitis B (HB) surface antigen (HBsAg) less than(<) 10 international unit per millilitre (IU/mL) and RGT was removed post protocol amendment 5 (PA 5).

### Pre-assignment

Screening details:

Nucleos(t)ide (NA) treatment completion criteria: HBsAg <10 IU/mL, HB envelop antigen (HBeAg)-negative, HB virus deoxyribonucleic acid (HBV DNA) <lower limit of quantification (LLOQ) and alanine aminotransferase (ALT) <3\*upper limit of normal (ULN).

### Period 1

|                              |  |
|------------------------------|--|
| Period 1 title               | IP:Day 1-Week 36(post-PA5)/52(prior-PA5) |
| Is this the baseline period? | Yes                                      |
| Allocation method            | Not applicable                           |
| Blinding used                | Not blinded                              |

### Arms

|                              |   |
|------------------------------|---|
| Are arms mutually exclusive? | Yes   |
| Arm title                    | Cohort 1 (Prior PA 5): JNJ-3989+JNJ-6379+NA + PegIFN-alpha-2a |

Arm description:

Prior to PA 5, in IP, enrolled participants received JNJ-3989 200 milligrams (mg) subcutaneous (SC) injection once every 4 weeks (Q4W) + JNJ-6379 250 mg tablets orally once daily (QD) + NA (TDF 245 mg/TAF 25 mg) tablet orally QD for  $\geq 36$  to  $\leq 52$  weeks. Participants who met RGT criterion/reached 52 weeks were considered to complete IP and entered 12-week CP and randomized to JNJ-3989 + JNJ-6379 + NA or JNJ-3989+JNJ-6379 + NA + PegIFN-alpha-2a 180 micrograms (mcg) SC injection once weekly (QW). Post PA 5, participant not reached IP Week 36, started PegIFN-alpha-2a at Week 36 for 12 weeks and who passed IP Week 36 and/or were randomized to CP without PegIFN-alpha-2a, started pegIFN-alpha-2a at their next visit. Per PA 6, JNJ-6379 treatment was stopped. Post CP Week 12, participants entered 48-week FU phase and stopped JNJ-3989+PegIFN-alpha-2a. If NA treatment completion criteria was met at CP Week 12, NA was stopped at FU phase Week 2, if not met, NA was continued till end of FU phase.

|  |                  |
|--|------------------|
| Arm type                               | Experimental     |
| Investigational medicinal product name | JNJ-73763989     |
| Investigational medicinal product code | JNJ-73763989     |
| Other name                             |                  |
| Pharmaceutical forms                   | Injection        |
| Routes of administration               | Subcutaneous use |

Dosage and administration details:

Participants received JNJ-3989 200 mg SC injection Q4W for  $\geq 36$ -weeks (post PA 5) to  $\leq 52$ -weeks (prior to PA 5)

|  |                       |
|--|-----------------------|
| Investigational medicinal product name | Tenofovir alafenamide |
| Investigational medicinal product code |                       |
| Other name                             |                       |
| Pharmaceutical forms                   | Tablet                |
| Routes of administration               | Oral use              |

Dosage and administration details:

Participants received TAF 25 mg tablet orally QD for up to  $\geq 36$ -weeks (post PA 5) to  $\leq 52$ -weeks (prior to PA 5)

|  |                      |
|--|----------------------|
| Investigational medicinal product name | Tenofovir disoproxil |
| Investigational medicinal product code |                      |
| Other name                             |                      |
| Pharmaceutical forms                   | Tablet               |
| Routes of administration               | Oral use             |

Dosage and administration details:

Participants received TAD 245 mg tablet orally

QD for up to  $\geq 36$ -weeks (post PA 5) to  $\leq 52$ -weeks (prior to PA 5)

|  |              |
|--|--------------|
| Investigational medicinal product name | JNJ-56136379 |
| Investigational medicinal product code | JNJ-56136379 |
| Other name                             |              |
| Pharmaceutical forms                   | Tablet       |
| Routes of administration               | Oral use     |

Dosage and administration details:

Participants received JNJ-6379 250 mg tablet

orally QD for  $\geq 36$ -weeks (post PA 5) to  $\leq 52$ -weeks (prior to PA 5)

|                  |   |
|------------------|---|
| <b>Arm title</b> | Cohort 1 (Per PA 5): JNJ-3989+ NA + PegIFN-alpha-2a |
|------------------|---|

Arm description:

Per PA 5, in the IP, enrolled participants received JNJ-3989 200 mg

SC injection Q4W + NA (TDF 245 mg/TAF 25 mg) tablets orally QD for 36 weeks.

After completion of IP Week 36, participants entered 12-week CP during which PegINF-alpha-2a 180 mcg SC injection QW was added to their treatment regimen for 12-weeks. After completion of 12-week CP, participants entered the 48-week FU phase and stopped treatment with JNJ-3989 plus PegIFN-alpha-2a. If NA treatment completion criteria was met at CP Week 12, NA was stopped at FU phase Week 2, if completion criteria was not met, NA was continued till the end of FU phase.

|  |                  |
|--|------------------|
| Arm type                               | Experimental     |
| Investigational medicinal product name | JNJ-73763989     |
| Investigational medicinal product code | JNJ-73763989     |
| Other name                             |                  |
| Pharmaceutical forms                   | Injection        |
| Routes of administration               | Subcutaneous use |

Dosage and administration details:

Participants received JNJ-3989 200 mg SC

injection Q4W for 36 weeks.

|  |                       |
|--|-----------------------|
| Investigational medicinal product name | Tenofovir alafenamide |
| Investigational medicinal product code |                       |
| Other name                             |                       |
| Pharmaceutical forms                   | Tablet                |
| Routes of administration               | Oral use              |

Dosage and administration details:

Participants received TAF 25 mg tablet orally

QD for 36 weeks.

|  |                      |
|--|----------------------|
| Investigational medicinal product name | Tenofovir disoproxil |
| Investigational medicinal product code |                      |
| Other name                             |                      |
| Pharmaceutical forms                   | Tablet               |
| Routes of administration               | Oral use             |

Dosage and administration details:

Participants received TAD 245 mg tablet orally

QD for 36 weeks.

|                  |   |
|------------------|---|
| <b>Arm title</b> | Cohort 2 (Per PA 6): JNJ-3989+ NA + PegIFN-alpha-2a |
|------------------|---|

Arm description:

In the IP, participants enrolled as per PA 6 received JNJ-3989 200 mg SC injection Q4W plus NA (TDF 245 mg/TAF 25 mg) tablet orally QD for 36 weeks. After completion of IP Week 36, participants entered 12-week CP during which PegIFN-alpha-2a 180 mcg SC injection QW was added to their treatment regimen for 12-weeks. After completion of 12-week CP, participants entered the 48-week FU phase and stopped treatment with JNJ-3989 plus PegIFN-alpha-2a. If NA treatment completion criteria was met at CP Week 12, NA was stopped at FU phase Week 2, if completion criteria was not met, NA was continued till the end of FU phase.

|  |                  |
|--|------------------|
| Arm type                               | Experimental     |
| Investigational medicinal product name | JNJ-73763989     |
| Investigational medicinal product code | JNJ-73763989     |
| Other name                             |                  |
| Pharmaceutical forms                   | Injection        |
| Routes of administration               | Subcutaneous use |

Dosage and administration details:

Participants received JNJ-3989 200 mg SC injection Q4W for 36 weeks.

|  |                       |
|--|-----------------------|
| Investigational medicinal product name | Tenofovir alafenamide |
| Investigational medicinal product code |                       |
| Other name                             |                       |
| Pharmaceutical forms                   | Tablet                |
| Routes of administration               | Oral use              |

Dosage and administration details:

Participants received TAF 25 mg tablet orally QD for 36 weeks.

|  |                      |
|--|----------------------|
| Investigational medicinal product name | Tenofovir disoproxil |
| Investigational medicinal product code |                      |
| Other name                             |                      |
| Pharmaceutical forms                   | Tablet               |
| Routes of administration               | Oral use             |

Dosage and administration details:

Participants received TAD 245 mg tablet orally QD for 36 weeks.

| <b>Number of subjects in period 1</b> | Cohort 1 (Prior PA 5): JNJ-3989+JNJ-6379+NA + PegIFN-alpha-2a | Cohort 1 (Per PA 5): JNJ-3989+ NA + PegIFN-alpha-2a | Cohort 2 (Per PA 6): JNJ-3989+ NA + PegIFN-alpha-2a |
|---------------------------------------|---|---|---|
| Started                               | 27  | 8   | 19  |
| Completed                             | 26  | 8   | 17  |
| Not completed                         | 1   | 0   | 2   |
| Consent withdrawn by subject          | 1   | -   | 2   |

**Period 2**

|                              |                           |
|------------------------------|---------------------------|
| Period 2 title               | CP Phase: CP Week 1 to 12 |
| Is this the baseline period? | No                        |
| Allocation method            | Randomised - controlled   |
| Blinding used                | Not blinded               |

**Arms**

|                              |   |
|------------------------------|---|
| Are arms mutually exclusive? | Yes   |
| <b>Arm title</b>             | Cohort 1 (Prior PA 5): JNJ-3989+JNJ-6379+NA + PegIFN-alpha-2a |

## Arm description:

Prior to PA 5, in IP, enrolled participants received JNJ-3989 200 milligrams (mg) subcutaneous (SC) injection once every 4 weeks (Q4W) + JNJ-6379 250 mg tablets orally once daily (QD) + NA (TDF 245 mg/TAF 25 mg) tablet orally QD for  $\geq 36$  to  $\leq 52$  weeks. Participants who met RGT criterion/reached 52 weeks were considered to complete IP and entered 12-week CP and randomized to JNJ-3989 + JNJ-6379 + NA or JNJ-3989+JNJ-6379 + NA + PegIFN-alpha-2a 180 micrograms (mcg) SC injection once weekly (QW). Post PA 5, participant not reached IP Week 36, started PegINF-alpha-2a at Week 36 for 12 weeks and who passed IP Week 36 and/or were randomized to CP without PegINF-alpha-2a, started pegINF-alpha-2a at their next visit. Per PA 6, JNJ-6379 treatment was stopped. Post CP Week 12, participants entered 48-week FU phase and stopped JNJ-3989+PegIFN-alpha-2a. If NA treatment completion criteria was met at CP Week 12, NA was stopped at FU phase Week 2, if not met, NA was continued till end of FU phase.

|  |                  |
|--|------------------|
| Arm type                               | Experimental     |
| Investigational medicinal product name | JNJ-73763989     |
| Investigational medicinal product code | JNJ-73763989     |
| Other name                             |                  |
| Pharmaceutical forms                   | Injection        |
| Routes of administration               | Subcutaneous use |

## Dosage and administration details:

Participants received JNJ-3989 200 mg SC injection Q4W from CP Week 1 to 12.

|  |              |
|--|--------------|
| Investigational medicinal product name | JNJ-56136379 |
| Investigational medicinal product code | JNJ-56136379 |
| Other name                             |              |
| Pharmaceutical forms                   | Tablet       |
| Routes of administration               | Oral use     |

## Dosage and administration details:

Participants received JNJ-6379 250 mg tablet orally QD from CP Week 1 to 12.

|  |                               |
|--|-------------------------------|
| Investigational medicinal product name | pegylated interferon alpha-2a |
| Investigational medicinal product code |                               |
| Other name                             |                               |
| Pharmaceutical forms                   | Injection                     |
| Routes of administration               | Subcutaneous use              |

## Dosage and administration details:

Participants received PegIFN-alpha-2a 180 mcg SC injection QW from IP Week 36 for 12 weeks. Those who passed IP W36 and/or were randomized to CP without PegINF-alpha-2a, started pegINF-alpha-2a from their next visit up to CP Week 12.

|  |                       |
|--|-----------------------|
| Investigational medicinal product name | Tenofovir alafenamide |
| Investigational medicinal product code |                       |
| Other name                             |                       |
| Pharmaceutical forms                   | Tablet                |
| Routes of administration               | Oral use              |

## Dosage and administration details:

Participants received TAF 25 mg tablet orally QD from CP Week 1 to 12.

|  |                      |
|--|----------------------|
| Investigational medicinal product name | Tenofovir disoproxil |
| Investigational medicinal product code |                      |
| Other name                             |                      |
| Pharmaceutical forms                   | Tablet               |
| Routes of administration               | Oral use             |

**Dosage and administration details:**

Participants received TAD 245 mg tablet orally  
QD from CP Week 1 to 12.

|                  |   |
|------------------|---|
| <b>Arm title</b> | Cohort 1 (Per PA 5): JNJ-3989+ NA + PegIFN-alpha-2a |
|------------------|---|

**Arm description:**

Per PA 5, in the IP, enrolled participants received JNJ-3989 200 mg SC injection Q4W + NA (TDF 245 mg/TAF 25 mg) tablets orally QD for 36 weeks. After completion of IP Week 36, participants entered 12-week CP during which PegINF-alpha-2a 180 mcg SC injection QW was added to their treatment regimen for 12-weeks. After completion of 12-week CP, participants entered the 48-week FU phase and stopped treatment with JNJ-3989 plus PegINF-alpha-2a. If NA treatment completion criteria was met at CP Week 12, NA was stopped at FU phase Week 2, if completion criteria was not met, NA was continued till the end of FU phase.

|  |                  |
|--|------------------|
| Arm type                               | Experimental     |
| Investigational medicinal product name | JNJ-73763989     |
| Investigational medicinal product code | JNJ-73763989     |
| Other name                             |                  |
| Pharmaceutical forms                   | Injection        |
| Routes of administration               | Subcutaneous use |

**Dosage and administration details:**

Participants received JNJ-3989 200 mg SC  
injection Q4W from CP Week 1 to 12.

|  |                               |
|--|-------------------------------|
| Investigational medicinal product name | pegylated interferon alpha-2a |
| Investigational medicinal product code |                               |
| Other name                             |                               |
| Pharmaceutical forms                   | Injection                     |
| Routes of administration               | Subcutaneous use              |

**Dosage and administration details:**

Participants received PegIFN-alpha-2a 180 mcg SC injection QW from IP Week 36 for 12 weeks. Those who passed IP W36 and/or were randomized to CP without PegINF-alpha-2a, started pegINF-alpha-2a from their next visit up to CP Week 12.

|  |                       |
|--|-----------------------|
| Investigational medicinal product name | Tenofovir alafenamide |
| Investigational medicinal product code |                       |
| Other name                             |                       |
| Pharmaceutical forms                   | Tablet                |
| Routes of administration               | Oral use              |

**Dosage and administration details:**

Participants received TAF 25 mg tablet orally  
QD from CP Week 1 to 12.

|  |                      |
|--|----------------------|
| Investigational medicinal product name | Tenofovir disoproxil |
| Investigational medicinal product code |                      |
| Other name                             |                      |
| Pharmaceutical forms                   | Tablet               |
| Routes of administration               | Oral use             |

**Dosage and administration details:**

Participants received TAD 245 mg tablet orally  
QD from CP Week 1 to 12.

|                  |   |
|------------------|---|
| <b>Arm title</b> | Cohort 2 (Per PA 6): JNJ-3989+ NA + PegIFN-alpha-2a |
|------------------|---|



Arm description:

In the IP, participants enrolled as per PA 6 received JNJ-3989 200 mg SC injection Q4W plus NA (TDF 245 mg/TAF 25 mg) tablet orally QD for 36 weeks. After completion of IP Week 36, participants entered 12-week CP during which PegIFN-alpha-2a 180 mcg SC injection QW was added to their treatment regimen for 12-weeks. After completion of 12-week CP, participants entered the 48-week FU phase and stopped treatment with JNJ-3989 plus PegIFN-alpha-2a. If NA treatment completion criteria was met at CP Week 12, NA was stopped at FU phase Week 2, if completion criteria was not met, NA was continued till the end of FU phase.

|  |                  |
|--|------------------|
| Arm type                               | Experimental     |
| Investigational medicinal product name | JNJ-73763989     |
| Investigational medicinal product code | JNJ-73763989     |
| Other name                             |                  |
| Pharmaceutical forms                   | Injection        |
| Routes of administration               | Subcutaneous use |

Dosage and administration details:

Participants received JNJ-3989 200 mg SC injection Q4W from CP Week 1 to 12.

|  |                               |
|--|-------------------------------|
| Investigational medicinal product name | pegylated interferon alpha-2a |
| Investigational medicinal product code |                               |
| Other name                             |                               |
| Pharmaceutical forms                   | Injection                     |
| Routes of administration               | Subcutaneous use              |

Dosage and administration details:

Participants received PegIFN-alpha-2a 180 mcg SC injection QW from IP Week 36 for 12 weeks. Those who passed IP W36 and/or were randomized to CP without PegINF-alpha-2a, started pegINF-alpha-2a from their next visit up to CP Week 12.

|  |                       |
|--|-----------------------|
| Investigational medicinal product name | Tenofovir alafenamide |
| Investigational medicinal product code |                       |
| Other name                             |                       |
| Pharmaceutical forms                   | Tablet                |
| Routes of administration               | Oral use              |

Dosage and administration details:

Participants received TAF 25 mg tablet orally QD from CP Week 1 to 12.

|  |                      |
|--|----------------------|
| Investigational medicinal product name | Tenofovir disoproxil |
| Investigational medicinal product code |                      |
| Other name                             |                      |
| Pharmaceutical forms                   | Tablet               |
| Routes of administration               | Oral use             |

Dosage and administration details:

Participants received TAD 245 mg tablet orally QD from CP Week 1 to 12.

| Number of subjects in period 2 | Cohort 1 (Prior PA 5): JNJ-3989+JNJ-6379+NA + PegIFN-alpha-2a | Cohort 1 (Per PA 5): JNJ-3989+ NA + PegIFN-alpha-2a | Cohort 2 (Per PA 6): JNJ-3989+ NA + PegIFN-alpha-2a |
|--------------------------------|---|---|---|
| Started                        | 26  | 8   | 17  |
| Subjects actually started CP   | 25 <sup>[1]</sup>   | 7 <sup>[2]</sup>                                    | 17  |

|           |    |   |    |
|-----------|----|---|----|
| Completed | 26 | 8 | 17 |
|-----------|----|---|----|

**Notes:**

[1] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: One participant discontinued JNJ-3989 treatment due to treatment failure/relapse and moved directly from IP to FU phase without CP.

[2] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: One participant discontinued JNJ-3989 treatment due to treatment failure/relapse and moved directly from IP to FU phase without CP.

**Period 3**

|                              |                           |
|------------------------------|---------------------------|
| Period 3 title               | FU Phase: FU Week 1 to 48 |
| Is this the baseline period? | No                        |
| Allocation method            | Not applicable            |
| Blinding used                | Not blinded               |

**Arms**

|                              |   |
|------------------------------|---|
| Are arms mutually exclusive? | Yes   |
| <b>Arm title</b>             | Cohort 1 (Prior PA 5): JNJ-3989+JNJ-6379+NA + PegIFN-alpha-2a |

**Arm description:**

Prior to PA 5, in IP, enrolled participants received JNJ-3989 200 milligrams (mg) subcutaneous (SC) injection once every 4 weeks (Q4W) + JNJ-6379 250 mg tablets orally once daily (QD) + NA (TDF 245 mg/TAF 25 mg) tablet orally QD for  $\geq 36$  to  $\leq 52$  weeks. Participants who met RGT criterion/reached 52 weeks were considered to complete IP and entered 12-week CP and randomized to JNJ-3989 + JNJ-6379 + NA or JNJ-3989+JNJ-6379 + NA + PegIFN-alpha-2a 180 micrograms (mcg) SC injection once weekly (QW). Post PA 5, participant not reached IP Week 36, started PegINF-alpha-2a at Week 36 for 12 weeks and who passed IP Week 36 and/or were randomized to CP without PegINF-alpha-2a, started pegINF-alpha-2a at their next visit. Per PA 6, JNJ-6379 treatment was stopped. Post CP Week 12, participants entered 48-week FU phase and stopped JNJ-3989+PegIFN-alpha-2a. If NA treatment completion criteria was met at CP Week 12, NA was stopped at FU phase Week 2, if not met, NA was continued till end of FU phase.

|  |                       |
|--|-----------------------|
| Arm type                               | Experimental          |
| Investigational medicinal product name | Tenofovir alafenamide |
| Investigational medicinal product code |                       |
| Other name                             |                       |
| Pharmaceutical forms                   | Tablet                |
| Routes of administration               | Oral use              |

**Dosage and administration details:**

Participants received TAF 25 mg tablet orally

QD up to FU Week 2. If NA treatment completion criteria was met at CP Week 12, NA was stopped at FU Week 2. If NA completion criteria was not met, NA was continued till the end of FU phase (FU Week 48).

|  |                      |
|--|----------------------|
| Investigational medicinal product name | Tenofovir disoproxil |
| Investigational medicinal product code |                      |
| Other name                             |                      |
| Pharmaceutical forms                   | Tablet               |
| Routes of administration               | Oral use             |

**Dosage and administration details:**

Participants received TDF 245 mg tablet orally

QD up to FU Week 2. If NA treatment completion criteria was met at CP Week 12, NA was stopped at FU Week 2. If NA completion criteria was not met, NA was continued till the end of FU phase (FU Week 48).

|                  |   |
|------------------|---|
| <b>Arm title</b> | Cohort 1 (Per PA 5): JNJ-3989+ NA + PegIFN-alpha-2a |
|------------------|---|

**Arm description:**

Per PA 5, in the IP, enrolled participants received JNJ-3989 200 mg SC injection Q4W + NA (TDF 245 mg/TAF 25 mg) tablets orally QD for 36 weeks. After completion of IP Week 36, participants entered 12-week CP during which PegIFN-alpha-2a 180 mcg SC injection QW was added to their treatment regimen for 12-weeks. After completion of 12-week CP, participants entered the 48-week FU phase and stopped treatment with JNJ-3989 plus PegIFN-alpha-2a. If NA treatment completion criteria was met at CP Week 12, NA was stopped at FU phase Week 2, if completion criteria was not met, NA was continued till the end of FU phase.

|  |                       |
|--|-----------------------|
| Arm type                               | Experimental          |
| Investigational medicinal product name | Tenofovir alafenamide |
| Investigational medicinal product code |                       |
| Other name                             |                       |
| Pharmaceutical forms                   | Tablet                |
| Routes of administration               | Oral use              |

**Dosage and administration details:**

Participants received TAF 25 mg tablet orally QD up to FU Week 2. If NA treatment completion criteria was met at CP Week 12, NA was stopped at FU Week 2. If NA completion criteria was not met, NA was continued till the end of FU phase (FU Week 48).

|  |                      |
|--|----------------------|
| Investigational medicinal product name | Tenofovir disoproxil |
| Investigational medicinal product code |                      |
| Other name                             |                      |
| Pharmaceutical forms                   | Tablet               |
| Routes of administration               | Oral use             |

**Dosage and administration details:**

Participants received TDF 245 mg tablet orally QD up to FU Week 2. If NA treatment completion criteria was met at CP Week 12, NA was stopped at FU Week 2. If NA completion criteria was not met, NA was continued till the end of FU phase (FU Week 48).

|                  |   |
|------------------|---|
| <b>Arm title</b> | Cohort 2 (Per PA 6): JNJ-3989+ NA + PegIFN-alpha-2a |
|------------------|---|

**Arm description:**

In the IP, participants enrolled as per PA 6 received JNJ-3989 200 mg SC injection Q4W plus NA (TDF 245 mg/TAF 25 mg) tablet orally QD for 36 weeks. After completion of IP Week 36, participants entered 12-week CP during which PegIFN-alpha-2a 180 mcg SC injection QW was added to their treatment regimen for 12-weeks. After completion of 12-week CP, participants entered the 48-week FU phase and stopped treatment with JNJ-3989 plus PegIFN-alpha-2a. If NA treatment completion criteria was met at CP Week 12, NA was stopped at FU phase Week 2, if completion criteria was not met, NA was continued till the end of FU phase.

|  |                       |
|--|-----------------------|
| Arm type                               | Experimental          |
| Investigational medicinal product name | Tenofovir alafenamide |
| Investigational medicinal product code |                       |
| Other name                             |                       |
| Pharmaceutical forms                   | Tablet                |
| Routes of administration               | Oral use              |

---

**Dosage and administration details:**

Participants received TAF 25 mg tablet orally

QD up to FU Week 2. If NA treatment completion criteria was met at CP Week 12, NA was stopped at FU Week 2. If NA completion criteria was not met, NA was continued till the end of FU phase (FU Week 48).

|  |                      |
|--|----------------------|
| Investigational medicinal product name | Tenofovir disoproxil |
| Investigational medicinal product code |                      |
| Other name                             |                      |
| Pharmaceutical forms                   | Tablet               |
| Routes of administration               | Oral use             |

**Dosage and administration details:**

Participants received TDF 245 mg tablet orally

QD up to FU Week 2. If NA treatment completion criteria was met at CP Week 12, NA was stopped at FU Week 2. If NA completion criteria was not met, NA was continued till the end of FU phase (FU Week 48).

| <b>Number of subjects in period 3</b> | Cohort 1 (Prior PA 5): JNJ-3989+JNJ-6379+NA + PegIFN-alpha-2a | Cohort 1 (Per PA 5): JNJ-3989+ NA + PegIFN-alpha-2a | Cohort 2 (Per PA 6): JNJ-3989+ NA + PegIFN-alpha-2a |
|---------------------------------------|---|---|---|
| Started                               | 26  | 8   | 17  |
| Completed                             | 26  | 6   | 17  |
| Not completed                         | 0   | 2   | 0   |
| Consent withdrawn by subject          | -   | 1   | -   |
| Unspecified                           | -   | 1   | -   |

## Baseline characteristics

### Reporting groups

|                       |   |
|-----------------------|---|
| Reporting group title | Cohort 1 (Prior PA 5): JNJ-3989+JNJ-6379+NA + PegIFN-alpha-2a |
|-----------------------|---|

#### Reporting group description:

Prior to PA 5, in IP, enrolled participants received JNJ-3989 200 milligrams (mg) subcutaneous (SC) injection once every 4 weeks (Q4W) + JNJ-6379 250 mg tablets orally once daily (QD) + NA (TDF 245 mg/TAF 25 mg) tablet orally QD for  $\geq 36$  to  $\leq 52$  weeks. Participants who met RGT criterion/reached 52 weeks were considered to complete IP and entered 12-week CP and randomized to JNJ-3989 + JNJ-6379 + NA or JNJ-3989+JNJ-6379 + NA + PegIFN-alpha-2a 180 micrograms (mcg) SC injection once weekly (QW). Post PA 5, participant not reached IP Week 36, started PegINF-alpha-2a at Week 36 for 12 weeks and who passed IP Week 36 and/or were randomized to CP without PegINF-alpha-2a, started pegINF-alpha-2a at their next visit. Per PA 6, JNJ-6379 treatment was stopped. Post CP Week 12, participants entered 48-week FU phase and stopped JNJ-3989+PegIFN-alpha-2a. If NA treatment completion criteria was met at CP Week 12, NA was stopped at FU phase Week 2, if not met, NA was continued till end of FU phase.

|                       |   |
|-----------------------|---|
| Reporting group title | Cohort 1 (Per PA 5): JNJ-3989+ NA + PegIFN-alpha-2a |
|-----------------------|---|

#### Reporting group description:

Per PA 5, in the IP, enrolled participants received JNJ-3989 200 mg SC injection Q4W + NA (TDF 245 mg/TAF 25 mg) tablets orally QD for 36 weeks. After completion of IP Week 36, participants entered 12-week CP during which PegINF-alpha-2a 180 mcg SC injection QW was added to their treatment regimen for 12-weeks. After completion of 12-week CP, participants entered the 48-week FU phase and stopped treatment with JNJ-3989 plus PegIFN-alpha-2a. If NA treatment completion criteria was met at CP Week 12, NA was stopped at FU phase Week 2, if completion criteria was not met, NA was continued till the end of FU phase.

|                       |   |
|-----------------------|---|
| Reporting group title | Cohort 2 (Per PA 6): JNJ-3989+ NA + PegIFN-alpha-2a |
|-----------------------|---|

#### Reporting group description:

In the IP, participants enrolled as per PA 6 received JNJ-3989 200 mg SC injection Q4W plus NA (TDF 245 mg/TAF 25 mg) tablet orally QD for 36 weeks. After completion of IP Week 36, participants entered 12-week CP during which PegIFN-alpha-2a 180 mcg SC injection QW was added to their treatment regimen for 12-weeks. After completion of 12-week CP, participants entered the 48-week FU phase and stopped treatment with JNJ-3989 plus PegIFN-alpha-2a. If NA treatment completion criteria was met at CP Week 12, NA was stopped at FU phase Week 2, if completion criteria was not met, NA was continued till the end of FU phase.

| Reporting group values  | Cohort 1 (Prior PA 5): JNJ-3989+JNJ-6379+NA + PegIFN-alpha-2a | Cohort 1 (Per PA 5): JNJ-3989+ NA + PegIFN-alpha-2a | Cohort 2 (Per PA 6): JNJ-3989+ NA + PegIFN-alpha-2a |
|---|---|---|---|
| Number of subjects  | 27  | 8   | 19  |
| Age Categorical<br>Units: Subjects                                      |   |   |   |
| Age continuous<br>Units: years<br>arithmetic mean<br>standard deviation | 35.6<br>± 9.95  | 27.3<br>± 9.95                                      | 33.6<br>± 11.15                                     |
| Gender categorical<br>Units: Subjects                                   |   |   |   |
| Male  | 12  | 5   | 11  |
| Female  | 15  | 3   | 8   |

|   |       |  |  |
|---|-------|--|--|
| <b>Reporting group values</b>   | Total |  |  |
| Number of subjects  | 54    |  |  |
| Age Categorical<br>Units: Subjects                                      |       |  |  |
| Age continuous<br>Units: years<br>arithmetic mean<br>standard deviation | -     |  |  |
| Gender categorical<br>Units: Subjects                                   |       |  |  |
| Male  | 28    |  |  |
| Female  | 26    |  |  |

## End points

### End points reporting groups

|   |   |
|---|---|
| Reporting group title   | Cohort 1 (Prior PA 5): JNJ-3989+JNJ-6379+NA + PegIFN-alpha-2a |
| Reporting group description:<br>Prior to PA 5, in IP, enrolled participants received JNJ-3989 200 milligrams (mg) subcutaneous (SC) injection once every 4 weeks (Q4W) + JNJ-6379 250 mg tablets orally once daily (QD) + NA (TDF 245 mg/TAF 25 mg) tablet orally QD for $\geq 36$ to $\leq 52$ weeks. Participants who met RGT criterion/reached 52 weeks were considered to complete IP and entered 12-week CP and randomized to JNJ-3989 + JNJ-6379 + NA or JNJ-3989+JNJ-6379 + NA + PegIFN-alpha-2a 180 micrograms (mcg) SC injection once weekly (QW). Post PA 5, participant not reached IP Week 36, started PegINF-alpha-2a at Week 36 for 12 weeks and who passed IP Week 36 and/or were randomized to CP without PegINF-alpha-2a, started pegINF-alpha-2a at their next visit. Per PA 6, JNJ-6379 treatment was stopped. Post CP Week 12, participants entered 48-week FU phase and stopped JNJ-3989+PegIFN-alpha-2a. If NA treatment completion criteria was met at CP Week 12, NA was stopped at FU phase Week 2, if not met, NA was continued till end of FU phase. |   |
| Reporting group title   | Cohort 1 (Per PA 5): JNJ-3989+ NA + PegIFN-alpha-2a           |
| Reporting group description:<br>Per PA 5, in the IP, enrolled participants received JNJ-3989 200 mg SC injection Q4W + NA (TDF 245 mg/TAF 25 mg) tablets orally QD for 36 weeks. After completion of IP Week 36, participants entered 12-week CP during which PegINF-alpha-2a 180 mcg SC injection QW was added to their treatment regimen for 12-weeks. After completion of 12-week CP, participants entered the 48-week FU phase and stopped treatment withJNJ-3989 plus PegIFN-alpha-2a. If NA treatment completion criteria was met at CP Week 12, NA was stopped at FU phase Week 2, if completion criteria was not met, NA was continued till the end of FU phase.  |   |
| Reporting group title   | Cohort 2 (Per PA 6): JNJ-3989+ NA + PegIFN-alpha-2a           |
| Reporting group description:<br>In the IP, participants enrolled as per PA 6 received JNJ-3989 200 mg SC injection Q4W plus NA (TDF 245 mg/TAF 25 mg) tablet orally QD for 36 weeks. After completion of IP Week 36, participants entered 12-week CP during which PegIFN-alpha-2a 180 mcg SC injection QW was added to their treatment regimen for 12-weeks. After completion of 12-week CP, participants entered the 48-week FU phase and stopped treatment with JNJ-3989 plus PegIFN-alpha-2a. If NA treatment completion criteria was met at CP Week 12, NA was stopped at FU phase Week 2, if completion criteria was not met, NA was continued till the end of FU phase.   |   |
| Reporting group title   | Cohort 1 (Prior PA 5): JNJ-3989+JNJ-6379+NA + PegIFN-alpha-2a |
| Reporting group description:<br>Prior to PA 5, in IP, enrolled participants received JNJ-3989 200 milligrams (mg) subcutaneous (SC) injection once every 4 weeks (Q4W) + JNJ-6379 250 mg tablets orally once daily (QD) + NA (TDF 245 mg/TAF 25 mg) tablet orally QD for $\geq 36$ to $\leq 52$ weeks. Participants who met RGT criterion/reached 52 weeks were considered to complete IP and entered 12-week CP and randomized to JNJ-3989 + JNJ-6379 + NA or JNJ-3989+JNJ-6379 + NA + PegIFN-alpha-2a 180 micrograms (mcg) SC injection once weekly (QW). Post PA 5, participant not reached IP Week 36, started PegINF-alpha-2a at Week 36 for 12 weeks and who passed IP Week 36 and/or were randomized to CP without PegINF-alpha-2a, started pegINF-alpha-2a at their next visit. Per PA 6, JNJ-6379 treatment was stopped. Post CP Week 12, participants entered 48-week FU phase and stopped JNJ-3989+PegIFN-alpha-2a. If NA treatment completion criteria was met at CP Week 12, NA was stopped at FU phase Week 2, if not met, NA was continued till end of FU phase. |   |
| Reporting group title   | Cohort 1 (Per PA 5): JNJ-3989+ NA + PegIFN-alpha-2a           |
| Reporting group description:<br>Per PA 5, in the IP, enrolled participants received JNJ-3989 200 mg SC injection Q4W + NA (TDF 245 mg/TAF 25 mg) tablets orally QD for 36 weeks. After completion of IP Week 36, participants entered 12-week CP during which PegINF-alpha-2a 180 mcg SC injection QW was added to their treatment regimen for 12-weeks. After completion of 12-week CP, participants entered the 48-week FU phase and stopped treatment withJNJ-3989 plus PegIFN-alpha-2a. If NA treatment completion criteria was met at CP Week 12, NA was stopped at FU phase Week 2, if completion criteria was not met, NA was continued till the end of FU   |   |

|  |   |
|--|---|
| phase.   |   |
| Reporting group title  | Cohort 2 (Per PA 6): JNJ-3989+ NA + PegIFN-alpha-2a           |
| Reporting group description:   |   |
| <p>In the IP, participants enrolled as per PA 6 received JNJ-3989 200 mg SC injection Q4W plus NA (TDF 245 mg/TAF 25 mg) tablet orally QD for 36 weeks. After completion of IP Week 36, participants entered 12-week CP during which PegIFN-alpha-2a 180 mcg SC injection QW was added to their treatment regimen for 12-weeks. After completion of 12-week CP, participants entered the 48-week FU phase and stopped treatment with JNJ-3989 plus PegIFN-alpha-2a. If NA treatment completion criteria was met at CP Week 12, NA was stopped at FU phase Week 2, if completion criteria was not met, NA was continued till the end of FU phase.</p>   |   |
| Reporting group title  | Cohort 1 (Prior PA 5): JNJ-3989+JNJ-6379+NA + PegIFN-alpha-2a |
| Reporting group description:   |   |
| <p>Prior to PA 5, in IP, enrolled participants received JNJ-3989 200 milligrams (mg) subcutaneous (SC) injection once every 4 weeks (Q4W) + JNJ-6379 250 mg tablets orally once daily (QD) + NA (TDF 245 mg/TAF 25 mg) tablet orally QD for &gt;=36 to &lt;=52 weeks. Participants who met RGT criterion/reached 52 weeks were considered to complete IP and entered 12-week CP and randomized to JNJ-3989 + JNJ-6379 + NA or JNJ-3989+JNJ-6379 + NA + PegIFN-alpha-2a 180 micrograms (mcg) SC injection once weekly (QW). Post PA 5, participant not reached IP Week 36, started PegINF-alpha-2a at Week 36 for 12 weeks and who passed IP Week 36 and/or were randomized to CP without PegINF-alpha-2a, started pegINF-alpha-2a at their next visit. Per PA 6, JNJ-6379 treatment was stopped. Post CP Week 12, participants entered 48-week FU phase and stopped JNJ-3989+PegIFN-alpha-2a. If NA treatment completion criteria was met at CP Week 12, NA was stopped at FU phase Week 2, if not met, NA was continued till end of FU phase.</p> |   |
| Reporting group title  | Cohort 1 (Per PA 5): JNJ-3989+ NA + PegIFN-alpha-2a           |
| Reporting group description:   |   |
| <p>Per PA 5, in the IP, enrolled participants received JNJ-3989 200 mg SC injection Q4W + NA (TDF 245 mg/TAF 25 mg) tablets orally QD for 36 weeks. After completion of IP Week 36, participants entered 12-week CP during which PegINF-alpha-2a 180 mcg SC injection QW was added to their treatment regimen for 12-weeks. After completion of 12-week CP, participants entered the 48-week FU phase and stopped treatment with JNJ-3989 plus PegIFN-alpha-2a. If NA treatment completion criteria was met at CP Week 12, NA was stopped at FU phase Week 2, if completion criteria was not met, NA was continued till the end of FU phase.</p>   |   |
| Reporting group title  | Cohort 2 (Per PA 6): JNJ-3989+ NA + PegIFN-alpha-2a           |
| Reporting group description:   |   |
| <p>In the IP, participants enrolled as per PA 6 received JNJ-3989 200 mg SC injection Q4W plus NA (TDF 245 mg/TAF 25 mg) tablet orally QD for 36 weeks. After completion of IP Week 36, participants entered 12-week CP during which PegIFN-alpha-2a 180 mcg SC injection QW was added to their treatment regimen for 12-weeks. After completion of 12-week CP, participants entered the 48-week FU phase and stopped treatment with JNJ-3989 plus PegIFN-alpha-2a. If NA treatment completion criteria was met at CP Week 12, NA was stopped at FU phase Week 2, if completion criteria was not met, NA was continued till the end of FU phase.</p>   |   |
| Subject analysis set title   | Cohort 1 (Prior PA 5): JNJ-3989+JNJ-6379+NA + PegIFN-alpha-2a |
| Subject analysis set type  | Per protocol  |
| Subject analysis set description:  |   |
| <p>Prior PA 5, participants received JNJ-3989 200 mg SC injection 4th weekly(Q4W) + JNJ-6379 250 mg tablets orally once daily (QD) + NA (TDF 245 mg/TAF 25 mg) tablet orally QD in IP for &gt;=36 to &lt;=60 weeks. Participants who met RGT criterion or reached 60 weeks were considered completed IP &amp; entered 12 week CP &amp; randomized to JNJ-3989 200 mg SC injection Q4W + JNJ-6379 250 mg tablets orally QD + NA (TDF 245 mg/TAF 25 mg) tablet orally QD or JNJ-3989 200 mg SC injection Q4W + JNJ-6379 250 mg tablets orally QD + NA (TDF 245 mg/TAF 25 mg) tablets orally QD + PegIFN-alpha-2a 180 mcg SC injection QW. Post PA 5, participants not reached IP Week (W)36, started PegINF-alpha-2a at W36 for 12 weeks &amp; who passed IP W36 &amp;/or were randomized to CP without PegINF-alpha-2a, started pegINF-alpha-2a at next visit. Per PA 6 JNJ-6379 treatment discontinued. Post 12 week CP, participants entered 48 week FU phase till FU Week 48 &amp; stopped JNJ-3989 + PegIFN-alpha-2a.</p>                       |   |
| Subject analysis set title   | Cohort 1 (Per PA 5): JNJ-3989+ NA + PegIFN-alpha-2a           |
| Subject analysis set type  | Per protocol  |



Subject analysis set description:

Per PA 5, participants in IP received JNJ-3989 200 mg SC injection for Q4W plus NA (tenofovir disoproxil 245 mg/tenofovir alafenamide 25 mg) tablets orally QD for 36 weeks. After completion of IP W36, all participants entered 12-week CP during which PegIFN-alpha-2a 180 mcg SC injection QW was added to their treatment regimen for 12-weeks. After completion of 12-week CP, all participants entered the 48-week FU phase and stopped treatment with JNJ-3989 plus PegIFN-alpha-2a. If NA treatment completion criteria was met at CP W12 NA was stopped at FU W2, if completion criteria was not met NA was continued till the end of FU phase.

|                            |   |
|----------------------------|---|
| Subject analysis set title | Cohort 2 (Per PA 6): JNJ-3989+ NA + PegIFN-alpha-2a |
| Subject analysis set type  | Per protocol  |

Subject analysis set description:

Participants enrolled as per PA 6 received JNJ-3989 200 mg SC injection for Q4W plus NA (tenofovir disoproxil 245 mg/tenofovir alafenamide 25 mg) tablet orally QD for 36 weeks in IP. After completion of IP, participants entered 12-week CP and received PegIFN-alpha-2a 180 mcg QW for 12-week. After completion of 12-week CP, all participants entered the 48-week FU phase and stopped treatment with JNJ-3989 plus NA plus PegIFN-alpha-2a. If NA treatment completion criteria was met at CP W12 NA was stopped at FU W2, if completion criteria was not met NA was continued till the end of FU phase

|                            |   |
|----------------------------|---|
| Subject analysis set title | IP: Cohort 1 (Prior PA 5): JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a |
| Subject analysis set type  | Per protocol  |

Subject analysis set description:

Prior to PA 5, participants received JNJ-3989 200 mg SC injection for Q4W + JNJ-6379 250 mg tablets orally QD plus NA (TAD 245 mg/TAF 25 mg) tablet orally QD in IP for a RGT duration for >=36-weeks to <=52-weeks.

|                            |  |
|----------------------------|--|
| Subject analysis set title | IP: Cohort 1 (Per PA 5): JNJ-3989 + NA + PegIFN-alpha-2a |
| Subject analysis set type  | Per protocol   |

Subject analysis set description:

Per PA 5, participants received JNJ-3989 200 mg SC injection for Q4W plus NA (TAD 245 mg/TAF 25 mg) tablets orally QD in IP for 36 weeks.

|                            |  |
|----------------------------|--|
| Subject analysis set title | IP: Cohort 2 (Per PA 6): JNJ-3989+NA+PegIFN-alpha-2a |
| Subject analysis set type  | Per protocol   |

Subject analysis set description:

Participants enrolled as per PA 6, received JNJ-3989 200 mg SC for Q4W plus NA (TAD 250 mg/TAF 25 mg) tablet orally QD in IP for 36 weeks.

|                            |   |
|----------------------------|---|
| Subject analysis set title | CP: Cohort 1 (Prior PA 5): JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a |
| Subject analysis set type  | Per protocol  |

Subject analysis set description:

After completion of IP, participants entered in 12 week CP and received JNJ-3989 200 mg SC Q4W plus JNJ-6379 250 tablets QD plus NA (either TAD 250 mg or TAF 25 mg) tablet orally QD from CP Week 1 to 12 and PegIFN-alpha-2a 180 mcg SC injection was added to their treatment regimen from IP Week 36 for 12 weeks.

|                            |   |
|----------------------------|---|
| Subject analysis set title | CP: Cohort 1 (Per PA 5): JNJ-3989+NA+ PegIFN-alpha-2a |
| Subject analysis set type  | Per protocol  |

Subject analysis set description:

After completion of IP, participants entered in 12-week CP and received JNJ-3989 200 mg SC injection Q4W + NA (TDF 245 mg/TAF 25 mg) tablets orally QD from CP Week 1 to 12 and PegIFN-alpha-2a 180 mcg SC QW was added to their treatment regimen from IP Week 36 for 12 weeks.

|                            |  |
|----------------------------|--|
| Subject analysis set title | CP: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a |
| Subject analysis set type  | Per protocol   |

Subject analysis set description:

After completion of IP, participants entered in 12-week CP and received JNJ-3989 200 mg SC injection Q4W + NA (TDF 245 mg/TAF 25 mg) tablets orally QD from CP Week 1 to 12 and PegIFN-alpha-2a 180 mcg SC QW was added to their treatment regimen from IP Week 36 for 12 weeks.

|                            |   |
|----------------------------|---|
| Subject analysis set title | FU: Cohort 1: JNJ-3989+ JNJ-6379+NA+PegIFN-alpha-2a |
|----------------------------|---|

|   |  |
|---|--|
| Subject analysis set type   | Per protocol   |
| Subject analysis set description:   |  |
| After completion of CP, all participants entered 48-Week FU phase and stopped treatment with JNJ-3989 plus JNJ-6379 plus NA (TAD 245 mg/TAF 25 mg) plus PegIFN-alpha2a. If NA treatment completion criteria was met at CP Week 12 NA was stopped at FU W2, if NA treatment completion criteria was not met, NA (TAD 245 mg/TAF 25 mg) was continued till the end of FU phase.   |  |
| Subject analysis set title  | FU: Cohort 1: JNJ-3989 + NA + PegIFN-alpha-2a            |
| Subject analysis set type   | Per protocol   |
| Subject analysis set description:   |  |
| After completion of CP, all participants entered 48-Week FU phase and stopped treatment with JNJ-3989 plus NA (TAD 245 mg/TAF 25 mg) plus PegIFN-alpha2a. If NA treatment completion criteria was met at CP Week 12, NA treatment was stopped at FU Week 2, if NA treatment completion criteria was not met, NA (TAD 245 mg/TAF 25 mg) was continued till the end of FU phase.  |  |
| Subject analysis set title  | FU: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a |
| Subject analysis set type   | Per protocol   |
| Subject analysis set description:   |  |
| After completion of CP, all participants entered 48-Week FU phase and stopped treatment with JNJ-3989 plus NA (TAD 245 mg/TAF 25 mg) plus PegIFN-alpha2a. If NA treatment completion criteria was met at CP Week 12, NA treatment was stopped at FU Week 2, if NA treatment completion criteria was not met, NA (TAD 245 mg/TAF 25 mg) was continued till the end of FU phase.  |  |
| Subject analysis set title  | Induction phase  |
| Subject analysis set type   | Per protocol   |
| Subject analysis set description:   |  |
| Prior PA 5, participants received JNJ-3989 200 mg SC injection for Q4W + JNJ-6379 250 mg tablets orally QD plus NA (TAD 245 mg/TAF 25 mg) tablet orally QD for >=36-weeks to <=52-weeks. Participants who met RGT criterion/reached 52 weeks were considered to complete IP and entered 12-week CP and randomized to JNJ-3989 + JNJ-6379 + NA or JNJ-3989+JNJ-6379 + NA + PegIFN-alpha-2a 180 micrograms (mcg) SC injection once weekly (QW). Per PA 5, participants received JNJ-3989 200 mg SC injection for Q4W plus NA (TAD 245 mg/TAF 25 mg) tablets orally QD for 36 weeks. Participants enrolled as per PA 6, received JNJ-3989 200 mg SC for Q4W plus NA (either tenofovir disoproxil 250 mg or 25 mg tenofovir alafenamide) tablet orally QD for 36 weeks in IP. Post PA 5, participant not reached IP Week 36, started PegINF-alpha-2a at Week 36 for 12 weeks and who passed IP Week 36 and/or were randomized to CP without PegINF-alpha-2a, started pegINF-alpha-2a at their next visit. |  |
| Subject analysis set title  | Consolidation phase                                      |
| Subject analysis set type   | Per protocol   |
| Subject analysis set description:   |  |
| After completion of IP, participants entered the 12 weeks CP and received JNJ-3989 200 mg SC Q4W plus JNJ-6379 250 tablets QD plus NA (either TDF 245 mg/TAF 25 mg) tablet orally QD plus PegIFN-alpha-2a 180 mcg SC QW. At the end of the CP, all participants entered the 48-weeks follow-up (FU) phase and stopped treatment with JNJ-3989 plus JNJ-6379 plus NA plus PegIFN-alpha-2a.If NA treatment completion criteria was met at CP Week 12, NA was stopped at FU phase Week 2, if not met, NA was continued till end of FU phase. If NA treatment completion criteria was met at CP Week 12, NA was stopped at FU phase Week 2, if not met, NA was continued till end of FU phase.  |  |
| Subject analysis set title  | Induction phase  |
| Subject analysis set type   | Per protocol   |
| Subject analysis set description:   |  |
| Prior PA 5, participants received JNJ-3989 200 mg SC injection for Q4W + JNJ-6379 250 mg tablets orally QD plus NA (TAD 245 mg/TAF 25 mg) tablet orally QD for >=36-weeks to <=52-weeks. Participants who met RGT criterion/reached 52 weeks were considered to complete IP and entered 12-week CP and randomized to JNJ-3989 + JNJ-6379 + NA or JNJ-3989+JNJ-6379 + NA + PegIFN-alpha-2a 180 micrograms (mcg) SC injection once weekly (QW). Per PA 5, participants received JNJ-3989 200 mg SC injection for Q4W plus NA (TAD 245 mg/TAF 25 mg) tablets orally QD for 36 weeks. Participants enrolled as per PA 6, received JNJ-3989 200 mg SC for Q4W plus NA (either tenofovir disoproxil 250 mg or 25 mg tenofovir alafenamide) tablet orally QD for 36 weeks in IP. Post PA 5, participant not reached IP Week 36, started PegINF-alpha-2a at Week 36 for 12 weeks and who passed IP Week 36 and/or were randomized to CP without PegINF-alpha-2a, started pegINF-alpha-2a at their next visit. |  |
| Subject analysis set title  | Consolidation phase                                      |

|                           |              |
|---------------------------|--------------|
| Subject analysis set type | Per protocol |
|---------------------------|--------------|

#### Subject analysis set description:

After completion of IP, participants entered the 12 weeks CP and received JNJ-3989 200 mg SC Q4W plus JNJ-6379 250 tablets QD plus NA (either TDF 245 mg/TAF 25 mg) tablet orally QD plus PegIFN-alpha-2a 180 mcg SC QW. At the end of the CP, all participants entered the 48-weeks follow-up (FU) phase and stopped treatment with JNJ-3989 plus JNJ-6379 plus NA plus PegIFN-alpha-2a. If NA treatment completion criteria was met at CP Week 12, NA was stopped at FU phase Week 2, if not met, NA was continued till end of FU phase. If NA treatment completion criteria was met at CP Week 12, NA was stopped at FU phase Week 2, if not met, NA was continued till end of FU phase.

|                            |                 |
|----------------------------|-----------------|
| Subject analysis set title | Induction phase |
|----------------------------|-----------------|

|                           |              |
|---------------------------|--------------|
| Subject analysis set type | Per protocol |
|---------------------------|--------------|

#### Subject analysis set description:

Prior PA 5, participants received JNJ-3989 200 mg SC injection for Q4W + JNJ-6379 250 mg tablets orally QD plus NA (TAD 245 mg/TAF 25 mg) tablet orally QD for  $\geq 36$ -weeks to  $\leq 52$ -weeks. Participants who met RGT criterion/reached 52 weeks were considered to complete IP and entered 12-week CP and randomized to JNJ-3989 + JNJ-6379 + NA or JNJ-3989+JNJ-6379 + NA + PegIFN-alpha-2a 180 micrograms (mcg) SC injection once weekly (QW). Per PA 5, participants received JNJ-3989 200 mg SC injection for Q4W plus NA (TAD 245 mg/TAF 25 mg) tablets orally QD for 36 weeks. Participants enrolled as per PA 6, received JNJ-3989 200 mg SC for Q4W plus NA (either tenofovir disoproxil 250 mg or 25 mg tenofovir alafenamide) tablet orally QD for 36 weeks in IP. Post PA 5, participant not reached IP Week 36, started PegINF-alpha-2a at Week 36 for 12 weeks and who passed IP Week 36 and/or were randomized to CP without PegINF-alpha-2a, started pegINF-alpha-2a at their next visit.

|                            |                     |
|----------------------------|---------------------|
| Subject analysis set title | Consolidation phase |
|----------------------------|---------------------|

|                           |              |
|---------------------------|--------------|
| Subject analysis set type | Per protocol |
|---------------------------|--------------|

#### Subject analysis set description:

After completion of IP, participants entered the 12 weeks CP and received JNJ-3989 200 mg SC Q4W plus JNJ-6379 250 tablets QD plus NA (either TDF 245 mg/TAF 25 mg) tablet orally QD plus PegIFN-alpha-2a 180 mcg SC QW. At the end of the CP, all participants entered the 48-weeks follow-up (FU) phase and stopped treatment with JNJ-3989 plus JNJ-6379 plus NA plus PegIFN-alpha-2a. If NA treatment completion criteria was met at CP Week 12, NA was stopped at FU phase Week 2, if not met, NA was continued till end of FU phase. If NA treatment completion criteria was met at CP Week 12, NA was stopped at FU phase Week 2, if not met, NA was continued till end of FU phase.

### **Primary: Percentage of Participants With Functional Cure: Hepatitis B Surface Antigen (HBsAg) Seroclearance at 24 Weeks After Stopping all Study Interventions at the end of Consolidation Phase (CP) and Without Restarting Nucleos(t)ide analog (NA) Treatment**

|                 |  |
|-----------------|--|
| End point title | Percentage of Participants With Functional Cure: Hepatitis B Surface Antigen (HBsAg) Seroclearance at 24 Weeks After Stopping all Study Interventions at the end of Consolidation Phase (CP) and Without Restarting Nucleos(t)ide analog (NA) Treatment <sup>[1]</sup> |
|-----------------|--|

#### End point description:

Percentage of participants with functional cure (defined as percentage of participants with HBsAg seroclearance at 24 weeks after stopping all study interventions at end of CP and without restarting NA treatment) were reported. Seroclearance of HBsAg was defined as a (quantitative) HBsAg level less than ( $<$ ) lower limit of quantification (LLOQ; 0.05 IU/mL). Per protocol analysis set: all randomised/enrolled participants who received at least 1 dose of CP study intervention and did not had any of the selected major protocol deviations that might affect the assessment of efficacy in terms of the primary endpoint at 24 weeks after stopping all study interventions of the CP.

|                |         |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

#### End point timeframe:

At follow-up (FU) phase Week 24

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No inferential statistics was done. Only descriptive statistics was performed.

| End point values                  | Cohort 1 (Prior PA 5): JNJ-3989+JNJ-6379+NA + PegIFN-alpha-2a | Cohort 1 (Per PA 5): JNJ-3989+ NA + PegIFN-alpha-2a | Cohort 2 (Per PA 6): JNJ-3989+ NA + PegIFN-alpha-2a |  |
|-----------------------------------|---|---|---|--|
| Subject group type                | Reporting group   | Reporting group                                     | Reporting group                                     |  |
| Number of subjects analysed       | 26  | 8   | 17  |  |
| Units: percentage of participants |   |   |   |  |
| number (not applicable)           | 0   | 0   | 0   |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Participants with Treatment Emergent Adverse Events (TEAEs)

|                 |   |
|-----------------|---|
| End point title | Number of Participants with Treatment Emergent Adverse Events (TEAEs) |
|-----------------|---|

End point description:

Number of participants with TEAEs were reported. An adverse event (AE) was any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the study intervention. Treatment-emergent AEs are all AEs with an onset on or after the first administration of study treatment or any ongoing event that worsened in severity, intensity or frequency after the first administration of study treatment. Safety analysis set (SAS) included all participants who received at least one dose of study intervention. Participants were analysed according to the study intervention they actually received.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

IP: From Day 1 up to end of IP (up to Week 36 per PA 5; up to Week 52 prior to PA 5); CP: CP Week 1 up to CP Week 12; FU phase: FU Week 1 up to FU Week 48

| End point values            | IP: Cohort 1(Prior PA 5): JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a | IP: Cohort 1 (Per PA 5): JNJ-3989 + NA + PegIFN-alpha-2a | IP:Cohort 2(Per PA 6): JNJ-3989+NA+PegIFN-alpha-2a | CP:Cohort 1(Prior PA 5):JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a |
|-----------------------------|--|--|--|--|
| Subject group type          | Subject analysis set   | Subject analysis set                                     | Subject analysis set                               | Subject analysis set   |
| Number of subjects analysed | 27   | 8  | 19   | 25 <sup>[2]</sup>  |
| Units: participants         | 22   | 8  | 15   | 22   |

Notes:

[2] - 1 participant who moved directly from IP to FU was not counted in this arm.

| End point values | CP: Cohort 1(Per PA 5): | CP: Cohort 2 (Per PA 6): | FU: Cohort 1: JNJ-3989+ | FU: Cohort 1: JNJ-3989 + NA |
|------------------|-------------------------|--------------------------|-------------------------|-----------------------------|
|------------------|-------------------------|--------------------------|-------------------------|-----------------------------|

|                             | JNJ-3989+NA+<br>PegIFN-alpha-<br>2a | JNJ-3989 + NA<br>+ PegIFN-<br>alpha-2a | JNJ-<br>6379+NA+PegI<br>FN-alpha-2a | + PegIFN-<br>alpha-2a |
|-----------------------------|-------------------------------------|--|-------------------------------------|-----------------------|
| Subject group type          | Subject analysis set                | Subject analysis set                   | Subject analysis set                | Subject analysis set  |
| Number of subjects analysed | 7 <sup>[3]</sup>                    | 17                                     | 26 <sup>[4]</sup>                   | 8 <sup>[5]</sup>      |
| Units: participants         | 7                                   | 13                                     | 17                                  | 5                     |

Notes:

[3] - 1 participant who moved directly from IP to FU was not counted in this arm.

[4] - 25 participants from CP + 1 participant moved directly from IP.

[5] - 7 participants from CP + 1 participant moved directly from IP.

| End point values            | FU: Cohort 2<br>(Per PA 6):<br>JNJ-3989 + NA<br>+ PegIFN-<br>alpha-2a |  |  |  |
|-----------------------------|---|--|--|--|
| Subject group type          | Subject analysis set  |  |  |  |
| Number of subjects analysed | 17  |  |  |  |
| Units: participants         | 11  |  |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Participants with Treatment Emergent Serious Adverse Events (TESAEs)

|                 |  |
|-----------------|--|
| End point title | Number of Participants with Treatment Emergent Serious Adverse Events (TESAEs) |
|-----------------|--|

End point description:

Number of participants with TESAEs were reported. An AE was any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the study intervention. A SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent AEs are all AEs with an onset on or after the first administration of study treatment or any ongoing event that worsened in severity, intensity or frequency after the first administration of study treatment. Safety analysis set included all participants who received at least one dose of study intervention. Participants were analysed according to the study intervention they actually received.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

IP: From Day 1 up to end of IP (up to Week 36 per PA 5; up to Week 52 prior to PA 5); CP: CP Week 1 up to CP Week 12; FU phase: FU Week 1 up to FU Week 48

| End point values            | IP: Cohort 1(Prior PA 5):<br>JNJ-3989+JNJ-<br>6379+NA+PegI<br>FN-alpha-2a | IP: Cohort 1<br>(Per PA 5):<br>JNJ-3989 + NA<br>+ PegIFN-<br>alpha-2a | IP:Cohort 2(Per PA 6):<br>JNJ-<br>3989+NA+PegI<br>FN-alpha-2a | CP:Cohort 1(Prior PA 5):JNJ-<br>3989+JNJ-<br>6379+NA+PegI |
|-----------------------------|---|---|---|---|
| Subject group type          | Subject analysis set  | Subject analysis set  | Subject analysis set  | Subject analysis set                                      |
| Number of subjects analysed | 27  | 8   | 19  | 25  |
| Units: participants         | 0   | 0   | 0   | 0   |

| End point values            | CP: Cohort 1(Per PA 5): JNJ-3989+NA+ PegIFN-alpha-2a | CP: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a | FU: Cohort 1: JNJ-3989+ JNJ-6379+NA+PegIFN-alpha-2a | FU: Cohort 1: JNJ-3989 + NA + PegIFN-alpha-2a |
|-----------------------------|--|--|---|---|
| Subject group type          | Subject analysis set                                 | Subject analysis set                                     | Subject analysis set                                | Subject analysis set                          |
| Number of subjects analysed | 7  | 17   | 26  | 8   |
| Units: participants         | 0  | 0  | 0   | 0   |

| End point values            | FU: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a |  |  |  |
|-----------------------------|--|--|--|--|
| Subject group type          | Subject analysis set                                     |  |  |  |
| Number of subjects analysed | 17   |  |  |  |
| Units: participants         | 1  |  |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Participants with Worst (Grade 3 or 4) Treatment-emergent DAIDS Toxicity Grade in Clinical Laboratory Tests

|                 |   |
|-----------------|---|
| End point title | Number of Participants with Worst (Grade 3 or 4) Treatment-emergent DAIDS Toxicity Grade in Clinical Laboratory Tests |
|-----------------|---|

End point description:

Laboratory parameters: Hematology (Hem): absolute lymphocyte count, (ALC), A neutrophil count (ANC), hemoglobin (Hb) , Neutrophils Band Form (NBF) , Neutrophils segmented (Neu Seg), WBC decreased (dcrsd); Chem: alanine aminotransferase (ALT) & serum glutamic pyruvic transaminase (SGPT), aspartate aminotransferase(AST)/serum glutamic oxaloacetic transaminase (SGOT), cholesterol (CLSTRL) (fasting[F]), creatinine Kinase (Cr Kin), Glomerular filtration rate (GFR) from Creatinine (Cr) Adjusted for body surface area ((Ad.BSA), GFR Cystatin (Cy) C (Ad. BSA), low-density lipoprotein (LDL: fasting[F]), triglycerides (Tglrds[F]); Urinalysis: glycosuria. DAIDS toxicity grades: Grade (Gr) 1 (Mild), Gr 2 (Moderate), Gr 3 (Severe), Gr 4 (Potentially Life-Threatening). Here, number of participants with TE DAIDS toxicity Grade 3 or 4 were reported in this endpoint. SAS was analysed. n=0, and 99999 signify that data were not collected & analysed as timepoint was not applicable to respective arm.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

IP: From Day 1 up to end of IP (up to Week 36 per PA 5; up to Week 52 prior to PA 5); CP: CP Week 1 up to CP Week 12; FU phase: FU Week 1 up to FU Week 48

| End point values                                    | IP: Cohort 1(Prior PA 5): JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a | IP: Cohort 1 (Per PA 5): JNJ-3989 + NA + PegIFN-alpha-2a | IP:Cohort 2(Per PA 6): JNJ-3989+NA+PegIFN-alpha-2a | CP:Cohort 1(Prior PA 5):JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a |
|---|--|--|--|--|
| Subject group type                                  | Subject analysis set   | Subject analysis set                                     | Subject analysis set                               | Subject analysis set   |
| Number of subjects analysed                         | 27   | 8  | 19   | 25   |
| Units: participants                                 |  |  |  |  |
| Hem:ALC:Low:Gr 3 :n=26,8,19,25,7,17,26,8,17         | 0  | 0  | 0  | 1  |
| Hem: ANC: Gr 3: n=26,8,19,25,7,17,26,8,17           | 0  | 0  | 0  | 2  |
| Hem: HB: Low: Gr 3 :n=26,8,19,25,7,17,26,8,17       | 0  | 0  | 0  | 1  |
| Hem: NBF: Low: Gr4:n=0,0,0,3,0,0,1,0,1              | 99999  | 99999  | 99999  | 3  |
| Hem:Neu Seg:Low:Gr3: n=26,8,19,25,7,17,26,8,17      | 0  | 0  | 0  | 2  |
| Hem:WBC   | 0  | 0  | 0  | 3  |
| dcrsd:Low:Gr3:n=26,8,19,25,7,17,26,8,5,7,17,26,8,17 | 1  | 0  | 0  | 1  |
| Chem:ALT/SGPT:High:Gr3:n=26,8,19,25,7,17,26,8,17    | 0  | 0  | 0  | 0  |
| Chem:AST/SGOT:High:Gr3:n=26,8,19,25,7,17,26,8,17    | 1  | 0  | 0  | 1  |
| Chem:CLSTRL(F):High:Gr3:n=26,8,19,25,7,17,26,8,17   | 0  | 0  | 0  | 0  |
| Kin:High:Gr3:n=26,8,19,25,7,17,26,8,17              | 1  | 0  | 0  | 0  |
| Chem: Cr  | 0  | 0  | 0  | 0  |
| Kin:High:Gr4:n=26,8,19,25,7,17,26,8,17              | 1  | 0  | 0  | 0  |
| Che:GFR:Cr  | 1  | 0  | 0  | 0  |
| Ad.BSA:L:Gr3:n=26,8,19,25,7,17,26,8,5,7,17,26,8,17  | 1  | 0  | 0  | 1  |
| Che:GFR:Cyc   | 0  | 0  | 0  | 0  |
| Ad.BSA:L:Gr4:n=26,8,19,25,7,17,26,8,5,7,17,26,8,17  | 2  | 0  | 0  | 1  |
| Chem:LDL(F):High:Gr3:n=26,8,19,25,7,17,26,8,17      | 0  | 0  | 1  | 1  |
| Chem:Tglrds(F):High:Gr3:n=26,8,19,25,7,17,26,8,17   | 0  | 0  | 0  | 0  |
| Urinalysis:Glycosuria:Gr3:n=17,7,7,13,6,6,12,8,5    | 0  | 0  | 0  | 0  |

| End point values                              | CP: Cohort 1(Per PA 5): JNJ-3989+NA+PegIFN-alpha-2a | CP: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a | FU: Cohort 1: JNJ-3989+ JNJ-6379+NA+PegIFN-alpha-2a | FU: Cohort 1: JNJ-3989 + NA + PegIFN-alpha-2a |
|---|---|--|---|---|
| Subject group type                            | Subject analysis set                                | Subject analysis set                                     | Subject analysis set                                | Subject analysis set                          |
| Number of subjects analysed                   | 7   | 17   | 26  | 8   |
| Units: participants                           |   |  |   |   |
| Hem:ALC:Low:Gr 3 :n=26,8,19,25,7,17,26,8,17   | 0   | 0  | 0   | 0   |
| Hem: ANC: Gr 3: n=26,8,19,25,7,17,26,8,17     | 0   | 0  | 0   | 0   |
| Hem: HB: Low: Gr 3 :n=26,8,19,25,7,17,26,8,17 | 0   | 0  | 0   | 1   |

|   |       |       |   |       |
|---|-------|-------|---|-------|
| Hem: NBF: Low:<br>Gr4:n=0,0,0,3,0,0,1,0,1             | 99999 | 99999 | 1 | 99999 |
| Hem:Neu Seg:Low:Gr3:<br>n=26,8,19,25,7,17,26,8,17     | 0     | 0     | 0 | 0     |
| Hem:WBC   | 0     | 1     | 1 | 0     |
| dcrsd:Low:Gr3:n=26,8,19,25,7,17,26,8,                 | 0     | 2     | 0 | 0     |
| Chem:ALT/SGPT:High:Gr3:n=26,8,19,2<br>5,7,17,26,8,17  | 0     | 1     | 0 | 0     |
| Chem:AST/SGOT:High:Gr3:n=26,8,19,2<br>5,7,17,26,8,17  | 0     | 0     | 1 | 0     |
| Chem:CLSTRL(F):High:Gr3:n=26,8,19,2<br>5,7,17,26,8,17 | 0     | 2     | 0 | 0     |
| Chem:Cr   | 0     | 0     | 0 | 0     |
| Kin:High:Gr3:n=26,8,19,25,7,17,26,8,1                 | 0     | 0     | 0 | 0     |
| Chem: Cr  | 0     | 0     | 0 | 0     |
| Kin:High:Gr4:n=26,8,19,25,7,17,26,8,1                 | 0     | 0     | 0 | 0     |
| Che:GFR:Cr  | 0     | 0     | 0 | 0     |
| Ad.BSA:L:Gr3:n=26,8,19,25,7,17,26,8,                  | 0     | 0     | 1 | 0     |
| Che:GFR:Cyc   | 0     | 0     | 0 | 0     |
| Ad.BSA:L:Gr3:n=26,8,19,25,7,17,26,8,                  | 0     | 0     | 0 | 0     |
| Che:GFR:Cyc   | 0     | 1     | 0 | 0     |
| Ad.BSA:L:Gr4:n=26,8,19,25,7,17,26,8,                  | 0     | 0     | 1 | 0     |
| Chem:LDL(F):High:Gr3:n=26,8,19,25,7,<br>17,26,8,17    | 0     | 0     | 0 | 0     |
| Chem:Tglrds(F):High:Gr3:n=26,8,19,25<br>,7,17,26,8,17 | 0     | 0     | 1 | 0     |
| Urinalysis:Glycosuria:Gr3:n=17,7,7,13,<br>6,6,12,8,5  | 0     | 0     | 0 | 1     |

|   |   |  |  |  |
|---|---|--|--|--|
| <b>End point values</b>                               | FU: Cohort 2<br>(Per PA 6):<br>JNJ-3989 + NA<br>+ PegIFN-<br>alpha-2a |  |  |  |
| Subject group type                                    | Subject analysis set  |  |  |  |
| Number of subjects analysed                           | 17  |  |  |  |
| Units: participants                                   |   |  |  |  |
| Hem:ALC:Low:Gr 3 :n=26,8,19,<br>25,7,17,26,8,17       | 0   |  |  |  |
| Hem: ANC: Gr 3: n=26,8,19,<br>25,7,17,26,8,17         | 0   |  |  |  |
| Hem: HB: Low: Gr 3 :n=26,8,19,<br>25,7,17,26,8,17     | 0   |  |  |  |
| Hem: NBF: Low:<br>Gr4:n=0,0,0,3,0,0,1,0,1             | 1   |  |  |  |
| Hem:Neu Seg:Low:Gr3:<br>n=26,8,19,25,7,17,26,8,17     | 0   |  |  |  |
| Hem:WBC   | 0   |  |  |  |
| dcrsd:Low:Gr3:n=26,8,19,25,7,17,26,8,                 | 0   |  |  |  |
| Chem:ALT/SGPT:High:Gr3:n=26,8,19,2<br>5,7,17,26,8,17  | 0   |  |  |  |
| Chem:AST/SGOT:High:Gr3:n=26,8,19,2<br>5,7,17,26,8,17  | 0   |  |  |  |
| Chem:CLSTRL(F):High:Gr3:n=26,8,19,2<br>5,7,17,26,8,17 | 0   |  |  |  |
| Chem:Cr   | 0   |  |  |  |
| Kin:High:Gr3:n=26,8,19,25,7,17,26,8,1                 |   |  |  |  |



|   |   |  |  |  |
|---|---|--|--|--|
| Chem: Cr<br>Kin:High:Gr4:n=26,8,19,25,7,17,26,8,1     | 0 |  |  |  |
| Che:GFR:Cr<br>Ad.BSA:L:Gr3:n=26,8,19,25,7,17,26,8,    | 0 |  |  |  |
| Che:GFR:Cyc<br>Ad.BSA:L:Gr3:n=26,8,19,25,7,17,26,8,   | 1 |  |  |  |
| Che:GFR:Cyc<br>Ad.BSA:L:Gr4:n=26,8,19,25,7,17,26,8,   | 1 |  |  |  |
| Chem:LDL(F):High:Gr3:n=26,8,19,25,7,<br>17,26,8,17    | 0 |  |  |  |
| Chem:Tglrds(F):High:Gr3:n=26,8,19,25<br>,7,17,26,8,17 | 0 |  |  |  |
| Urinalysis:Glycosuria:Gr3:n=17,7,7,13,<br>6,6,12,8,5  | 0 |  |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Participants With Worst Treatment-emergent Abnormality in Electrocardiogram (ECGs)

| End point title  | Number of Participants With Worst Treatment-emergent Abnormality in Electrocardiogram (ECGs) |
|--|--|
| End point description:<br>Number of participants with worst treatment-emergent abnormality in ECG were reported. Treatment-emergent abnormality was defined as the abnormalities that were worsened as compared to the abnormality at baseline; which also included the shift from abnormally high to abnormally low and vice-versa. ECG parameters included heart rate (HR; abnormally low, HR <45 beats per minute (bpm) and (abnormally high HR ≥ 120 bpm; PR interval abnormally high >220 milliseconds (ms); QRS interval abnormally high ≥ 120 ms; QT corrected (Fridericia QTcF) categories; borderline prolonged QTc interval <450 to ≤480 ms), prolonged QTc interval <480 to ≤500 ms) and pathologically prolonged QTc interval >500 ms). Safety analysis set included all participants who received at least one dose of study intervention. Participants were analysed according to the study intervention they actually received. |  |
| End point type   | Secondary  |
| End point timeframe:<br>IP: From Day 1 up to end of IP (up to Week 36 per PA 5; up to Week 52 prior to PA 5); CP: CP Week 1 up to CP Week 12; FU phase: FU Week 1 up to FU Week 48   |  |

| End point values            | IP: Cohort 1(Prior PA 5): JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a | IP: Cohort 1 (Per PA 5): JNJ-3989 + NA + PegIFN-alpha-2a | IP:Cohort 2(Per PA 6): JNJ-3989+NA+PegIFN-alpha-2a | CP:Cohort 1(Prior PA 5):JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a |
|-----------------------------|--|--|--|--|
| Subject group type          | Subject analysis set   | Subject analysis set                                     | Subject analysis set                               | Subject analysis set   |
| Number of subjects analysed | 27   | 8  | 19   | 25   |
| Units: participants         | 0  | 0  | 0  | 0  |

| End point values | CP: Cohort 1(Per PA 5): | CP: Cohort 2 (Per PA 6): | FU: Cohort 1: JNJ-3989+ | FU: Cohort 1: JNJ-3989 + NA |
|------------------|-------------------------|--------------------------|-------------------------|-----------------------------|
|------------------|-------------------------|--------------------------|-------------------------|-----------------------------|

|                             | JNJ-3989+NA+<br>PegIFN-alpha-<br>2a | JNJ-3989 + NA<br>+ PegIFN-<br>alpha-2a | JNJ-<br>6379+NA+PegI<br>FN-alpha-2a | + PegIFN-<br>alpha-2a |
|-----------------------------|-------------------------------------|--|-------------------------------------|-----------------------|
| Subject group type          | Subject analysis set                | Subject analysis set                   | Subject analysis set                | Subject analysis set  |
| Number of subjects analysed | 7                                   | 17                                     | 26                                  | 8                     |
| Units: participants         | 0                                   | 0                                      | 0                                   | 0                     |

|                             |   |  |  |  |
|-----------------------------|---|--|--|--|
| <b>End point values</b>     | FU: Cohort 2<br>(Per PA 6):<br>JNJ-3989 + NA<br>+ PegIFN-<br>alpha-2a |  |  |  |
| Subject group type          | Subject analysis set  |  |  |  |
| Number of subjects analysed | 17  |  |  |  |
| Units: participants         | 0   |  |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Participants With Worst Treatment-emergent Abnormalities in Vital Signs

|                 |   |
|-----------------|---|
| End point title | Number of Participants With Worst Treatment-emergent Abnormalities in Vital Signs |
|-----------------|---|

End point description:

Number of participants with worst treatment-emergent abnormalities in vital signs were reported. Treatment-emergent abnormality was defined as the abnormalities that were worsened as compared to the abnormality at baseline; which also included the shift from abnormally high to abnormally low and vice-versa. Abnormalities in vital signs included abnormal pulse rate (PR); abnormally low,  $\leq 45$  bpm and abnormally high  $\geq 120$  bpm; diastolic blood pressure (DBP) abnormally low  $\leq 50$  mmHg, systolic blood pressure (SBP) abnormally low  $\leq 90$  mmHg. Additionally, abnormal low SBP and DBP were  $\leq 50$  mmHg and  $< +90$  mmHg. Only those categories in which at least one participant had data were reported.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

IP: From Day 1 up to end of IP (up to Week 36 per PA 5; up to Week 52 prior to PA 5); CP: CP Week 1 up to CP Week 12; FU phase: FU Week 1 up to FU Week 48

|                             |   |   |   |   |
|-----------------------------|---|---|---|---|
| <b>End point values</b>     | IP: Cohort 1(Prior PA 5):<br>JNJ-3989+JNJ-<br>6379+NA+PegI<br>FN-alpha-2a | IP: Cohort 1<br>(Per PA 5):<br>JNJ-3989 + NA<br>+ PegIFN-<br>alpha-2a | IP:Cohort 2(Per PA 6):<br>JNJ-<br>3989+NA+PegI<br>FN-alpha-2a | CP:Cohort 1(Prior PA 5):JNJ-<br>3989+JNJ-<br>6379+NA+PegI |
| Subject group type          | Subject analysis set  | Subject analysis set  | Subject analysis set  | Subject analysis set                                      |
| Number of subjects analysed | 26  | 8   | 19  | 25  |
| Units: participants         |   |   |   |   |
| DBP: High:                  | 3   | 1   | 1   | 1   |

|                  |   |   |   |   |
|------------------|---|---|---|---|
| SBP: Low         | 0 | 1 | 0 | 1 |
| SBP: High        | 2 | 1 | 3 | 1 |
| Pulse rate: High | 0 | 1 | 0 | 0 |

| End point values            | CP: Cohort 1(Per PA 5): JNJ-3989+NA+ PegIFN-alpha-2a | CP: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a | FU: Cohort 1: JNJ-3989+ JNJ-6379+NA+PegIFN-alpha-2a | FU: Cohort 1: JNJ-3989 + NA + PegIFN-alpha-2a |
|-----------------------------|--|--|---|---|
| Subject group type          | Subject analysis set                                 | Subject analysis set                                     | Subject analysis set                                | Subject analysis set                          |
| Number of subjects analysed | 7  | 17   | 26  | 8   |
| Units: participants         |  |  |   |   |
| DBP: High:                  | 0  | 1  | 1   | 1   |
| SBP: Low                    | 1  | 1  | 1   | 0   |
| SBP: High                   | 0  | 0  | 2   | 1   |
| Pulse rate: High            | 0  | 1  | 0   | 0   |

| End point values            | FU: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a |  |  |  |
|-----------------------------|--|--|--|--|
| Subject group type          | Subject analysis set                                     |  |  |  |
| Number of subjects analysed | 17   |  |  |  |
| Units: participants         |  |  |  |  |
| DBP: High:                  | 0  |  |  |  |
| SBP: Low                    | 0  |  |  |  |
| SBP: High                   | 1  |  |  |  |
| Pulse rate: High            | 0  |  |  |  |

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Participants With Clinically Important Abnormalities in Physical Examination

|                 |  |
|-----------------|--|
| End point title | Number of Participants With Clinically Important Abnormalities in Physical Examination |
|-----------------|--|

End point description:

Number of participants with clinically important abnormalities in physical examination were reported. Safety analysis was based on safety analysis set which included all participants who received at least one dose of study intervention and were analysed according to the study intervention they actually received.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

IP: From Day 1 up to end of IP (up to Week 36 per PA 5; up to Week 52 prior to

| End point values            | IP: Cohort 1(Prior PA 5): JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a | IP: Cohort 1 (Per PA 5): JNJ-3989 + NA + PegIFN-alpha-2a | IP:Cohort 2(Per PA 6): JNJ-3989+NA+PegIFN-alpha-2a | CP:Cohort 1(Prior PA 5):JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a |
|-----------------------------|--|--|--|--|
| Subject group type          | Subject analysis set   | Subject analysis set                                     | Subject analysis set                               | Subject analysis set   |
| Number of subjects analysed | 27   | 8  | 19   | 25   |
| Units: participants         | 0  | 0  | 0  | 0  |

| End point values            | CP: Cohort 1(Per PA 5): JNJ-3989+NA+PegIFN-alpha-2a | CP: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a | FU: Cohort 1: JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a | FU: Cohort 1: JNJ-3989 + NA + PegIFN-alpha-2a |
|-----------------------------|---|--|--|---|
| Subject group type          | Subject analysis set                                | Subject analysis set                                     | Subject analysis set                               | Subject analysis set                          |
| Number of subjects analysed | 7   | 17   | 26   | 8   |
| Units: participants         | 0   | 0  | 0  | 0   |

| End point values            | FU: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a |  |  |  |
|-----------------------------|--|--|--|--|
| Subject group type          | Subject analysis set                                     |  |  |  |
| Number of subjects analysed | 17   |  |  |  |
| Units: participants         | 0  |  |  |  |

### Statistical analyses

No statistical analyses for this end point

### Secondary: Percentage of Participants Who Reached HBsAg Less Than (<) 10 (International Units Per Milliliter [IU/mL]) at the End of the Induction Phase (EOI)

|                 |  |
|-----------------|--|
| End point title | Percentage of Participants Who Reached HBsAg Less Than (<) 10 (International Units Per Milliliter [IU/mL]) at the End of the Induction Phase (EOI) |
|-----------------|--|

End point description:

Percentage of participants who reached HBsAg <10 IU/mL at the end induction phase were reported. Treated analysis set included all participants who received at least 1 dose of study treatment within this Intervention-specific appendix (ISA). Here, "n"(number analysed) signifies participants who were evaluable at specified timepoints. Data for this endpoint were planned to be collected and analysed for IP only. Here, 99999 signifies that no participant was available for the analysis.

|  |           |
|--|-----------|
| End point type   | Secondary |
| End point timeframe:   |           |
| At IP Week 36 and EOI; anytime up to IP Week 36 (after PA 5) or up to IP Week 52 (prior to PA 5) |           |

|                                      |  |  |  |  |
|--------------------------------------|--|--|--|--|
| <b>End point values</b>              | IP: Cohort 1(Prior PA 5): JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a | IP: Cohort 1 (Per PA 5): JNJ-3989 + NA + PegIFN-alpha-2a | IP:Cohort 2(Per PA 6): JNJ-3989+NA+PegIFN-alpha-2a |  |
| Subject group type                   | Subject analysis set   | Subject analysis set                                     | Subject analysis set                               |  |
| Number of subjects analysed          | 26   | 7  | 19   |  |
| Units: percentage of participants    |  |  |  |  |
| number (not applicable)              |  |  |  |  |
| IP Week 36 (n=13, 0, 1)              | 0  | 99999  | 10   |  |
| End of Induction phase (n=26, 7, 19) | 15.4   | 37.5   | 10.5   |  |

### Statistical analyses

No statistical analyses for this end point

### Secondary: Time to Achieve First Occurrence of HBsAg <10 IU/mL

|   |   |
|---|---|
| End point title   | Time to Achieve First Occurrence of HBsAg <10 IU/mL |
| End point description:  |   |
| Time to achieve first occurrence of HBsAg <10 IU/mL] were reported. Time to HBsAg <10 IU/mL was defined as the number of days between the date of first study treatment intake and the date of the first occurrence of HBsAg <10 IU/mL. Kaplan-Meier method was used for the estimation. Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA. Here, 99999 signifies that upper limit and lower limit of CI was not estimable due to insufficient number of participants with events. |   |
| End point type  | Secondary   |
| End point timeframe:  |   |
| From Baseline (Day 1 of IP) to Follow up Week 48  |   |

|                                  |   |   |   |  |
|----------------------------------|---|---|---|--|
| <b>End point values</b>          | Cohort 1 (Prior PA 5): JNJ-3989+JNJ-6379+NA + PegIFN-alpha-2a | Cohort 1 (Per PA 5): JNJ-3989+ NA + PegIFN-alpha-2a | Cohort 2 (Per PA 6): JNJ-3989+ NA + PegIFN-alpha-2a |  |
| Subject group type               | Reporting group   | Reporting group                                     | Reporting group                                     |  |
| Number of subjects analysed      | 27  | 8   | 19  |  |
| Units: weeks                     |   |   |   |  |
| median (confidence interval 90%) | 48.1 (-99999 to 99999)  | 84.3 (2.1 to 99999)                                 | 48.3 (36.1 to 99999)                                |  |

## Statistical analyses

No statistical analyses for this end point

### Secondary: FU Phase: Percentage of Participants With HBsAg Seroclearance 48 Weeks After

#### Stopping All Study Interventions of the Consolidation Phase and Without Restarting NA Treatment During Follow up Phase

|  |  |
|--|--|
| End point title  | FU Phase: Percentage of Participants With HBsAg Seroclearance 48 Weeks After<br>Stopping All Study Interventions of the Consolidation Phase and Without Restarting NA Treatment During Follow up Phase |
| End point description:<br>Percentage of participants with HBsAg seroclearance 48 weeks after stopping all study interventions at the consolidation phase and without restarting NA treatment during follow up phase were reported. HBsAg seroclearance was defined as (quantitative) HBsAg < LLOQ (HBsAg 0.05 IU/mL). Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA. Here "N" (Number of participants analysed) signifies the number of participants that were evaluable for this endpoint. |  |
| End point type   | Secondary  |
| End point timeframe:<br>FU phase Week 48   |  |

| End point values                  | FU: Cohort 1:<br>JNJ-3989+<br>JNJ-<br>6379+NA+PegIFN-alpha-2a | FU: Cohort 1:<br>JNJ-3989 + NA<br>+ PegIFN-<br>alpha-2a | FU: Cohort 2<br>(Per PA 6):<br>JNJ-3989 + NA<br>+ PegIFN-<br>alpha-2a |  |
|-----------------------------------|---|---|---|--|
| Subject group type                | Subject analysis set  | Subject analysis set                                    | Subject analysis set  |  |
| Number of subjects analysed       | 26  | 6   | 17  |  |
| Units: percentage of participants |   |   |   |  |
| number (not applicable)           | 11.5  | 16.7  | 11.8  |  |

## Statistical analyses

No statistical analyses for this end point

### Secondary: FU Phase: Percentage of Participants With Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) <LLOQ 48 Weeks After Stopping All Study Interventions of the Consolidation Phase and Without Restarting NA Treatment During Follow up Phase

|                 |   |
|-----------------|---|
| End point title | FU Phase: Percentage of Participants With Hepatitis B Virus |
|-----------------|---|

## End point description:

Percentage of participants with HBV DNA <LLOQ (<20 IU/mL) 48 weeks after stopping all study interventions of the consolidation phase and without restarting NA treatment during follow up phase were reported. Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA. Here "N" (Number of participants analysed) signifies the number of participants that were evaluable for this endpoint. Here, N=0 signifies that data were not collected and analysed for participants who stopped NA at the end of treatment.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

FU phase: FU Week 1 up to FU Week 48

| End point values                  | FU: Cohort 1:<br>JNJ-3989+<br>JNJ-<br>6379+NA+PegI<br>FN-alpha-2a | FU: Cohort 1:<br>JNJ-3989 + NA<br>+ PegIFN-<br>alpha-2a | FU: Cohort 2<br>(Per PA 6):<br>JNJ-3989 + NA<br>+ PegIFN-<br>alpha-2a |  |
|-----------------------------------|---|---|---|--|
| Subject group type                | Subject analysis set  | Subject analysis set                                    | Subject analysis set  |  |
| Number of subjects analysed       | 0 <sup>[6]</sup>  | 0 <sup>[7]</sup>  | 1   |  |
| Units: percentage of participants |   |   |   |  |
| number (not applicable)           |   |   | 0   |  |

Notes:

[6] - N=0 signifies data were not collected & analysed for participants who stopped NA at end of treatment

[7] - N=0 signifies data were not collected & analysed for participants who stopped NA at end of treatment

**Statistical analyses**

No statistical analyses for this end point

**Secondary: Percentage of Participants Who Met Nucleos(t)Ide Analog (NA)  
Treatment Completion  
Criteria at the End of Consolidation Phase**

|                 |  |
|-----------------|--|
| End point title | Percentage of Participants Who Met Nucleos(t)Ide Analog (NA)<br>Treatment Completion<br>Criteria at the End of Consolidation Phase |
|-----------------|--|

End point description:

Percentage of participants meeting the protocol-defined NA treatment completion criteria at EOC were reported. NA treatment completion criteria at CP Week 12 was defined as HBsAg <10 IU/mL; HBeAg-negative; HBV DNA <20 IU/mL, that is, lower limit of quantification (LLOQ); alanine aminotransferase(ALT) <3\*ULN. Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA. Here "N" (Number of participants analysed) signifies participants who were evaluable for this endpoint.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

At CP Week 12

| End point values                  | CP: Cohort 1 (Prior PA 5): JNJ-3989+JNJ-6379+NA+PegI | CP: Cohort 1 (Per PA 5): JNJ-3989+NA+ PegIFN-alpha-2a | CP: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a |  |
|-----------------------------------|--|---|--|--|
| Subject group type                | Subject analysis set                                 | Subject analysis set                                  | Subject analysis set                                     |  |
| Number of subjects analysed       | 25   | 7   | 16   |  |
| Units: percentage of participants |  |   |  |  |
| number (not applicable)           | 0  | 0   | 5.9  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: FU Phase: Number of Participants with Off-treatment Virologic HBV Flares During Follow up Phase

|   |   |
|---|---|
| End point title   | FU Phase: Number of Participants with Off-treatment Virologic HBV Flares During Follow up Phase |
| End point description:  |   |
| <p>Number of participants with off-treatment virologic HBV flares were reported. Virologic flare was defined as confirmed HBV DNA &gt;peak threshold (lowest peak to qualify as virologic flare was HBV DNA &gt;200 IU/mL) in participants who were off-treatment and had HBV DNA &lt;LLOQ (&lt;20 IU/mL) at the last observed time point on all study treatments. The 3 thresholds of virologic flare was 20,000 IU/mL, 2,000 IU/mL and 200 IU/mL. Confirmed means that the criteria was fulfilled at 2 or more consecutive time points or at the last observed time point. Off-treatment was defined as the time period after stopping all study treatments (including NA). Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA. Here "N" (Number of participants analysed) signifies the number of participants that were evaluable for this endpoint. Here, N=0 signifies that data were not collected and analysed for participants who stopped NA at the end of treatment.</p> |   |
| End point type  | Secondary   |
| End point timeframe:  |   |
| FU phase: FU Week 1 up to FU Week 48  |   |

| End point values            | FU: Cohort 1: JNJ-3989+ JNJ-6379+NA+PegI FN-alpha-2a | FU: Cohort 1: JNJ-3989 + NA + PegIFN-alpha-2a | FU: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a |  |
|-----------------------------|--|---|--|--|
| Subject group type          | Subject analysis set                                 | Subject analysis set                          | Subject analysis set                                     |  |
| Number of subjects analysed | 0 <sup>[8]</sup>                                     | 0 <sup>[9]</sup>                              | 1  |  |
| Units: participants         |  |   | 0  |  |

Notes:

[8] - N=0 signifies data were not collected & analysed for participants who stopped NA at end of treatment

[9] - N=0 signifies data were not collected & analysed for participants who stopped NA at end of treatment

## Statistical analyses

No statistical analyses for this end point

## Secondary: FU Phase: Number of Participants with Off-treatment Biochemical HBV Flares During



## Follow-up Phase

|   |   |
|---|---|
| End point title   | FU Phase: Number of Participants with Off-treatment Biochemical HBV Flares During Follow-up Phase |
| End point description:<br>Number of participants with off-treatment biochemical HBV flares were reported. Biochemical flare was defined as first date of 2 consecutive visits with confirmed ALT and/or AST $\geq 3 \times \text{ULN}$ and $\geq 3 \times \text{nadir}$ (lowest value observed up to start of flare). Confirmed means that the criteria was fulfilled at 2 or more consecutive time points or at the last observed time point. Off-treatment was defined as the time period after stopping all study treatments (including NA). Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA. Here "N" (Number of participants analysed) signifies the number of participants that were evaluable for this endpoint. Here, N=0 signifies that data were not collected and analysed for participants who stopped NA at the end of treatment. |   |
| End point type  | Secondary   |
| End point timeframe:<br>FU phase: FU Week 1 up to FU Week 48  |   |

| End point values            | FU: Cohort 1: JNJ-3989+ JNJ-6379+NA+PegIFN-alpha-2a | FU: Cohort 1: JNJ-3989 + NA + PegIFN-alpha-2a | FU: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a |  |
|-----------------------------|---|---|--|--|
| Subject group type          | Subject analysis set                                | Subject analysis set                          | Subject analysis set                                     |  |
| Number of subjects analysed | 0 <sup>[10]</sup>                                   | 0 <sup>[11]</sup>                             | 1  |  |
| Units: participants         |   |   | 0  |  |

Notes:

[10] - N=0 signifies data were not collected & analysed for participants who stopped NA at end of treatment

[11] - N=0 signifies data were not collected & analysed for participants who stopped NA at end of treatment

## Statistical analyses

No statistical analyses for this end point

## Secondary: FU Phase: Number of Participants With On-treatment Biochemical Flares During Follow-up Phase

|   |  |
|---|--|
| End point title   | FU Phase: Number of Participants With On-treatment Biochemical Flares During Follow-up Phase |
| End point description:<br>Number of participants with on-treatment biochemical HBV flares were reported. Biochemical flare was defined as first date of 2 consecutive visits with confirmed ALT and/or AST $\geq 3 \times \text{ULN}$ and $\geq 3 \times \text{nadir}$ (lowest value observed up to start of flare). Confirmed means that the criteria was fulfilled at 2 or more consecutive time points or at the last observed time point. On-treatment was defined as the time period during which the participant received any of the study drugs. Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA. |  |
| End point type  | Secondary  |
| End point timeframe:<br>FU phase: FU Week 1 up to FU Week 48  |  |

| End point values            | FU: Cohort 1:<br>JNJ-3989+<br>JNJ-<br>6379+NA+PegIFN-alpha-2a | FU: Cohort 1:<br>JNJ-3989 + NA<br>+ PegIFN-<br>alpha-2a | FU: Cohort 2<br>(Per PA 6):<br>JNJ-3989 + NA<br>+ PegIFN-<br>alpha-2a |  |
|-----------------------------|---|---|---|--|
| Subject group type          | Subject analysis set  | Subject analysis set                                    | Subject analysis set  |  |
| Number of subjects analysed | 26  | 8   | 17  |  |
| Units: participants         | 2   | 0   | 2   |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: FU Phase: Number of Participants With Off-treatment Clinical Flares During Follow-up Phase

|                 |  |
|-----------------|--|
| End point title | FU Phase: Number of Participants With Off-treatment Clinical Flares During Follow-up Phase |
|-----------------|--|

End point description:

Clinical flares occurred either when a virologic flare (confirmed HBV DNA >peak threshold) & biochemical flare (ALT and/or AST  $\geq 3 \times \text{ULN}$  &  $\geq 3 \times \text{nadir}$  [lowest value observed during off-treatment period up to time point of meeting the flare criteria]) overlapped in time or when a biochemical flare started within 4 weeks following the end of a virologic flare. The HBV DNA thresholds were: 20,000 IU/mL, 2,000 IU/mL and 200 IU/mL. Confirmed means that criteria was fulfilled at 2 or more consecutive time points or at last observed time point. Off-treatment was defined as time period after stopping all study drugs (including NA). The start date of a clinical flare was minimum start date of virologic flare and biochemical flare. Treated analysis set was used. Here "N" (Number of participants analysed) signifies the number of participants that were evaluable for this endpoint. Here, N=0 signifies that data were not collected and analysed for participants who stopped NA at the end of treatment.

|                                      |           |
|--------------------------------------|-----------|
| End point type                       | Secondary |
| End point timeframe:                 |           |
| FU phase: FU Week 1 up to FU Week 48 |           |

| End point values            | FU: Cohort 1:<br>JNJ-3989+<br>JNJ-<br>6379+NA+PegIFN-alpha-2a | FU: Cohort 1:<br>JNJ-3989 + NA<br>+ PegIFN-<br>alpha-2a | FU: Cohort 2<br>(Per PA 6):<br>JNJ-3989 + NA<br>+ PegIFN-<br>alpha-2a |  |
|-----------------------------|---|---|---|--|
| Subject group type          | Subject analysis set  | Subject analysis set                                    | Subject analysis set  |  |
| Number of subjects analysed | 0 <sup>[12]</sup>   | 0 <sup>[13]</sup>                                       | 1   |  |
| Units: participants         |   |   | 0   |  |

Notes:

[12] - N=0 signifies data were not collected & analysed for participants who stopped NA at end of treatment

[13] - N=0 signifies data were not collected & analysed for participants who stopped NA at end of treatment

## Statistical analyses

No statistical analyses for this end point

**Secondary: FU phase: Percentage of Participants Who Achieved Reduction (Sustained) in HBsAg Response (Per Definition 1) at Follow-up Week 48**

|   |   |
|---|---|
| End point title   | FU phase: Percentage of Participants Who Achieved Reduction (Sustained) in HBsAg Response (Per Definition 1) at Follow-up Week 48 |
| End point description:<br>Percentage of participants with sustained (reduction) HBsAg response (per Definition 1) were reported. Sustained HBsAg response (definition 1) was defined as: For participants with FU Week 48 data: participants who had a >1 log10 decline from baseline in HBsAg and HBsAg <000 IU/mL at FU Week 48. For participants without FU Week 48 data: participants who had a HBsAg decline from baseline of >2 log10 at FU Week 24 or >1.5 log10 at FU Week 36 (most recent value used) and had HBsAg <1000 IU/mL at the last available timepoint. |   |
| End point type  | Secondary   |
| End point timeframe:<br>At FU Phase Week 48   |   |

| End point values                  | FU: Cohort 1: JNJ-3989+ JNJ-6379+NA+PegIFN-alpha-2a | FU: Cohort 1: JNJ-3989 + NA + PegIFN-alpha-2a | FU: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a |  |
|-----------------------------------|---|---|--|--|
| Subject group type                | Subject analysis set                                | Subject analysis set                          | Subject analysis set                                     |  |
| Number of subjects analysed       | 26  | 7   | 17   |  |
| Units: percentage of participants |   |   |  |  |
| number (not applicable)           | 53.85   | 57.1  | 70.6   |  |

**Statistical analyses**

No statistical analyses for this end point

**Secondary: FU Phase: Percentage of Participants Who Required NA Re-treatment During Follow-Up Phase**

|   |  |
|---|--|
| End point title   | FU Phase: Percentage of Participants Who Required NA Re-treatment During Follow-Up Phase |
| End point description:<br>Percentage of participants who required NA re-treatment during follow-up phase were reported. A responder was defined as a participant who met the criteria for NA re-treatment at any time during follow-up, for those participants who met the NA treatment completion criteria at any time during the study and actually stopped NA treatment. Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA. Here "N" (Number of participants analysed) signifies the number of participants that were evaluable for this endpoint. Here, N=0 signifies that data were not collected and analysed for participants who stopped NA at the end of treatment. |  |
| End point type  | Secondary  |
| End point timeframe:<br>FU phase: FU Week 1 up to FU Week 48  |  |

| End point values                  | FU: Cohort 1:<br>JNJ-3989+<br>JNJ-<br>6379+NA+PegIFN-alpha-2a | FU: Cohort 1:<br>JNJ-3989 + NA<br>+ PegIFN-<br>alpha-2a | FU: Cohort 2<br>(Per PA 6):<br>JNJ-3989 + NA<br>+ PegIFN-<br>alpha-2a |  |
|-----------------------------------|---|---|---|--|
| Subject group type                | Subject analysis set  | Subject analysis set                                    | Subject analysis set  |  |
| Number of subjects analysed       | 0 <sup>[14]</sup>   | 0 <sup>[15]</sup>                                       | 1   |  |
| Units: percentage of participants |   |   |   |  |
| number (not applicable)           |   |   | 0   |  |

Notes:

[14] - N=0 signifies data were not collected & analysed for participants who stopped NA at end of treatment

[15] - N=0 signifies data were not collected & analysed for participants who stopped NA at end of treatment

## Statistical analyses

No statistical analyses for this end point

## Secondary: Percentage of Participants Who Achieved Reduction (Sustained) in HBsAg Response (Per Definition 2) at Follow-up Week 48

|                 |   |
|-----------------|---|
| End point title | Percentage of Participants Who Achieved Reduction (Sustained) in HBsAg Response (Per Definition 2) at Follow-up Week 48 |
|-----------------|---|

End point description:

Percentage of participants with sustained (reduction) HBsAg response (per Definition 2) were reported. Sustained HBsAg response (per Definition 2) was defined as: for participants with a >1 log decline in HBsAg from baseline at last follow-up visit: Among the most recent three visits, the difference between log<sub>10</sub> HBsAg at 2 of 3 last visit and 1 of 3 last visit was <0.2, and the difference between log<sub>10</sub> HBsAg at 3 of 3 last visit and 1 of 3 last visit was <0.2. Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA. Here "N" (Number of participants analysed) signifies participants who were evaluable for this endpoint.

|                      |           |
|----------------------|-----------|
| End point type       | Secondary |
| End point timeframe: |           |
| At FU Phase Week 48  |           |

| End point values                  | FU: Cohort 1:<br>JNJ-3989+<br>JNJ-<br>6379+NA+PegIFN-alpha-2a | FU: Cohort 1:<br>JNJ-3989 + NA<br>+ PegIFN-<br>alpha-2a | FU: Cohort 2<br>(Per PA 6):<br>JNJ-3989 + NA<br>+ PegIFN-<br>alpha-2a |  |
|-----------------------------------|---|---|---|--|
| Subject group type                | Subject analysis set  | Subject analysis set                                    | Subject analysis set  |  |
| Number of subjects analysed       | 26  | 7   | 17  |  |
| Units: percentage of participants |   |   |   |  |
| number (not applicable)           | 65.4  | 42.9  | 70.6  |  |

## Statistical analyses

No statistical analyses for this end point

### Secondary: Percentage of Participants Who Achieved Reduction (Sustained) in HBsAg Response (Per Definition 3) at Follow-up Week 48

|                 |   |
|-----------------|---|
| End point title | Percentage of Participants Who Achieved Reduction (Sustained) in HBsAg Response (Per Definition 3) at Follow-up Week 48 |
|-----------------|---|

End point description:

Percentage of participants with sustained (reduction) HBsAg response (per definition 3) were reported. Sustained HBsAg response (per Definition 3) was defined as: for participants with a >1 log decline in HBsAg from baseline at last follow-up visit: Among the most recent three visits, the difference between log10 HBsAg at 2 of 3 last visit and 1 of 3 last visit was <0.2, and the difference between log10 HBsAg at 3 of 3 last visit and 1 of 3 last visit was <0.2 and had an HBsAg <1000 IU/mL at the last available timepoint. Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA. Here "N" (Number of participants analysed) signifies participants who were evaluable for this endpoint.

|                            |           |
|----------------------------|-----------|
| End point type             | Secondary |
| End point timeframe:       |           |
| At Follow up Phase Week 48 |           |

| End point values                  | FU: Cohort 1: JNJ-3989+ JNJ-6379+NA+PegIFN-alpha-2a | FU: Cohort 1: JNJ-3989 + NA + PegIFN-alpha-2a | FU: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a |  |
|-----------------------------------|---|---|--|--|
| Subject group type                | Subject analysis set                                | Subject analysis set                          | Subject analysis set                                     |  |
| Number of subjects analysed       | 26  | 7   | 17   |  |
| Units: percentage of participants |   |   |  |  |
| number (not applicable)           | 42.3  | 28.6  | 52.9   |  |

## Statistical analyses

No statistical analyses for this end point

### Secondary: Percentage of Participants Who Achieved Reduction (Sustained) in HBsAg Response (Per Definition 4) at Follow-up Week 48

|                 |   |
|-----------------|---|
| End point title | Percentage of Participants Who Achieved Reduction (Sustained) in HBsAg Response (Per Definition 4) at Follow-up Week 48 |
|-----------------|---|

End point description:

Percentage of participants with sustained (reduction) HBsAg response per Definition 4 were reported. Sustained HBsAg response (per Definition 4) was defined as stable level, decreasing level, and increasing level. Stable level: when HBsAg change from consolidation week 12 to last available follow-up timepoint was within 0.2 log10. Decreasing level: when HBsAg change from consolidation week 12 to last available follow-up timepoint was less than -0.2 log10. Increasing level: when HBsAg change from consolidation week 12 to last available follow-up timepoint was more than 0.2 log10. Treated analysis set included all participants who received at least 1 dose of study

treatment within this ISA. Here "N" (Number of participants analysed) signifies participants who were evaluable for this endpoint.

|                            |           |
|----------------------------|-----------|
| End point type             | Secondary |
| End point timeframe:       |           |
| At Follow up Phase Week 48 |           |

| End point values                  | FU: Cohort 1:<br>JNJ-3989+<br>JNJ-<br>6379+NA+PegI<br>FN-alpha-2a | FU: Cohort 1:<br>JNJ-3989 + NA<br>+ PegIFN-<br>alpha-2a | FU: Cohort 2<br>(Per PA 6):<br>JNJ-3989 + NA<br>+ PegIFN-<br>alpha-2a |  |
|-----------------------------------|---|---|---|--|
| Subject group type                | Subject analysis set  | Subject analysis set                                    | Subject analysis set  |  |
| Number of subjects analysed       | 26  | 7   | 17  |  |
| Units: percentage of participants |   |   |   |  |
| number (not applicable)           |   |   |   |  |
| Stable: within +/-0.2 log10 IU/mL | 0   | 14.3  | 11.8  |  |
| Decreased: <0.2 log10 IU/mL       | 19.2  | 14.3  | 17.6  |  |
| Increased: > +0.2 log10 IU/mL     | 76.9  | 71.4  | 70.6  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Percentage of Participants With HBsAg Seroclearance at Follow-up Week 48

|                 |  |
|-----------------|--|
| End point title | Percentage of Participants With HBsAg Seroclearance at Follow-up Week 48 |
|-----------------|--|

End point description:

Percentage of Participants with HBsAg Seroclearance were reported. HBsAg seroclearance was defined as (quantitative) HBsAg level <LLOQ (<0.05 IU/mL). Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA. Here "N" (Number of participants analysed) signifies participants who were evaluable for this endpoint.

|                      |           |
|----------------------|-----------|
| End point type       | Secondary |
| End point timeframe: |           |
| At Follow up Week 48 |           |

| End point values                  | FU: Cohort 1:<br>JNJ-3989+<br>JNJ-<br>6379+NA+PegI<br>FN-alpha-2a | FU: Cohort 1:<br>JNJ-3989 + NA<br>+ PegIFN-<br>alpha-2a | FU: Cohort 2<br>(Per PA 6):<br>JNJ-3989 + NA<br>+ PegIFN-<br>alpha-2a |  |
|-----------------------------------|---|---|---|--|
| Subject group type                | Subject analysis set  | Subject analysis set                                    | Subject analysis set  |  |
| Number of subjects analysed       | 26  | 6   | 17  |  |
| Units: percentage of participants |   |   |   |  |
| number (not applicable)           | 11.5  | 16.7  | 11.8  |  |

## Statistical analyses

No statistical analyses for this end point

### Secondary: Percentage of Participants with HBeAg Seroclearance at Follow-up Week 48

|                 |  |
|-----------------|--|
| End point title | Percentage of Participants with HBeAg Seroclearance at Follow-up Week 48 |
|-----------------|--|

End point description:

Percentage of participants with HBeAg seroclearance were reported. HBeAg seroclearance was defined as (quantitative) HBeAg levels <LLOQ (<0.11 IU/mL). Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA. Here "N" (Number of participants analysed) signifies the number of participants that were evaluable for this endpoint.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

At Follow up Week 48

| End point values                  | FU: Cohort 1:<br>JNJ-3989+<br>JNJ-<br>6379+NA+PegI<br>FN-alpha-2a | FU: Cohort 1:<br>JNJ-3989 + NA<br>+ PegIFN-<br>alpha-2a | FU: Cohort 2<br>(Per PA 6):<br>JNJ-3989 + NA<br>+ PegIFN-<br>alpha-2a |  |
|-----------------------------------|---|---|---|--|
| Subject group type                | Subject analysis set  | Subject analysis set                                    | Subject analysis set  |  |
| Number of subjects analysed       | 25  | 6   | 17  |  |
| Units: percentage of participants |   |   |   |  |
| number (not applicable)           | 28.0  | 33.3  | 17.6  |  |

## Statistical analyses

No statistical analyses for this end point

### Secondary: Percentage of Participants with HBsAg Seroconversion

|                 |  |
|-----------------|--|
| End point title | Percentage of Participants with HBsAg Seroconversion |
|-----------------|--|

End point description:

Seroconversion of HBsAg was defined as having achieved HBsAg seroclearance (defined as quantitative HBsAg <LLOQ [<0.05 IU/mL]) and appearance of anti-HBs antibodies (defined as a baseline anti-HBs antibodies [quantitative] <LLOQ [<5 milli-international units per milliliter (mIU/mL)] and a post-baseline assessment  $\geq$  LLOQ [ $\geq$  5 mIU/mL]). Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA. Here "N" (Number of participants analysed) signifies participants who were evaluable for this endpoint and "n" (number analysed) signifies participants evaluable at specified timepoints and n=0, and 99999 signify that data were not collected and analysed as that timepoint was not applicable to the respective arm.

|  |           |
|--|-----------|
| End point type                             | Secondary |
| End point timeframe:                       |           |
| IP Week 24; CP: Week 12, FU phase: Week 48 |           |

| End point values                                 | IP: Cohort 1(Prior PA 5): JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a | IP: Cohort 1 (Per PA 5): JNJ-3989 + NA + PegIFN-alpha-2a | IP:Cohort 2(Per PA 6): JNJ-3989+NA+PegIFN-alpha-2a | CP:Cohort 1(Prior PA 5):JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a |
|--|--|--|--|--|
| Subject group type                               | Subject analysis set   | Subject analysis set                                     | Subject analysis set                               | Subject analysis set   |
| Number of subjects analysed                      | 25   | 7  | 15   | 24   |
| Units: percentage of participants                |  |  |  |  |
| number (not applicable)                          |  |  |  |  |
| IP: Week 24 (n=25, 7, 15, 0, 0, 0, 0, 0, 0)      | 0  | 0  | 0  | 99999  |
| CP: Week 12 (n=0, 0, 0, 24,6,15, 0, 0, 0)        | 99999  | 99999  | 99999  | 8.3  |
| FU phase Week 48 (n=0, 0, 0, 0, 0, 0, 25, 7, 15) | 99999  | 99999  | 99999  | 99999  |

| End point values                                 | CP: Cohort 1(Per PA 5): JNJ-3989+NA+ PegIFN-alpha-2a | CP: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a | FU: Cohort 1: JNJ-3989+ JNJ-6379+NA+PegIFN-alpha-2a | FU: Cohort 1: JNJ-3989 + NA + PegIFN-alpha-2a |
|--|--|--|---|---|
| Subject group type                               | Subject analysis set                                 | Subject analysis set                                     | Subject analysis set                                | Subject analysis set                          |
| Number of subjects analysed                      | 6  | 15   | 25  | 7   |
| Units: percentage of participants                |  |  |   |   |
| number (not applicable)                          |  |  |   |   |
| IP: Week 24 (n=25, 7, 15, 0, 0, 0, 0, 0, 0)      | 99999  | 99999  | 99999   | 99999   |
| CP: Week 12 (n=0, 0, 0, 24,6,15, 0, 0, 0)        | 33.3   | 6.7  | 99999   | 99999   |
| FU phase Week 48 (n=0, 0, 0, 0, 0, 0, 25, 7, 15) | 99999  | 99999  | 12.0  | 99999   |

| End point values                            | FU: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a |  |  |  |
|---|--|--|--|--|
| Subject group type                          | Subject analysis set                                     |  |  |  |
| Number of subjects analysed                 | 15   |  |  |  |
| Units: percentage of participants           |  |  |  |  |
| number (not applicable)                     |  |  |  |  |
| IP: Week 24 (n=25, 7, 15, 0, 0, 0, 0, 0, 0) | 99999  |  |  |  |
| CP: Week 12 (n=0, 0, 0, 24,6,15, 0, 0, 0)   | 99999  |  |  |  |



|  |     |  |  |  |
|--|-----|--|--|--|
| FU phase Week 48 (n=0, 0, 0, 0, 0, 0, 25, 7, 15) | 6.7 |  |  |  |
|--|-----|--|--|--|

## Statistical analyses

No statistical analyses for this end point

## Secondary: Percentage of Participants with HBeAg Seroconversion

|                 |  |
|-----------------|--|
| End point title | Percentage of Participants with HBeAg Seroconversion |
|-----------------|--|

End point description:

Percentage of participants with HBeAg seroconversion were reported.

Seroconversion of HBeAg was defined as having achieved HBeAg seroclearance (defined as [quantitative] HBeAg <LLOQ [ $<0.11$  IU/mL]) together with appearance of anti-HBe antibodies (defined as a baseline anti-HBe antibodies [qualitative] with a "negative" result and a post-baseline assessment with "positive" result). Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA. Data were planned to be collected and analysed for CP and FU phase only. Here, n=0, and 99999 signify that data were not collected and analysed as that timepoint was not applicable to the respective arm.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

CP: Week 12; FU phase: FU Week 48

| End point values                        | CP: Cohort 1 (Prior PA 5): JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a | CP: Cohort 1 (Per PA 5): JNJ-3989+NA+PegIFN-alpha-2a | CP: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a | FU: Cohort 1: JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a |
|---|---|--|--|--|
| Subject group type                      | Subject analysis set  | Subject analysis set                                 | Subject analysis set                                     | Subject analysis set                               |
| Number of subjects analysed             | 21  | 6  | 11   | 22   |
| Units: percentage of participants       |   |  |  |  |
| number (not applicable)                 |   |  |  |  |
| CP: Week 12 (n=21, 6, 11, 0, 0, 0)      | 0   | 16.7   | 9.1  | 99999  |
| FU phase week 48 (n=0, 0, 0, 22, 7, 11) | 99999   | 99999  | 99999  | 18.2   |

| End point values                        | FU: Cohort 1: JNJ-3989 + NA + PegIFN-alpha-2a | FU: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a |  |  |
|---|---|--|--|--|
| Subject group type                      | Subject analysis set                          | Subject analysis set                                     |  |  |
| Number of subjects analysed             | 7   | 11   |  |  |
| Units: percentage of participants       |   |  |  |  |
| number (not applicable)                 |   |  |  |  |
| CP: Week 12 (n=21, 6, 11, 0, 0, 0)      | 99999   | 99999  |  |  |
| FU phase week 48 (n=0, 0, 0, 22, 7, 11) | 20.0  | 27.3   |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change from baseline over time in HBsAg Levels

|                 |  |
|-----------------|--|
| End point title | Change from baseline over time in HBsAg Levels |
|-----------------|--|

End point description:

Change from baseline over time in HBsAg levels at specified timepoints were reported. Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA. Here "n"(number analysed) signifies participants evaluable at specified timepoints. Here, 99999 at IP Week 36 category for Cohort 2 (Per PA 6) signifies that standard deviation was not estimable as only 1 participant was analysed. Here, n=0, and 99999 signify that data were not collected and analysed as that timepoint was not applicable to the respective arm.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline (Day 1 of IP), IP: Week 36; CP: Week 12; FU phase: Week 48

| End point values                         | IP: Cohort 1(Prior PA 5): JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a | IP: Cohort 1 (Per PA 5): JNJ-3989 + NA + PegIFN-alpha-2a | IP:Cohort 2(Per PA 6): JNJ-3989+NA+PegIFN-alpha-2a | CP:Cohort 1(Prior PA 5):JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a |
|--|--|--|--|--|
| Subject group type                       | Subject analysis set   | Subject analysis set                                     | Subject analysis set                               | Subject analysis set   |
| Number of subjects analysed              | 27   | 8  | 19   | 25   |
| Units: log10 IU/mL                       |  |  |  |  |
| arithmetic mean (standard error)         |  |  |  |  |
| IP: Week 36 (n=13,0,1,0,0,0,0,0)         | -2.29 (± 0.211)  | 99999 (± 99999)  | -4.08 (± 99999)                                    | 99999 (± 99999)  |
| CP: Week 12(n=0,0,0,25,7,17,0,0,0)       | 99999 (± 99999)  | 99999 (± 99999)  | 99999 (± 99999)                                    | -3.51 (± 0.275)  |
| FU phase: Week 48(n=0,0,0,0,0,0,26,8,17) | 99999 (± 99999)  | 99999 (± 99999)  | 99999 (± 99999)                                    | 99999 (± 99999)  |

| End point values                 | CP: Cohort 1(Per PA 5): JNJ-3989+NA+ PegIFN-alpha-2a | CP: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a | FU: Cohort 1: JNJ-3989+ JNJ-6379+NA+PegIFN-alpha-2a | FU: Cohort 1: JNJ-3989 + NA + PegIFN-alpha-2a |
|----------------------------------|--|--|---|---|
| Subject group type               | Subject analysis set                                 | Subject analysis set                                     | Subject analysis set                                | Subject analysis set                          |
| Number of subjects analysed      | 7  | 17   | 26  | 6   |
| Units: log10 IU/mL               |  |  |   |   |
| arithmetic mean (standard error) |  |  |   |   |
| IP: Week 36 (n=13,0,1,0,0,0,0,0) | 99999 (± 99999)                                      | 99999 (± 99999)  | 99999 (± 99999)                                     | 99999 (± 99999)                               |

|  |                 |                 |                 |                 |
|--|-----------------|-----------------|-----------------|-----------------|
| CP: Week 12(n=0,0,0,25,7,17,0,0,0)     | -4.17 (± 0.444) | -3.53 (± 0.285) | 99999 (± 99999) | 99999 (± 99999) |
| FU phase: Week 48(n=0,0,0,0,0,26,8,17) | 99999 (± 99999) | 99999 (± 99999) | -2.41 (± 0.364) | -3.14 (± 0.747) |

|  |  |  |  |  |
|--|--|--|--|--|
| <b>End point values</b>                | FU: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a |  |  |  |
| Subject group type                     | Subject analysis set                                     |  |  |  |
| Number of subjects analysed            | 17   |  |  |  |
| Units: log10 IU/mL                     |  |  |  |  |
| arithmetic mean (standard error)       |  |  |  |  |
| IP: Week 36 (n=13,0,1,0,0,0,0,0,0)     | 99999 (± 99999)  |  |  |  |
| CP: Week 12(n=0,0,0,25,7,17,0,0,0)     | 99999 (± 99999)  |  |  |  |
| FU phase: Week 48(n=0,0,0,0,0,26,8,17) | -2.82 (± 0.425)  |  |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change from baseline over time in HBeAg Levels

|                 |  |
|-----------------|--|
| End point title | Change from baseline over time in HBeAg Levels |
|-----------------|--|

End point description:

Change from baseline over time in HBeAg levels were reported. Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA. Here "N" (Number of participants analysed) signifies participants who were evaluable for this outcome measure and "n"(number analysed) signifies participants evaluable at specified timepoints. Here, 99999 at IP Week 36 category for Cohort 2 (Per PA 6) signifies that standard deviation was not estimable as only 1 participant was analysed. Here, "n"=number of subjects analysed at specified categories n=0, and 99999 signify that data were not collected and analysed as that timepoint was not applicable to the respective arm.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline (Day 1 of IP), IP: Week 36; CP: Week 12; FU phase: Week 48

|                                  |  |  |  |  |
|----------------------------------|--|--|--|--|
| <b>End point values</b>          | IP: Cohort 1(Prior PA 5): JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a | IP: Cohort 1 (Per PA 5): JNJ-3989 + NA + PegIFN-alpha-2a | IP:Cohort 2(Per PA 6): JNJ-3989+NA+PegIFN-alpha-2a | CP:Cohort 1(Prior PA 5):JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a |
| Subject group type               | Subject analysis set   | Subject analysis set                                     | Subject analysis set                               | Subject analysis set   |
| Number of subjects analysed      | 27   | 8  | 19   | 24   |
| Units: log10 IU/mL               |  |  |  |  |
| arithmetic mean (standard error) |  |  |  |  |

|  |                 |                 |                 |                 |
|--|-----------------|-----------------|-----------------|-----------------|
| IP: Week 36(n=12,0,1,0,0,0,0,0,0)        | -1.66 (± 0.159) | 99999 (± 99999) | -2.85 (± 99999) | 99999 (± 99999) |
| CP: Week 12(n=0,0,0,24,7,17,0,0,0)       | 99999 (± 99999) | 99999 (± 99999) | 99999 (± 99999) | -2.14 (± 0.146) |
| FU phase: Week 48(n=0,0,0,0,0,0,25,8,17) | 99999 (± 99999) | 99999 (± 99999) | 99999 (± 99999) | 99999 (± 99999) |

| End point values                         | CP: Cohort 1(Per PA 5): JNJ-3989+NA+ PegIFN-alpha-2a | CP: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a | FU: Cohort 1: JNJ-3989+ JNJ-6379+NA+PegIFN-alpha-2a | FU: Cohort 1: JNJ-3989 + NA + PegIFN-alpha-2a |
|--|--|--|---|---|
| Subject group type                       | Subject analysis set                                 | Subject analysis set                                     | Subject analysis set                                | Subject analysis set                          |
| Number of subjects analysed              | 7  | 17   | 25  | 8   |
| Units: log10 IU/mL                       |  |  |   |   |
| arithmetic mean (standard error)         |  |  |   |   |
| IP: Week 36(n=12,0,1,0,0,0,0,0,0)        | 99999 (± 99999)                                      | 99999 (± 99999)  | 99999 (± 99999)                                     | 99999 (± 99999)                               |
| CP: Week 12(n=0,0,0,24,7,17,0,0,0)       | -2.39 (± 0.162)                                      | -2.22 (± 0.234)  | 99999 (± 99999)                                     | 99999 (± 99999)                               |
| FU phase: Week 48(n=0,0,0,0,0,0,25,8,17) | 99999 (± 99999)                                      | 99999 (± 99999)  | -2.45 (± 0.243)                                     | -2.59 (± 0.508)                               |

| End point values                         | FU: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a |  |  |  |
|--|--|--|--|--|
| Subject group type                       | Subject analysis set                                     |  |  |  |
| Number of subjects analysed              | 17   |  |  |  |
| Units: log10 IU/mL                       |  |  |  |  |
| arithmetic mean (standard error)         |  |  |  |  |
| IP: Week 36(n=12,0,1,0,0,0,0,0,0)        | 99999 (± 99999)  |  |  |  |
| CP: Week 12(n=0,0,0,24,7,17,0,0,0)       | 99999 (± 99999)  |  |  |  |
| FU phase: Week 48(n=0,0,0,0,0,0,25,8,17) | -2.47 (± 0.278)  |  |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change from Baseline Over Time in HBV DNA Levels

|                 |  |
|-----------------|--|
| End point title | Change from Baseline Over Time in HBV DNA Levels |
|-----------------|--|

End point description:

Change from baseline over time in HBV DNA Levels were reported. Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA. Here "N" (Number of participants analysed) signifies participants who were evaluable for this outcome measure and "n"(number analysed) signifies participants

evaluable at specified timepoints. Here, 99999 at IP Week 36 category for Cohort 2 (Per PA 6) signifies that standard deviation was not estimable as only 1 participant was analysed. Here, "n"=number of subjects analysed at specified categories and n=0, and 99999 signify that data were not collected and analysed as that timepoint was not applicable to the respective arm.

|   |           |
|---|-----------|
| End point type  | Secondary |
| End point timeframe:  |           |
| Baseline (Day 1 of IP), IP: Week 36; CP: Week 12; FU phase: Week 48 |           |

| End point values                         | IP: Cohort 1(Prior PA 5): JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a | IP: Cohort 1 (Per PA 5): JNJ-3989 + NA + PegIFN-alpha-2a | IP:Cohort 2(Per PA 6): JNJ-3989+NA+PegIFN-alpha-2a | CP:Cohort 1(Prior PA 5):JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a |
|--|--|--|--|--|
| Subject group type                       | Subject analysis set   | Subject analysis set                                     | Subject analysis set                               | Subject analysis set   |
| Number of subjects analysed              | 27   | 8  | 19   | 25   |
| Units: log10 IU/mL                       |  |  |  |  |
| arithmetic mean (standard error)         |  |  |  |  |
| IP: Week 36 (n=14,0,1,0,0,0,0,0)         | -5.84 (± 0.427)  | 99999 (± 99999)  | -6.99 (± 99999)                                    | 99999 (± 99999)  |
| CP: Week 12(n=0,0,0,25,6,17,0,0,0)       | 99999 (± 99999)  | 99999 (± 99999)  | 99999 (± 99999)                                    | -6.29 (± 0.205)  |
| FU phase: Week 48(n=0,0,0,0,0,0,26,6,17) | 99999 (± 99999)  | 99999 (± 99999)  | 99999 (± 99999)                                    | 99999 (± 99999)  |

| End point values                         | CP: Cohort 1(Per PA 5): JNJ-3989+NA+ PegIFN-alpha-2a | CP: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a | FU: Cohort 1: JNJ-3989+ JNJ-6379+NA+PegIFN-alpha-2a | FU: Cohort 1: JNJ-3989 + NA + PegIFN-alpha-2a |
|--|--|--|---|---|
| Subject group type                       | Subject analysis set                                 | Subject analysis set                                     | Subject analysis set                                | Subject analysis set                          |
| Number of subjects analysed              | 6  | 17   | 26  | 8   |
| Units: log10 IU/mL                       |  |  |   |   |
| arithmetic mean (standard error)         |  |  |   |   |
| IP: Week 36 (n=14,0,1,0,0,0,0,0)         | 99999 (± 99999)                                      | 99999 (± 99999)  | 99999 (± 99999)                                     | 99999 (± 99999)                               |
| CP: Week 12(n=0,0,0,25,6,17,0,0,0)       | -6.30 (± 0.350)                                      | -6.07 (± 0.269)  | 99999 (± 99999)                                     | 99999 (± 99999)                               |
| FU phase: Week 48(n=0,0,0,0,0,0,26,6,17) | 99999 (± 99999)                                      | 99999 (± 99999)  | -6.79 (± 0.203)                                     | -5.95 (± 0.563)                               |

| End point values                 | FU: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a |  |  |  |
|----------------------------------|--|--|--|--|
| Subject group type               | Subject analysis set                                     |  |  |  |
| Number of subjects analysed      | 17   |  |  |  |
| Units: log10 IU/mL               |  |  |  |  |
| arithmetic mean (standard error) |  |  |  |  |

|  |                 |  |  |  |
|--|-----------------|--|--|--|
| IP: Week 36 (n=14,0,1,0,0,0,0,0)       | 99999 (± 99999) |  |  |  |
| CP: Week 12(n=0,0,0,25,6,17,0,0)       | 99999 (± 99999) |  |  |  |
| FU phase: Week 48(n=0,0,0,0,0,26,6,17) | -6.70 (± 0.257) |  |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Time to Achieve First HBsAg Seroclearance

|   |   |
|---|---|
| End point title   | Time to Achieve First HBsAg Seroclearance |
| End point description:<br>Time to achieve first HBsAg seroclearance (defined as quantitative HBsAg <LLOQ; HBsAg <0.05 IU/mL) were reported. Time to HBsAg seroclearance was defined as the number of days between the date of first study intervention intake and the date of the first occurrence of HBsAg seroclearance. Kaplan-Meier method was used for the estimation. Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA. Here "N" (Number of participants analysed) signifies participants who were evaluable for this endpoint. Here, 99999 signifies that that median [90% CI] data were not estimable due to low number of events. Per planned analysis data for this outcome measure was analysed per pooled cohorts only. |   |
| End point type  | Secondary                                 |
| End point timeframe:<br>From baseline (Day 1 of IP) to Follow up Week 48  |   |

| End point values                 | Cohort 1 (Prior PA 5): JNJ-3989+JNJ-6379+NA + PegIFN-alpha-2a | Cohort 1 (Per PA 5): JNJ-3989+ NA + PegIFN-alpha-2a | Cohort 2 (Per PA 6): JNJ-3989+ NA + PegIFN-alpha-2a |  |
|----------------------------------|---|---|---|--|
| Subject group type               | Reporting group   | Reporting group                                     | Reporting group                                     |  |
| Number of subjects analysed      | 27  | 8   | 19  |  |
| Units: weeks                     |   |   |   |  |
| median (confidence interval 90%) | 99999 (99999 to 99999)  | 99999 (6.1 to 99999)                                | 99999 (99999 to 99999)                              |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Time to Achieve First HBeAg Seroclearance

|   |   |
|---|---|
| End point title   | Time to Achieve First HBeAg Seroclearance |
| End point description:<br>Time to achieve first occurrence of HBeAg seroclearance (HBeAg <LLOQ [ $<0.11$ IU/mL]) were reported. Time to first occurrence of the HBeAg seroclearance was defined as the number of days between the date of first study intervention intake and |   |

the date of the first occurrence of the HBeAg seroclearance. Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA. Here "N" (Number of participants analysed) signifies participants who were evaluable for this endpoint. Per planned analysis data for this outcome measure was analysed per pooled cohorts only. Here, 99999 signifies that Median and upper interval of [90% CI] data were not estimable due to low number of events.

|  |           |
|--|-----------|
| End point type                                   | Secondary |
| End point timeframe:                             |           |
| From baseline (Day 1 of IP) to Follow up Week 48 |           |

| End point values                 | Cohort 1 (Prior PA 5): JNJ-3989+JNJ-6379+NA + PegIFN-alpha-2a | Cohort 1 (Per PA 5): JNJ-3989+ NA + PegIFN-alpha-2a | Cohort 2 (Per PA 6): JNJ-3989+ NA + PegIFN-alpha-2a |  |
|----------------------------------|---|---|---|--|
| Subject group type               | Reporting group   | Reporting group                                     | Reporting group                                     |  |
| Number of subjects analysed      | 27  | 8   | 19  |  |
| Units: weeks                     |   |   |   |  |
| median (confidence interval 90%) | 112 (96.1 to 99999)   | 100.3 (48.0 to 99999)                               | 99999 (59.1 to 99999)                               |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Time to Achieve First HBV DNA <LLOQ

|  |                                     |
|--|-------------------------------------|
| End point title  | Time to Achieve First HBV DNA <LLOQ |
| End point description:   |                                     |
| Time to achieve first occurrence of HBV DNA < LLOQ (<20 IU/mL) were reported. Time to first occurrence of the HBV DNA < LLOQ was defined as the number of days between the date of first study intervention intake and the date of the first occurrence of the HBV DNA < LLOQ. Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA. Here "N" (Number of participants analysed) signifies participants who were evaluable for this endpoint. Per planned analysis data for this outcome measure was analysed per pooled cohorts only. Here 99999 signifies upper interval of [90% CI] data were not estimable due to low number of events. |                                     |
| End point type   | Secondary                           |
| End point timeframe:   |                                     |
| From baseline (Day 1 of IP) to Follow up Week 48   |                                     |

| End point values            | Cohort 1 (Prior PA 5): JNJ-3989+JNJ-6379+NA + PegIFN-alpha-2a | Cohort 1 (Per PA 5): JNJ-3989+ NA + PegIFN-alpha-2a | Cohort 2 (Per PA 6): JNJ-3989+ NA + PegIFN-alpha-2a |  |
|-----------------------------|---|---|---|--|
| Subject group type          | Reporting group   | Reporting group                                     | Reporting group                                     |  |
| Number of subjects analysed | 27  | 8   | 19  |  |

|                                  |                     |                      |                     |  |
|----------------------------------|---------------------|----------------------|---------------------|--|
| Units: weeks                     |                     |                      |                     |  |
| median (confidence interval 90%) | 35.9 (28.1 to 52.1) | 53.3 (12.1 to 99999) | 38.1 (24.1 to 50.1) |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Percentage of participants with HBeAg Levels Below Different Cut-offs

|  |   |
|--|---|
| End point title  | Percentage of participants with HBeAg Levels Below Different Cut-offs |
| End point description:   |   |
| Percentage of participants with HBeAg levels below different cut-offs were reported. The cut-offs for HBeAg levels were : <LLOQ (<0.11 IU/mL), < 1 IU/mL, < 10 IU/mL, <100 IU/mL. Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA. Here "N" (Number of participants analysed) signifies participants who were evaluable for this endpoint. Here, n=0, and 99999 signify that data were not collected and analysed as that timepoint was not applicable to the respective arm. |   |
| End point type   | Secondary   |
| End point timeframe:   |   |
| IP: Week 36, CP: Week 12; FU phase: Week 48  |   |

| End point values                                  | IP: Cohort 1(Prior PA 5): JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a | IP: Cohort 1 (Per PA 5): JNJ-3989 + NA + PegIFN-alpha-2a | IP:Cohort 2(Per PA 6): JNJ-3989+NA+PegIFN-alpha-2a | CP:Cohort 1(Prior PA 5):JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a |
|---|--|--|--|--|
| Subject group type                                | Subject analysis set   | Subject analysis set                                     | Subject analysis set                               | Subject analysis set   |
| Number of subjects analysed                       | 26   | 8  | 19   | 24   |
| Units: percentage of participants                 |  |  |  |  |
| number (not applicable)                           |  |  |  |  |
| IP Week 36: <0.11 IU/mL(n=12,0,1,0,0,0,0,0,0)     | 8.3  | 99999  | 0  | 99999  |
| IP Week 36: <1 IU/mL (n=12,0,1,0,0,0,0,0,0)       | 25.0   | 99999  | 0  | 99999  |
| IP Week 36: <10 IU/mL(n=12,0,1,0,0,0,0,0,0)       | 50.0   | 99999  | 100.0  | 99999  |
| IP Week 36: <100 IU/mL(n=12,0,1,0,0,0,0,0,0)      | 100.0  | 99999  | 100.0  | 99999  |
| CP Week 12: <0.11 IU/mL (n=0, 0, 0,24,7,17,0,0,0) | 99999  | 99999  | 99999  | 12.5   |
| CP Week 12: <1 IU/mL(n=0, 0, 0,24,7,17,0,0,0)     | 99999  | 99999  | 99999  | 37.5   |
| CP Week 12: <10 IU/mL(n=0, 0, 0,24,7,17,0,0,0)    | 99999  | 99999  | 99999  | 75.0   |
| CP Week 12: <100 IU/mL(n=0, 0, 0,24,7,17,0,0,0)   | 99999  | 99999  | 99999  | 95.8   |
| FU Week 48: <0.11 IU/mL (n=0, 0, 0,0,0,0,25,6,17) | 99999  | 99999  | 99999  | 99999  |
| FU Week 48: <1 IU/mL(n=0, 0, 0,0,0,0,25,6,17)     | 99999  | 99999  | 99999  | 99999  |



|  |       |       |       |       |
|--|-------|-------|-------|-------|
| FU Week 48: <10 IU/mL(n=0, 0, 0,0,0,0,25,6,17) | 99999 | 99999 | 99999 | 99999 |
| FU Week 48: <100IU/mL(n=0, 0, 0,0,0,0,25,6,17) | 99999 | 99999 | 99999 | 99999 |

| End point values                                  | CP: Cohort 1(Per PA 5): JNJ-3989+NA+ PegIFN-alpha-2a | CP: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a | FU: Cohort 1: JNJ-3989+ JNJ-6379+NA+PegIFN-alpha-2a | FU: Cohort 1: JNJ-3989 + NA + PegIFN-alpha-2a |
|---|--|--|---|---|
| Subject group type                                | Subject analysis set                                 | Subject analysis set                                     | Subject analysis set                                | Subject analysis set                          |
| Number of subjects analysed                       | 7  | 17   | 25  | 8   |
| Units: percentage of participants                 |  |  |   |   |
| number (not applicable)                           |  |  |   |   |
| IP Week 36: <0.11 IU/mL(n=12,0,1,0,0,0,0,0)       | 99999  | 99999  | 99999   | 99999   |
| IP Week 36: <1 IU/mL (n=12,0,1,0,0,0,0,0)         | 99999  | 99999  | 99999   | 99999   |
| IP Week 36: <10 IU/mL(n=12,0,1,0,0,0,0,0)         | 99999  | 99999  | 99999   | 99999   |
| IP Week 36: <100 IU/mL(n=12,0,1,0,0,0,0,0)        | 99999  | 99999  | 99999   | 99999   |
| CP Week 12: <0.11 IU/mL (n=0, 0, 0,24,7,17,0,0,0) | 14.3   | 17.6   | 99999   | 99999   |
| CP Week 12: <1 IU/mL(n=0, 0, 0,24,7,17,0,0,0)     | 14.3   | 47.1   | 99999   | 99999   |
| CP Week 12: <10 IU/mL(n=0, 0, 0,24,7,17,0,0,0)    | 100.0  | 76.5   | 99999   | 99999   |
| CP Week 12: <100 IU/mL(n=0, 0, 0,24,7,17,0,0,0)   | 100.0  | 94.1   | 99999   | 99999   |
| FU Week 48: <0.11 IU/mL (n=0, 0, 0,0,0,0,25,6,17) | 99999  | 99999  | 28.0  | 33.3  |
| FU Week 48: <1 IU/mL(n=0, 0, 0,0,0,0,25,6,17)     | 99999  | 99999  | 44.0  | 50.0  |
| FU Week 48: <10 IU/mL(n=0, 0, 0,0,0,0,25,6,17)    | 99999  | 99999  | 80.0  | 83.3  |
| FU Week 48: <100IU/mL(n=0, 0, 0,0,0,0,25,6,17)    | 99999  | 99999  | 96.0  | 100   |

| End point values                            | FU: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a |  |  |  |
|---|--|--|--|--|
| Subject group type                          | Subject analysis set                                     |  |  |  |
| Number of subjects analysed                 | 17   |  |  |  |
| Units: percentage of participants           |  |  |  |  |
| number (not applicable)                     |  |  |  |  |
| IP Week 36: <0.11 IU/mL(n=12,0,1,0,0,0,0,0) | 99999  |  |  |  |
| IP Week 36: <1 IU/mL (n=12,0,1,0,0,0,0,0)   | 99999  |  |  |  |
| IP Week 36: <10 IU/mL(n=12,0,1,0,0,0,0,0)   | 99999  |  |  |  |

|   |       |  |  |  |
|---|-------|--|--|--|
| IP Week 36: <100 IU/mL(n=12,0,1,0,0,0,0,0)        | 99999 |  |  |  |
| CP Week 12: <0.11 IU/mL (n=0, 0, 0,24,7,17,0,0,0) | 99999 |  |  |  |
| CP Week 12: <1 IU/mL(n=0, 0, 0,24,7,17,0,0,0)     | 99999 |  |  |  |
| CP Week 12: <10 IU/mL(n=0, 0, 0,24,7,17,0,0,0)    | 99999 |  |  |  |
| CP Week 12: <100 IU/mL(n=0, 0, 0,24,7,17,0,0,0)   | 99999 |  |  |  |
| FU Week 48: <0.11 IU/mL (n=0, 0, 0,0,0,0,25,6,17) | 17.6  |  |  |  |
| FU Week 48: <1 IU/mL(n=0, 0, 0,0,0,0,25,6,17)     | 52.9  |  |  |  |
| FU Week 48: <10 IU/mL(n=0, 0, 0,0,0,0,25,6,17)    | 76.5  |  |  |  |
| FU Week 48: <100IU/mL(n=0, 0, 0,0,0,0,25,6,17)    | 100   |  |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Percentage of Participants With HBsAg Levels Below Different Cut-offs

|                 |   |
|-----------------|---|
| End point title | Percentage of Participants With HBsAg Levels Below Different Cut-offs |
|-----------------|---|

End point description:

Percentage of participants with HBsAg levels below different cut-offs were reported. The cut-offs for HBsAg level were: <LLOQ (<0.05 IU/mL), <1 IU/mL, <10 IU/mL, <100 IU/mL, <1000 IU/mL. Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA. Here, "n"=number of subjects analysed at specified categories. n=0, and 99999 signify that data were not collected and analysed as that timepoint was not applicable to the respective arm.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

IP: Week 36, CP: Week 12; FU phase: Week 48

| End point values                              | IP: Cohort 1(Prior PA 5): JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a | IP: Cohort 1 (Per PA 5): JNJ-3989 + NA + PegIFN-alpha-2a | IP:Cohort 2(Per PA 6): JNJ-3989+NA+PegIFN-alpha-2a | CP:Cohort 1(Prior PA 5):JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a |
|---|--|--|--|--|
| Subject group type                            | Subject analysis set   | Subject analysis set                                     | Subject analysis set                               | Subject analysis set   |
| Number of subjects analysed                   | 27   | 8  | 19   | 25   |
| Units: percentage of participants             |  |  |  |  |
| number (not applicable)                       |  |  |  |  |
| IP Week 36: <0.05 IU/mL(n=13,0,1,0,0,0,0,0,0) | 0  | 99999  | 0  | 99999  |
| IP Week 36: <1 IU/mL(n=13,0,1,0,0,0,0,0,0)    | 0  | 99999  | 0  | 99999  |
| IP Week 36: <10 IU/mL(n=13,0,1,0,0,0,0,0,0)   | 0  | 99999  | 100.0  | 99999  |

|   |       |       |       |       |
|---|-------|-------|-------|-------|
| IP Week 36: <100<br>IU/mL(n=13,0,1,0,0,0,0,0)     | 23.1  | 99999 | 100.0 | 99999 |
| IP Week 36: <1000<br>IU/mL(n=13,0,1,0,0,00,0,0)   | 69.2  | 99999 | 100.0 | 99999 |
| CP Week 12: <0.05<br>IU/mL(n=0,0,0,25,7,17,0,0,0) | 99999 | 99999 | 99999 | 8.0   |
| CP Week 12: <1<br>IU/mL(n=0,0,0,25,7,17,0,0,0)    | 99999 | 99999 | 99999 | 20.0  |
| CP Week 12: <10<br>IU/mL(n=0,0,0,25,7,17,0,0,0)   | 99999 | 99999 | 99999 | 40.0  |
| CP Week 12: <100<br>IU/mL(n=0,0,0,25,7,17,0,0,0)  | 99999 | 99999 | 99999 | 60.0  |
| CP Week 12: <1000<br>IU/mL(n=0,0,0,25,7,17,0,0,0) | 99999 | 99999 | 99999 | 100.0 |
| FU Week 48: <0.05<br>IU/mL(n=0,0,0,0,0,0,26,6,17) | 99999 | 99999 | 99999 | 99999 |
| FU Week 48: <1<br>IU/mL(n=0,0,0,0,0,0,26,6,17)    | 99999 | 99999 | 99999 | 99999 |
| FU Week 48: <10<br>IU/mL(n=0,0,0,0,0,0,26,6,17)   | 99999 | 99999 | 99999 | 99999 |
| FU Week 48: <100<br>IU/mL(n=0,0,0,0,0,0,26,6,17)  | 99999 | 99999 | 99999 | 99999 |
| FU Week 48: <1000<br>IU/mL(n=0,0,0,0,0,0,26,6,17) | 99999 | 99999 | 99999 | 99999 |

| End point values                                  | CP: Cohort 1(Per PA 5):<br>JNJ-3989+NA+<br>PegIFN-alpha-<br>2a | CP: Cohort 2<br>(Per PA 6):<br>JNJ-3989 + NA<br>+ PegIFN-<br>alpha-2a | FU: Cohort 1:<br>JNJ-3989+<br>JNJ-<br>6379+NA+PegI<br>FN-alpha-2a | FU: Cohort 1:<br>JNJ-3989 + NA<br>+ PegIFN-<br>alpha-2a |
|---|--|---|---|---|
| Subject group type                                | Subject analysis set   | Subject analysis set  | Subject analysis set  | Subject analysis set                                    |
| Number of subjects analysed                       | 7  | 17  | 26  | 8   |
| Units: percentage of participants                 |  |   |   |   |
| number (not applicable)                           |  |   |   |   |
| IP Week 36: <0.05<br>IU/mL(n=13,0,1,0,0,0,0,0)    | 99999  | 99999   | 99999   | 99999   |
| IP Week 36: <1<br>IU/mL(n=13,0,1,0,0,0,0,0)       | 99999  | 99999   | 99999   | 99999   |
| IP Week 36: <10<br>IU/mL(n=13,0,1,0,0,0,0,0)      | 99999  | 99999   | 99999   | 99999   |
| IP Week 36: <100<br>IU/mL(n=13,0,1,0,0,0,0,0)     | 99999  | 99999   | 99999   | 99999   |
| IP Week 36: <1000<br>IU/mL(n=13,0,1,0,0,00,0,0)   | 99999  | 99999   | 99999   | 99999   |
| CP Week 12: <0.05<br>IU/mL(n=0,0,0,25,7,17,0,0,0) | 42.9   | 5.9   | 99999   | 99999   |
| CP Week 12: <1<br>IU/mL(n=0,0,0,25,7,17,0,0,0)    | 42.9   | 23.5  | 99999   | 99999   |
| CP Week 12: <10<br>IU/mL(n=0,0,0,25,7,17,0,0,0)   | 42.9   | 47.1  | 99999   | 99999   |
| CP Week 12: <100<br>IU/mL(n=0,0,0,25,7,17,0,0,0)  | 71.4   | 76.5  | 99999   | 99999   |
| CP Week 12: <1000<br>IU/mL(n=0,0,0,25,7,17,0,0,0) | 100.0  | 94.1  | 99999   | 99999   |
| FU Week 48: <0.05<br>IU/mL(n=0,0,0,0,0,0,26,6,17) | 99999  | 99999   | 11.5  | 16.7  |
| FU Week 48: <1<br>IU/mL(n=0,0,0,0,0,0,26,6,17)    | 99999  | 99999   | 11.5  | 33.3  |

|   |       |       |      |      |
|---|-------|-------|------|------|
| FU Week 48: <10<br>IU/mL(n=0,0,0,0,0,0,26,6,17)   | 99999 | 99999 | 19.2 | 50.0 |
| FU Week 48: <100<br>IU/mL(n=0,0,0,0,0,0,26,6,17)  | 99999 | 99999 | 26.9 | 50.0 |
| FU Week 48: <1000<br>IU/mL(n=0,0,0,0,0,0,26,6,17) | 99999 | 99999 | 57.7 | 66.7 |

|   |   |  |  |  |
|---|---|--|--|--|
| <b>End point values</b>                           | FU: Cohort 2<br>(Per PA 6):<br>JNJ-3989 + NA<br>+ PegIFN-<br>alpha-2a |  |  |  |
| Subject group type                                | Subject analysis set  |  |  |  |
| Number of subjects analysed                       | 17  |  |  |  |
| Units: percentage of participants                 |   |  |  |  |
| number (not applicable)                           |   |  |  |  |
| IP Week 36: <0.05<br>IU/mL(n=13,0,1,0,0,0,0,0,0)  | 99999   |  |  |  |
| IP Week 36: <1<br>IU/mL(n=13,0,1,0,0,0,0,0,0)     | 99999   |  |  |  |
| IP Week 36: <10<br>IU/mL(n=13,0,1,0,0,0,0,0,0)    | 99999   |  |  |  |
| IP Week 36: <100<br>IU/mL(n=13,0,1,0,0,0,0,0,0)   | 99999   |  |  |  |
| IP Week 36: <1000<br>IU/mL(n=13,0,1,0,0,0,0,0,0)  | 99999   |  |  |  |
| CP Week 12: <0.05<br>IU/mL(n=0,0,0,25,7,17,0,0,0) | 99999   |  |  |  |
| CP Week 12: <1<br>IU/mL(n=0,0,0,25,7,17,0,0,0)    | 99999   |  |  |  |
| CP Week 12: <10<br>IU/mL(n=0,0,0,25,7,17,0,0,0)   | 99999   |  |  |  |
| CP Week 12: <100<br>IU/mL(n=0,0,0,25,7,17,0,0,0)  | 99999   |  |  |  |
| CP Week 12: <1000<br>IU/mL(n=0,0,0,25,7,17,0,0,0) | 99999   |  |  |  |
| FU Week 48: <0.05<br>IU/mL(n=0,0,0,0,0,0,26,6,17) | 11.8  |  |  |  |
| FU Week 48: <1<br>IU/mL(n=0,0,0,0,0,0,26,6,17)    | 17.6  |  |  |  |
| FU Week 48: <10<br>IU/mL(n=0,0,0,0,0,0,26,6,17)   | 29.4  |  |  |  |
| FU Week 48: <100<br>IU/mL(n=0,0,0,0,0,0,26,6,17)  | 47.1  |  |  |  |
| FU Week 48: <1000<br>IU/mL(n=0,0,0,0,0,0,26,6,17) | 76.5  |  |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Percentage of Participants With HBV DNA Levels Below Different Cut-offs

|                 |  |
|-----------------|--|
| End point title | Percentage of Participants With HBV DNA Levels Below |
|-----------------|--|

End point description:

Percentage of participants with HBV DNA levels below cut-offs were reported.

The cut-offs for HBV DNA were as follows: <LLOQ (<20 IU/mL) for target detected or not detected (Td and Nd), < LLOQ for target not detected (TNd), and < LLOQ for target detected (TD), <60 IU/mL, <100 IU/mL, <200 IU/mL, <1000 IU/mL, <2000 IU/mL, <20000 IU/mL. Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA. Here, "n"(number of participants analysed) signifies participants analysed at specified categories. Here, n=0, and 99999 signify that data were not collected and analysed as that timepoint was not applicable to the respective arm.

End point type Secondary

End point timeframe:

IP: Week 36; CP: Week 12; FU phase: Week 48

| End point values                                | IP: Cohort 1(Prior PA 5): JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a | IP: Cohort 1 (Per PA 5): JNJ-3989 + NA + PegIFN-alpha-2a | IP:Cohort 2(Per PA 6): JNJ-3989+NA+PegIFN-alpha-2a | CP:Cohort 1(Prior PA 5):JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a |
|---|--|--|--|--|
| Subject group type                              | Subject analysis set   | Subject analysis set                                     | Subject analysis set                               | Subject analysis set   |
| Number of subjects analysed                     | 14   | 0 <sup>[16]</sup>  | 1  | 25   |
| Units: percentage of participants               |  |  |  |  |
| number (not applicable)                         |  |  |  |  |
| IP Week 36:<LLOQ Td & Nd (n=14,0,1,0,0,0,0,0)   | 42.9   |  | 100.0  | 99999  |
| IP Week 36:<LLOQ for TNd(n=14,0,1,0,0,0,0,0)    | 0  |  | 0  | 99999  |
| IP Week 36:<LLOQ for Td(14,0,1,0,0,0,0,0)       | 42.9   |  | 100.0  | 99999  |
| IP Week 36:<60 IU/mL(14,0,1,0,0,0,0,0)          | 64.3   |  | 100.0  | 99999  |
| IP Week 36:<100 IU/mL (14,0,1,0,0,0,0,0)        | 71.4   |  | 100.0  | 99999  |
| IP Week 36:<200 IU/mL (14,0,1,0,0,0,0,0)        | 78.6   |  | 100.0  | 99999  |
| IP Week 36:<1000 IU/mL(n=14,0,1,0,0,0,0,0)      | 92.9   |  | 100.0  | 99999  |
| IP Week 36:<2000 IU/mL(n=14,0,1,0,0,0,0,0)      | 92.9   |  | 100.0  | 99999  |
| IP Week 36:<20000 IU/mL(n=14,0,1,0,0,0,0,0)     | 92.9   |  | 100.0  | 99999  |
| CP Week 12:<LLOQ:Td & Nd(n=0,0,0,25,6,17,0,0,0) | 99999  |  | 99999  | 32.0   |
| CP Week 12:<LLOQ for TNd(n=0,0,0,25,6,17,0,0,0) | 99999  |  | 99999  | 0  |
| CP Week 12:<LLOQ for Td(n=0,0,0,25,6,17,0,0,0)  | 99999  |  | 99999  | 32.0   |
| CP Week 12:<60 IU/mL(n=0,0,0,25,6,17,0,0,0)     | 99999  |  | 99999  | 76.0   |
| CP Week 12:<100 IU/mL(n=0,0,0,25,6,17,0,0,0)    | 99999  |  | 99999  | 92.0   |
| CP Week 12:<200 IU/mL(n=0,0,0,25,6,17,0,0,0)    | 99999  |  | 99999  | 96.0   |
| CP Week 12:<1000 IU/mL(n=0,0,0,25,6,17,0,0,0)   | 99999  |  | 99999  | 100.0  |
| CP Week 12:<2000 IU/mL(n=0,0,0,25,6,17,0,0,0)   | 99999  |  | 99999  | 100.0  |

|  |       |  |       |       |
|--|-------|--|-------|-------|
| CP Week 12: <20000<br>IU/mL(n=0,0,0,25,6,17,0,0,0)   | 99999 |  | 99999 | 100.0 |
| FU Week 48: <LLOQ Td &<br>Nd(n=0,0,0,0,0,0,26,6,17)  | 99999 |  | 99999 | 99999 |
| FU Week 48: <LLOQ for TNd<br>(n=0,0,0,0,0,0,26,6,17) | 99999 |  | 99999 | 99999 |
| FU Week 48: <LLOQ for<br>Td(n=0,0,0,0,0,0,26,6,17)   | 99999 |  | 99999 | 99999 |
| FU Week 48: <60<br>IU/mL(n=0,0,0,0,0,0,26,6,17)      | 99999 |  | 99999 | 99999 |
| FU Week 48: <100<br>IU/mL(n=0,0,0,0,0,0,26,6,17)     | 99999 |  | 99999 | 99999 |
| FU Week 48: <200<br>IU/mL(n=0,0,0,0,0,0,26,6,17)     | 99999 |  | 99999 | 99999 |
| FU Week 48: <1000<br>IU/mL(n=0,0,0,0,0,0,26,6,17)    | 99999 |  | 99999 | 99999 |
| FU Week 48: <2000<br>IU/mL(n=0,0,0,0,0,0,26,6,17)    | 99999 |  | 99999 | 99999 |
| FU Week 48: <20000<br>IU/mL(n=0,0,0,0,0,0,26,6,17)   | 99999 |  | 99999 | 99999 |

Notes:

[16] - No participant was available for the analysis.

| End point values                                    | CP: Cohort 1(Per PA 5):<br>JNJ-3989+NA+<br>PegIFN-alpha-<br>2a | CP: Cohort 2<br>(Per PA 6):<br>JNJ-3989 + NA<br>+ PegIFN-<br>alpha-2a | FU: Cohort 1:<br>JNJ-3989+<br>JNJ-<br>6379+NA+PegI<br>FN-alpha-2a | FU: Cohort 1:<br>JNJ-3989 + NA<br>+ PegIFN-<br>alpha-2a |
|---|--|---|---|---|
| Subject group type                                  | Subject analysis set   | Subject analysis set  | Subject analysis set  | Subject analysis set                                    |
| Number of subjects analysed                         | 6  | 17  | 26  | 8   |
| Units: percentage of participants                   |  |   |   |   |
| number (not applicable)                             |  |   |   |   |
| IP Week 36: <LLOQ Td & Nd (n=14,0,1,<br>0,0,0,0,0)  | 99999  | 99999   | 99999   | 99999   |
| IP Week 36: <LLOQ for TNd(n=14,0,1,<br>0,0,0,0,0)   | 99999  | 99999   | 99999   | 99999   |
| IP Week 36: <LLOQ for Td(14,0,1,<br>0,0,0,0,0)      | 99999  | 99999   | 99999   | 99999   |
| IP Week 36: <60 IU/mL(14,0,1,<br>0,0,0,0,0)         | 99999  | 99999   | 99999   | 99999   |
| IP Week 36: <100 IU/mL (14,0,1,<br>0,0,0,0,0)       | 99999  | 99999   | 99999   | 99999   |
| IP Week 36: <200 IU/mL (14,0,1,<br>0,0,0,0,0)       | 99999  | 99999   | 99999   | 99999   |
| IP Week 36: <1000 IU/mL(n=14,0,1,<br>0,0,0,0,0)     | 99999  | 99999   | 99999   | 99999   |
| IP Week 36: <2000 IU/mL(n=14,0,1,<br>0,0,0,0,0)     | 99999  | 99999   | 99999   | 99999   |
| IP Week 36: <20000 IU/mL(n=14,0,1,<br>0,0,0,0,0)    | 99999  | 99999   | 99999   | 99999   |
| CP Week 12: <LLOQ:Td &<br>Nd(n=0,0,0,25,6,17,0,0,0) | 33.3   | 29.4  | 99999   | 99999   |
| CP Week 12: <LLOQ for<br>TNd(n=0,0,0,25,6,17,0,0,0) | 0  | 0   | 99999   | 99999   |
| CP Week 12: <LLOQ for<br>Td(n=0,0,0,25,6,17,0,0,0)  | 33.3   | 29.4  | 99999   | 99999   |
| CP Week 12: <60<br>IU/mL(n=0,0,0,25,6,17,0,0,0)     | 50.0   | 58.8  | 99999   | 99999   |
| CP Week 12: <100<br>IU/mL(n=0,0,0,25,6,17,0,0,0)    | 83.3   | 64.7  | 99999   | 99999   |

|  |       |       |       |       |
|--|-------|-------|-------|-------|
| CP Week 12: <200<br>IU/mL(n=0,0,0,25,6,17,0,0,0)     | 83.3  | 82.4  | 99999 | 99999 |
| CP Week 12: <1000<br>IU/mL(n=0,0,0,25,6,17,0,0,0)    | 100.0 | 94.1  | 99999 | 99999 |
| CP Week 12: <2000<br>IU/mL(n=0,0,0,25,6,17,0,0,0)    | 100.0 | 100.0 | 99999 | 99999 |
| CP Week 12: <20000<br>IU/mL(n=0,0,0,25,6,17,0,0,0)   | 100.0 | 100.0 | 99999 | 99999 |
| FU Week 48: <LLOQ Td &<br>Nd(n=0,0,0,0,0,0,26,6,17)  | 99999 | 99999 | 84.6  | 50.0  |
| FU Week 48: <LLOQ for TNd<br>(n=0,0,0,0,0,0,26,6,17) | 99999 | 99999 | 34.6  | 16.7  |
| FU Week 48: <LLOQ for<br>Td(n=0,0,0,0,0,0,26,6,17)   | 99999 | 99999 | 50.0  | 33.3  |
| FU Week 48: <60<br>IU/mL(n=0,0,0,0,0,0,26,6,17)      | 99999 | 99999 | 92.3  | 50.0  |
| FU Week 48: <100<br>IU/mL(n=0,0,0,0,0,0,26,6,17)     | 99999 | 99999 | 100.0 | 66.7  |
| FU Week 48: <200<br>IU/mL(n=0,0,0,0,0,0,26,6,17)     | 99999 | 99999 | 100.0 | 83.3  |
| FU Week 48: <1000<br>IU/mL(n=0,0,0,0,0,0,26,6,17)    | 99999 | 99999 | 100.0 | 83.3  |
| FU Week 48: <2000<br>IU/mL(n=0,0,0,0,0,0,26,6,17)    | 99999 | 99999 | 100.0 | 83.3  |
| FU Week 48: <20000<br>IU/mL(n=0,0,0,0,0,0,26,6,17)   | 99999 | 99999 | 100.0 | 100.0 |

|  |   |  |  |  |
|--|---|--|--|--|
| <b>End point values</b>                              | FU: Cohort 2<br>(Per PA 6):<br>JNJ-3989 + NA<br>+ PegIFN-<br>alpha-2a |  |  |  |
| Subject group type                                   | Subject analysis set  |  |  |  |
| Number of subjects analysed                          | 17  |  |  |  |
| Units: percentage of participants                    |   |  |  |  |
| number (not applicable)                              |   |  |  |  |
| IP Week 36: <LLOQ Td & Nd (n=14,0,1,<br>0,0,0,0,0,0) | 99999   |  |  |  |
| IP Week 36: <LLOQ for TNd(n=14,0,1,<br>0,0,0,0,0,0)  | 99999   |  |  |  |
| IP Week 36: <LLOQ for Td(14,0,1,<br>0,0,0,0,0,0)     | 99999   |  |  |  |
| IP Week 36: <60 IU/mL(14,0,1,<br>0,0,0,0,0,0)        | 99999   |  |  |  |
| IP Week 36: <100 IU/mL (14,0,1,<br>0,0,0,0,0,0)      | 99999   |  |  |  |
| IP Week 36: <200 IU/mL (14,0,1,<br>0,0,0,0,0,0)      | 99999   |  |  |  |
| IP Week 36: <1000 IU/mL(n=14,0,1,<br>0,0,0,0,0,0)    | 99999   |  |  |  |
| IP Week 36: <2000 IU/mL(n=14,0,1,<br>0,0,0,0,0,0)    | 99999   |  |  |  |
| IP Week 36: <20000 IU/mL(n=14,0,1,<br>0,0,0,0,0,0)   | 99999   |  |  |  |
| CP Week 12: <LLOQ:Td &<br>Nd(n=0,0,0,25,6,17,0,0,0)  | 99999   |  |  |  |
| CP Week 12: <LLOQ for<br>TNd(n=0,0,0,25,6,17,0,0,0)  | 99999   |  |  |  |

|   |       |  |  |  |
|---|-------|--|--|--|
| CP Week 12: <LLOQ for Td (n=0,0,0,25,6,17,0,0,0)  | 99999 |  |  |  |
| CP Week 12: <60 IU/mL (n=0,0,0,25,6,17,0,0,0)     | 99999 |  |  |  |
| CP Week 12: <100 IU/mL (n=0,0,0,25,6,17,0,0,0)    | 99999 |  |  |  |
| CP Week 12: <200 IU/mL (n=0,0,0,25,6,17,0,0,0)    | 99999 |  |  |  |
| CP Week 12: <1000 IU/mL (n=0,0,0,25,6,17,0,0,0)   | 99999 |  |  |  |
| CP Week 12: <2000 IU/mL (n=0,0,0,25,6,17,0,0,0)   | 99999 |  |  |  |
| CP Week 12: <20000 IU/mL (n=0,0,0,25,6,17,0,0,0)  | 99999 |  |  |  |
| FU Week 48: <LLOQ Td & Nd (n=0,0,0,0,0,0,26,6,17) | 88.2  |  |  |  |
| FU Week 48: <LLOQ for TNd (n=0,0,0,0,0,0,26,6,17) | 17.6  |  |  |  |
| FU Week 48: <LLOQ for Td (n=0,0,0,0,0,0,26,6,17)  | 70.6  |  |  |  |
| FU Week 48: <60 IU/mL (n=0,0,0,0,0,0,26,6,17)     | 94.1  |  |  |  |
| FU Week 48: <100 IU/mL (n=0,0,0,0,0,0,26,6,17)    | 100.0 |  |  |  |
| FU Week 48: <200 IU/mL (n=0,0,0,0,0,0,26,6,17)    | 100.0 |  |  |  |
| FU Week 48: <1000 IU/mL (n=0,0,0,0,0,0,26,6,17)   | 100.0 |  |  |  |
| FU Week 48: <2000 IU/mL (n=0,0,0,0,0,0,26,6,17)   | 100.0 |  |  |  |
| FU Week 48: <20000 IU/mL (n=0,0,0,0,0,0,26,6,17)  | 100.0 |  |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Percentage of Participants with Virologic Breakthrough

|                 |  |
|-----------------|--|
| End point title | Percentage of Participants with Virologic Breakthrough |
|-----------------|--|

End point description:

Percentage of participants with virologic breakthrough on treatment were reported. Virological breakthrough was defined as confirmed on-treatment HBV DNA increase by >1 log<sub>10</sub> IU/mL from nadir level (lowest level reached during treatment) in participants who did not have on-treatment HBV DNA level < LLOQ (<20 IU/mL) or confirmed on-treatment HBV DNA level >200 IU/mL in participants who had on-treatment HBV DNA level <LLOQ of the HBV DNA assay. Confirmed HBV DNA increase/level means that the criterion was fulfilled at 2 or more consecutive time points or at the last observed on-treatment time point. Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

IP: From Day 1 up to end of IP (up to Week 36 per PA 5; up to Week 52 prior to PA 5); CP: CP Week 1 up to CP Week 12; FU phase: FU Week 1 up to FU Week 48



|                                   |  |  |  |  |
|-----------------------------------|--|--|--|--|
| <b>End point values</b>           | IP: Cohort 1(Prior PA 5): JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a | IP: Cohort 1 (Per PA 5): JNJ-3989 + NA + PegIFN-alpha-2a | IP:Cohort 2(Per PA 6): JNJ-3989+NA+PegIFN-alpha-2a | CP:Cohort 1(Prior PA 5):JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a |
| Subject group type                | Subject analysis set   | Subject analysis set                                     | Subject analysis set                               | Subject analysis set   |
| Number of subjects analysed       | 27   | 8  | 19   | 25   |
| Units: percentage of participants |  |  |  |  |
| number (not applicable)           | 3.7  | 12.5   | 0  | 0  |

|                                   |   |  |   |   |
|-----------------------------------|---|--|---|---|
| <b>End point values</b>           | CP: Cohort 1(Per PA 5): JNJ-3989+NA+PegIFN-alpha-2a | CP: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a | FU: Cohort 1: JNJ-3989+ JNJ-6379+NA+PegIFN-alpha-2a | FU: Cohort 1: JNJ-3989 + NA + PegIFN-alpha-2a |
| Subject group type                | Subject analysis set                                | Subject analysis set                                     | Subject analysis set                                | Subject analysis set                          |
| Number of subjects analysed       | 7   | 17   | 26  | 8   |
| Units: percentage of participants |   |  |   |   |
| number (not applicable)           | 0   | 0  | 0   | 50.0  |

|                                   |  |  |  |  |
|-----------------------------------|--|--|--|--|
| <b>End point values</b>           | FU: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a |  |  |  |
| Subject group type                | Subject analysis set                                     |  |  |  |
| Number of subjects analysed       | 17   |  |  |  |
| Units: percentage of participants |  |  |  |  |
| number (not applicable)           | 0  |  |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Maximum Observed Plasma Concentration (Cmax) of JNJ-73763989 (Molecules: JNJ-73763976 [JNJ3976], JNJ-73763924 [JNJ-3924])

|   |   |
|---|---|
| End point title   | Maximum Observed Plasma Concentration (Cmax) of JNJ-73763989 (Molecules: JNJ-73763976 [JNJ3976], JNJ-73763924 [JNJ-3924]) |
| End point description:  |   |
| Cmax of JNJ-73763989 (molecules: JNJ-73763976 [JNJ3976], JNJ-73763924 [JNJ-3924]) were reported. Noncompartmental analysis were conducted to analyze Cmax JNJ-73763989 and its molecules. Pharmacokinetics analysis set (PK): included participants who had received at least 1 dose of any of the study interventions and had at least 1 valid blood sample drawn for PK analysis. Data for this endpoint was planned to be collected and analysed as pooled cohort in induction phase and consolidation phase only. |   |
| End point type  | Secondary   |

End point timeframe:

IP : Predose (0 hour), post dose on 0.25, 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours  
on IP Week 24; CP: Predose (0 hour), post dose on 0.25, 0.5, 1, 2, 3, 4, 6, 8, 10 and 24  
hours on CP Week 8

| End point values                        | Induction phase      | Consolidation phase  |  |  |
|---|----------------------|----------------------|--|--|
| Subject group type                      | Subject analysis set | Subject analysis set |  |  |
| Number of subjects analysed             | 8                    | 6                    |  |  |
| Units: nanogram per milliliters (ng/mL) |                      |                      |  |  |
| arithmetic mean (standard deviation)    |                      |                      |  |  |
| JNJ-73763976                            | 1376 (± 1266)        | 700 (± 227)          |  |  |
| JNJ-73763924                            | 279 (± 308)          | 135 (± 39.9)         |  |  |

### Statistical analyses

No statistical analyses for this end point

### Secondary: Percentage of Participants Who Reached HBV DNA Undetectability After Re-start of NA Treatment During Follow-up

|                                      |  |
|--------------------------------------|--|
| End point title                      | Percentage of Participants Who Reached HBV DNA Undetectability After Re-start of NA Treatment During Follow-up   |
| End point description:               | Percentage of participants who reached HBV DNA undetectability after re-start of NA treatment during follow-up were reported. Undetectability of HBV DNA was defined as HBV DNA<LLOQ that is <20 IU/mL. Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA. Here "N" (Number of participants analysed) signifies the number of participants that were evaluable for this endpoint. |
| End point type                       | Secondary  |
| End point timeframe:                 |  |
| FU phase: FU Week 1 up to FU Week 48 |  |

| End point values                  | FU: Cohort 1: JNJ-3989+ JNJ-6379+NA+PegIFN-alpha-2a | FU: Cohort 1: JNJ-3989 + NA + PegIFN-alpha-2a | FU: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a |  |
|-----------------------------------|---|---|--|--|
| Subject group type                | Subject analysis set                                | Subject analysis set                          | Subject analysis set                                     |  |
| Number of subjects analysed       | 27  | 8   | 19   |  |
| Units: percentage of participants |   |   |  |  |
| number (not applicable)           | 0   | 0   | 0  |  |

## Statistical analyses

No statistical analyses for this end point

### Secondary: Plasma Concentration 24 Hours After Administration (C24h) of JNJ-73763989 (Molecules: JNJ-73763976 [JNJ3976], JNJ-73763924 [JNJ-3924])

|                 |   |
|-----------------|---|
| End point title | Plasma Concentration 24 Hours After Administration (C24h) of JNJ-73763989<br>(Molecules: JNJ-73763976 [JNJ3976], JNJ-73763924 [JNJ-3924]) |
|-----------------|---|

End point description:

Plasma concentration 24 hours after administration (C24h) of JNJ-73763989 (molecules: JNJ-73763976 [JNJ3976], JNJ-73763924 [JNJ-3924]) were reported. Non-compartmental analysis were conducted to analyze C24h of JNJ-73763989 and its molecules. Pharmacokinetics analysis set (PK): included participants who have received at least 1 dose of any of the study interventions and had at least 1 valid blood sample drawn for PK analysis. Here "N" (Number of participants analysed) signifies the number of participants that were evaluable for this endpoint. Data for this endpoint was planned to be collected and analysed as pooled cohort in induction phase and consolidation phase only.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

IP: 24 hours post dose on Week 24 visit; CP: 24 hours post dose on Week 8 visit

| End point values                     | Induction phase      | Consolidation phase  |  |  |
|--------------------------------------|----------------------|----------------------|--|--|
| Subject group type                   | Subject analysis set | Subject analysis set |  |  |
| Number of subjects analysed          | 7                    | 6                    |  |  |
| Units: ng/mL                         |                      |                      |  |  |
| arithmetic mean (standard deviation) |                      |                      |  |  |
| JNJ-73763976                         | 315 (± 213)          | 381 (± 155)          |  |  |
| JNJ-73763924                         | 36.9 (± 27.9)        | 54.7 (± 25.0)        |  |  |

## Statistical analyses

No statistical analyses for this end point

### Secondary: Time to Reach the Maximum Observed Plasma Concentration (tmax) of JNJ-73763989 (molecules: JNJ-73763976 [JNJ3976], JNJ-73763924 [JNJ-3924])

|                 |  |
|-----------------|--|
| End point title | Time to Reach the Maximum Observed Plasma Concentration (tmax) of JNJ-73763989<br>(molecules: JNJ-73763976 [JNJ3976], JNJ-73763924 [JNJ-3924]) |
|-----------------|--|

End point description:

Time to reach the maximum observed plasma concentration (tmax) of JNJ-73763989 (molecules: JNJ-73763976 [JNJ3976], JNJ-73763924 [JNJ-3924]) were reported. Non-compartmental analysis were conducted to analyze tmax of JNJ-73763989 and its molecules. Pharmacokinetics analysis set (PK): included participants who have received at least 1 dose of any of the study interventions and had at least 1 valid blood sample drawn for PK analysis. Here "N" (Number of participants analysed) signifies the number

of participants that were evaluable for this endpoint. Data for this endpoint was planned to be collected and analysed as pooled cohort in induction phase and consolidation phase only.

|  |           |
|--|-----------|
| End point type   | Secondary |
| End point timeframe:   |           |
| IP : Predose (0 hour), post dose on 0.25, 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours on IP Week 24; CP: Predose (0 hour), post dose on 0.25, 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours on CP Week 8 |           |

| End point values              | Induction phase      | Consolidation phase  |  |  |
|-------------------------------|----------------------|----------------------|--|--|
| Subject group type            | Subject analysis set | Subject analysis set |  |  |
| Number of subjects analysed   | 8                    | 6                    |  |  |
| Units: hour                   |                      |                      |  |  |
| median (full range (min-max)) |                      |                      |  |  |
| JNJ-73763976                  | 5.53 (2.50 to 6.00)  | 3.99 (2.98 to 6.00)  |  |  |
| JNJ-73763924                  | 4.00 (0.50 to 5.73)  | 2.99 (1.00 to 4.00)  |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Area Under the Plasma Concentration-time Curve From Time Zero to 24 Hours [AUC (0-24 hours)] of JNJ-73763989 (molecules: JNJ-73763976 [JNJ3976], JNJ-73763924 [JNJ-3924])

|                 |   |
|-----------------|---|
| End point title | Area Under the Plasma Concentration-time Curve From Time Zero to 24 Hours [AUC (0-24 hours)] of JNJ-73763989 (molecules: JNJ-73763976 [JNJ3976], JNJ-73763924 [JNJ-3924]) |
|-----------------|---|

End point description:

Area under the plasma concentration-time curve from time zero to 24hours (AUC0 to 24h) of JNJ-73763989 (molecules:JNJ-73763976 [JNJ3976], JNJ-73763924 [JNJ-3924]) were reported. Non-compartmental analysis were conducted toanalyze AUC0 to 24h of JNJ-73763989 and its molecules. Pharmacokinetics analysis set (PK): included participants who have received at least 1 dose of any of the study interventions and had at least 1 valid blood sample drawn for PK analysis. Here "N" (Number of participants analysed) signifies the number of participants that were evaluable for this endpoint. Data for this endpoint was planned to be collected and analysed as pooled cohort in induction phase and consolidation phase only.

|   |           |
|---|-----------|
| End point type  | Secondary |
| End point timeframe:  |           |
| IP: 24 hours post dose on Week 24 visit; CP: 24 hours post dose on Week 8 visit |           |

| End point values                                | Induction phase      | Consolidation phase  |  |  |
|---|----------------------|----------------------|--|--|
| Subject group type                              | Subject analysis set | Subject analysis set |  |  |
| Number of subjects analysed                     | 7                    | 6                    |  |  |
| Units: nanograms*hour per milliliters (ng*h/mL) |                      |                      |  |  |
| arithmetic mean (standard deviation)            |                      |                      |  |  |
| JNJ-73763976                                    | 19109 (± 12482)      | 12219 (± 3499)       |  |  |
| JNJ-73763924                                    | 3089 (± 1964)        | 2117 (± 639)         |  |  |

### Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

IP: From Day 1 up to end of IP (up to Week 36 per PA 5; up to Week 52 prior to PA 5); CP: CP Week 1 up to CP Week 12; FU phase: FU Week 1 up to FU Week 48

Adverse event reporting additional description:

Safety analysis was based on safety analysis set which included all participants who received at least one dose of study intervention and were analysed according to the study intervention they actually received.

|                 |                |
|-----------------|----------------|
| Assessment type | Non-systematic |
|-----------------|----------------|

### Dictionary used

|                 |        |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

|                    |      |
|--------------------|------|
| Dictionary version | 26.1 |
|--------------------|------|

### Reporting groups

|                       |  |
|-----------------------|--|
| Reporting group title | IP: Cohort 1-Per PA 5: JNJ-3989 + NA + PegIFN-alpha-2a |
|-----------------------|--|

Reporting group description:

Per PA 5, participants received JNJ-3989 200 mg SC injection for Q4W plus NA (TAD 245 mg/TAF 25 mg) tablets orally QD in IP for 36 weeks.

|                       |  |
|-----------------------|--|
| Reporting group title | IP: Cohort 1-prior PA5: JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a |
|-----------------------|--|

Reporting group description:

Prior to PA 5, participants received JNJ-3989 200 mg SC injection for Q4W + JNJ-6379 250 mg tablets orally QD plus NA (TAD 245 mg/TAF 25 mg) tablet orally QD in IP for a RGT duration for >=36-weeks to <=52-weeks.

|                       |  |
|-----------------------|--|
| Reporting group title | FU: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a |
|-----------------------|--|

Reporting group description:

After completion of CP, all participants entered 48-Week FU phase and stopped treatment with JNJ-3989 plus NA (TAD 245 mg/TAF 25 mg) plus PegIFN-alpha2a. If NA treatment completion criteria was met at CP Week 12, NA treatment was stopped at FU Week 2, if NA treatment completion criteria was not met, NA (TAD 245 mg/TAF 25 mg) was continued till the end of FU phase.

|                       |  |
|-----------------------|--|
| Reporting group title | CP: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a |
|-----------------------|--|

Reporting group description:

After completion of IP, participants entered in 12-week CP and received JNJ-3989 200 mg SC injection Q4W + NA (TAD 245 mg/TAF 25 mg) tablets orally QD from CP Week 1 to 12 and PegIFN-alpha2a 180 mcg SC QW was added to their treatment regimen from IP Week 36 for 12 weeks.

|                       |   |
|-----------------------|---|
| Reporting group title | FU: Cohort 1: JNJ-3989+ JNJ-6379+NA+PegIFN-alpha-2a |
|-----------------------|---|

Reporting group description:

After completion of CP, all participants entered 48-Week FU phase and stopped treatment with JNJ-3989 plus JNJ-6379 plus NA (TAD 245 mg/TAF 25 mg) plus PegIFN-alpha2a. If NA treatment completion criteria was met at CP Week 12 NA was stopped at FU W2, if NA treatment completion criteria was not met, NA (TAD 245 mg/TAF 25 mg) was continued till the end of FU phase.

|                       |   |
|-----------------------|---|
| Reporting group title | FU: Cohort 1: JNJ-3989 + NA + PegIFN-alpha-2a |
|-----------------------|---|

Reporting group description:

After completion of CP, all participants entered 48-Week FU phase and stopped treatment with JNJ-3989 plus NA (TAD 245 mg/TAF 25 mg) plus PegIFN-alpha2a. If NA treatment completion criteria was met at CP Week 12, NA treatment was stopped at FU Week 2, if NA treatment completion criteria was not met, NA (TAD 245 mg/TAF 25 mg) was continued till the end of FU phase.

|                       |  |
|-----------------------|--|
| Reporting group title | CP:Cohort 1(Prior PA 5):JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a |
|-----------------------|--|

Reporting group description:

After completion of IP, participants entered in 12 week CP and received JNJ-3989 200 mg SC Q4W plus JNJ-6379 250 tablets QD plus NA (either TAD 250 mg or TAF

25 mg) tablet orally QD from CP Week 1 to 12 and PegIFN-alpha-2a 180 mcg SC injection was added to their treatment regimen from IP Week 36 for 12 weeks.

|   |  |
|---|--|
| Reporting group title   | IP: Cohort 2 - Per PA 6: JNJ-3989 + NA + PegIFN-alpha-2a |
| Reporting group description:  |  |
| Participants enrolled as per PA 6, received JNJ-3989 200 mg SC for Q4W plus NA (TAD 250 mg/TAF 25 mg) tablet orally QD in IP for 36 weeks.  |  |
| Reporting group title   | CP: Cohort 1(Per PA 5): JNJ-3989+NA+ PegIFN-alpha-2a     |
| Reporting group description:  |  |
| After completion of IP, participants entered in 12-week CP and received JNJ-3989 200 mg SC injection Q4W + NA (TDF 245 mg/TAF 25 mg) tablets orally QD from CP Week 1 to 12 and PegIFN-alpha2a 180 mcg SC QW was added to their treatment regimen from IP Week 36 for 12 weeks. |  |

| Serious adverse events                            | IP: Cohort 1-Per PA 5: JNJ-3989 + NA + PegIFN-alpha-2a | IP: Cohort 1-prior PA5: JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a | FU: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a |
|---|--|--|--|
| Total subjects affected by serious adverse events |  |  |  |
| subjects affected / exposed                       | 0 / 8 (0.00%)  | 0 / 27 (0.00%)   | 1 / 17 (5.88%)   |
| number of deaths (all causes)                     | 0  | 0  | 0  |
| number of deaths resulting from adverse events    | 0  | 0  | 0  |
| Pregnancy, puerperium and perinatal conditions    |  |  |  |
| Ectopic Pregnancy                                 |  |  |  |
| subjects affected / exposed                       | 0 / 8 (0.00%)  | 0 / 27 (0.00%)   | 1 / 17 (5.88%)   |
| occurrences causally related to treatment / all   | 0 / 0  | 0 / 0  | 0 / 1  |
| deaths causally related to treatment / all        | 0 / 0  | 0 / 0  | 0 / 0  |

| Serious adverse events                            | CP: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a | FU: Cohort 1: JNJ-3989+ JNJ-6379+NA+PegIFN-alpha-2a | FU: Cohort 1: JNJ-3989 + NA + PegIFN-alpha-2a |
|---|--|---|---|
| Total subjects affected by serious adverse events |  |   |   |
| subjects affected / exposed                       | 0 / 17 (0.00%)   | 0 / 26 (0.00%)                                      | 0 / 8 (0.00%)                                 |
| number of deaths (all causes)                     | 0  | 0   | 0   |
| number of deaths resulting from adverse events    | 0  | 0   | 0   |
| Pregnancy, puerperium and perinatal conditions    |  |   |   |
| Ectopic Pregnancy                                 |  |   |   |
| subjects affected / exposed                       | 0 / 17 (0.00%)   | 0 / 26 (0.00%)                                      | 0 / 8 (0.00%)                                 |
| occurrences causally related to treatment / all   | 0 / 0  | 0 / 0   | 0 / 0   |
| deaths causally related to treatment / all        | 0 / 0  | 0 / 0   | 0 / 0   |

| Serious adverse events | CP:Cohort 1(Prior PA 5):JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a | IP: Cohort 2 - Per PA 6: JNJ-3989 + NA + PegIFN-alpha-2a | CP: Cohort 1(Per PA 5): JNJ-3989+NA+ PegIFN-alpha-2a |
|------------------------|--|--|--|
|------------------------|--|--|--|

|   |                |                |               |
|---|----------------|----------------|---------------|
| Total subjects affected by serious adverse events |                |                |               |
| subjects affected / exposed                       | 0 / 25 (0.00%) | 0 / 19 (0.00%) | 0 / 7 (0.00%) |
| number of deaths (all causes)                     | 0              | 0              | 0             |
| number of deaths resulting from adverse events    | 0              | 0              | 0             |
| Pregnancy, puerperium and perinatal conditions    |                |                |               |
| Ectopic Pregnancy                                 |                |                |               |
| subjects affected / exposed                       | 0 / 25 (0.00%) | 0 / 19 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all   | 0 / 0          | 0 / 0          | 0 / 0         |
| deaths causally related to treatment / all        | 0 / 0          | 0 / 0          | 0 / 0         |

Frequency threshold for reporting non-serious adverse events: 5 %

| <b>Non-serious adverse events</b>                                   | IP: Cohort 1-Per PA5: JNJ-3989 + NA + PegIFN-alpha-2a | IP: Cohort 1-prior PA5: JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a | FU: Cohort 2 (Per PA6): JNJ-3989 + NA + PegIFN-alpha-2a |
|---|---|--|---|
| Total subjects affected by non-serious adverse events               |   |  |   |
| subjects affected / exposed   | 8 / 8 (100.00%)                                       | 19 / 27 (70.37%)   | 11 / 17 (64.71%)  |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) |   |  |   |
| Haemangioma of Liver  |   |  |   |
| subjects affected / exposed   | 0 / 8 (0.00%)   | 0 / 27 (0.00%)   | 0 / 17 (0.00%)  |
| occurrences (all)   | 0   | 0  | 0   |
| General disorders and administration site conditions                |   |  |   |
| Hyperthermia  |   |  |   |
| subjects affected / exposed   | 0 / 8 (0.00%)   | 0 / 27 (0.00%)   | 0 / 17 (0.00%)  |
| occurrences (all)   | 0   | 0  | 0   |
| Fatigue   |   |  |   |
| subjects affected / exposed   | 2 / 8 (25.00%)  | 1 / 27 (3.70%)   | 0 / 17 (0.00%)  |
| occurrences (all)   | 3   | 1  | 0   |
| Chills  |   |  |   |
| subjects affected / exposed   | 0 / 8 (0.00%)   | 0 / 27 (0.00%)   | 0 / 17 (0.00%)  |
| occurrences (all)   | 0   | 0  | 0   |
| Asthenia  |   |  |   |
| subjects affected / exposed   | 0 / 8 (0.00%)   | 2 / 27 (7.41%)   | 0 / 17 (0.00%)  |
| occurrences (all)   | 0   | 3  | 0   |
| Injection Site Erythema   |   |  |   |



|                               |                |                |                |
|-------------------------------|----------------|----------------|----------------|
| subjects affected / exposed   | 1 / 8 (12.50%) | 0 / 27 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all)             | 1              | 0              | 0              |
| Injection Site Bruising       |                |                |                |
| subjects affected / exposed   | 0 / 8 (0.00%)  | 0 / 27 (0.00%) | 1 / 17 (5.88%) |
| occurrences (all)             | 0              | 0              | 1              |
| Influenza Like Illness        |                |                |                |
| subjects affected / exposed   | 0 / 8 (0.00%)  | 0 / 27 (0.00%) | 1 / 17 (5.88%) |
| occurrences (all)             | 0              | 0              | 1              |
| Injection Site Pain           |                |                |                |
| subjects affected / exposed   | 1 / 8 (12.50%) | 0 / 27 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all)             | 2              | 0              | 0              |
| Injection Site Pruritus       |                |                |                |
| subjects affected / exposed   | 0 / 8 (0.00%)  | 0 / 27 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all)             | 0              | 0              | 0              |
| Injection Site Rash           |                |                |                |
| subjects affected / exposed   | 0 / 8 (0.00%)  | 0 / 27 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all)             | 0              | 0              | 0              |
| Injection Site Reaction       |                |                |                |
| subjects affected / exposed   | 0 / 8 (0.00%)  | 0 / 27 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all)             | 0              | 0              | 0              |
| Injury Associated with Device |                |                |                |
| subjects affected / exposed   | 0 / 8 (0.00%)  | 0 / 27 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all)             | 0              | 0              | 0              |
| Pyrexia                       |                |                |                |
| subjects affected / exposed   | 1 / 8 (12.50%) | 1 / 27 (3.70%) | 1 / 17 (5.88%) |
| occurrences (all)             | 1              | 2              | 1              |
| Pain                          |                |                |                |
| subjects affected / exposed   | 0 / 8 (0.00%)  | 0 / 27 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all)             | 0              | 0              | 0              |
| Non-Cardiac Chest Pain        |                |                |                |
| subjects affected / exposed   | 0 / 8 (0.00%)  | 0 / 27 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all)             | 0              | 0              | 0              |
| Temperature Intolerance       |                |                |                |
| subjects affected / exposed   | 0 / 8 (0.00%)  | 0 / 27 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all)             | 0              | 0              | 0              |
| Immune system disorders       |                |                |                |

|   |                     |                     |                      |
|---|---------------------|---------------------|----------------------|
| Seasonal Allergy<br>subjects affected / exposed<br>occurrences (all)  | 2 / 8 (25.00%)<br>3 | 0 / 27 (0.00%)<br>0 | 0 / 17 (0.00%)<br>0  |
| Mite Allergy<br>subjects affected / exposed<br>occurrences (all)  | 1 / 8 (12.50%)<br>1 | 0 / 27 (0.00%)<br>0 | 0 / 17 (0.00%)<br>0  |
| Food Allergy<br>subjects affected / exposed<br>occurrences (all)  | 0 / 8 (0.00%)<br>0  | 0 / 27 (0.00%)<br>0 | 1 / 17 (5.88%)<br>1  |
| Reproductive system and breast disorders<br>Vaginal Haemorrhage<br>subjects affected / exposed<br>occurrences (all)       | 0 / 8 (0.00%)<br>0  | 0 / 27 (0.00%)<br>0 | 1 / 17 (5.88%)<br>1  |
| Respiratory, thoracic and mediastinal disorders<br>Oropharyngeal Pain<br>subjects affected / exposed<br>occurrences (all) | 0 / 8 (0.00%)<br>0  | 1 / 27 (3.70%)<br>1 | 2 / 17 (11.76%)<br>4 |
| Epistaxis<br>subjects affected / exposed<br>occurrences (all)   | 1 / 8 (12.50%)<br>1 | 0 / 27 (0.00%)<br>0 | 0 / 17 (0.00%)<br>0  |
| Dyspnoea Exertional<br>subjects affected / exposed<br>occurrences (all)   | 0 / 8 (0.00%)<br>0  | 0 / 27 (0.00%)<br>0 | 0 / 17 (0.00%)<br>0  |
| Dry Throat<br>subjects affected / exposed<br>occurrences (all)  | 0 / 8 (0.00%)<br>0  | 0 / 27 (0.00%)<br>0 | 0 / 17 (0.00%)<br>0  |
| Cough<br>subjects affected / exposed<br>occurrences (all)   | 1 / 8 (12.50%)<br>1 | 0 / 27 (0.00%)<br>0 | 2 / 17 (11.76%)<br>4 |
| Allergic Sinusitis<br>subjects affected / exposed<br>occurrences (all)  | 0 / 8 (0.00%)<br>0  | 0 / 27 (0.00%)<br>0 | 0 / 17 (0.00%)<br>0  |
| Dyspnoea<br>subjects affected / exposed<br>occurrences (all)  | 0 / 8 (0.00%)<br>0  | 0 / 27 (0.00%)<br>0 | 0 / 17 (0.00%)<br>0  |
| Respiratory Tract Congestion  |                     |                     |                      |

|  |                |                 |                |
|--|----------------|-----------------|----------------|
| subjects affected / exposed            | 0 / 8 (0.00%)  | 0 / 27 (0.00%)  | 0 / 17 (0.00%) |
| occurrences (all)                      | 0              | 0               | 0              |
| Rhinitis Allergic                      |                |                 |                |
| subjects affected / exposed            | 1 / 8 (12.50%) | 1 / 27 (3.70%)  | 0 / 17 (0.00%) |
| occurrences (all)                      | 1              | 1               | 0              |
| Rhinorrhoea                            |                |                 |                |
| subjects affected / exposed            | 0 / 8 (0.00%)  | 0 / 27 (0.00%)  | 1 / 17 (5.88%) |
| occurrences (all)                      | 0              | 0               | 1              |
| Sinus Congestion                       |                |                 |                |
| subjects affected / exposed            | 0 / 8 (0.00%)  | 0 / 27 (0.00%)  | 1 / 17 (5.88%) |
| occurrences (all)                      | 0              | 0               | 1              |
| Productive Cough                       |                |                 |                |
| subjects affected / exposed            | 0 / 8 (0.00%)  | 0 / 27 (0.00%)  | 0 / 17 (0.00%) |
| occurrences (all)                      | 0              | 0               | 0              |
| Psychiatric disorders                  |                |                 |                |
| Insomnia                               |                |                 |                |
| subjects affected / exposed            | 0 / 8 (0.00%)  | 0 / 27 (0.00%)  | 1 / 17 (5.88%) |
| occurrences (all)                      | 0              | 0               | 1              |
| Depressed Mood                         |                |                 |                |
| subjects affected / exposed            | 0 / 8 (0.00%)  | 0 / 27 (0.00%)  | 0 / 17 (0.00%) |
| occurrences (all)                      | 0              | 0               | 0              |
| Apathy                                 |                |                 |                |
| subjects affected / exposed            | 1 / 8 (12.50%) | 0 / 27 (0.00%)  | 0 / 17 (0.00%) |
| occurrences (all)                      | 1              | 0               | 0              |
| Anxiety Disorder                       |                |                 |                |
| subjects affected / exposed            | 1 / 8 (12.50%) | 0 / 27 (0.00%)  | 0 / 17 (0.00%) |
| occurrences (all)                      | 1              | 0               | 0              |
| Investigations                         |                |                 |                |
| Alanine Aminotransferase Increased     |                |                 |                |
| subjects affected / exposed            | 0 / 8 (0.00%)  | 8 / 27 (29.63%) | 1 / 17 (5.88%) |
| occurrences (all)                      | 0              | 13              | 1              |
| Aspartate Aminotransferase Increased   |                |                 |                |
| subjects affected / exposed            | 0 / 8 (0.00%)  | 2 / 27 (7.41%)  | 0 / 17 (0.00%) |
| occurrences (all)                      | 0              | 4               | 0              |
| Blood Creatine Phosphokinase Increased |                |                 |                |

|  |               |                |                |
|--|---------------|----------------|----------------|
| subjects affected / exposed                    | 0 / 8 (0.00%) | 0 / 27 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all)                              | 0             | 0              | 0              |
| Blood Alkaline Phosphatase Increased           |               |                |                |
| subjects affected / exposed                    | 0 / 8 (0.00%) | 0 / 27 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all)                              | 0             | 0              | 0              |
| Blood Glucose Increased                        |               |                |                |
| subjects affected / exposed                    | 0 / 8 (0.00%) | 1 / 27 (3.70%) | 0 / 17 (0.00%) |
| occurrences (all)                              | 0             | 1              | 0              |
| Body Temperature Increased                     |               |                |                |
| subjects affected / exposed                    | 0 / 8 (0.00%) | 0 / 27 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all)                              | 0             | 0              | 0              |
| Glucose Urine Present                          |               |                |                |
| subjects affected / exposed                    | 0 / 8 (0.00%) | 0 / 27 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all)                              | 0             | 0              | 0              |
| Liver Scan Abnormal                            |               |                |                |
| subjects affected / exposed                    | 0 / 8 (0.00%) | 0 / 27 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all)                              | 0             | 0              | 0              |
| Ultrasound Liver Abnormal                      |               |                |                |
| subjects affected / exposed                    | 0 / 8 (0.00%) | 0 / 27 (0.00%) | 1 / 17 (5.88%) |
| occurrences (all)                              | 0             | 0              | 1              |
| White Blood Cell Count Decreased               |               |                |                |
| subjects affected / exposed                    | 0 / 8 (0.00%) | 0 / 27 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all)                              | 0             | 0              | 0              |
| Weight Decreased                               |               |                |                |
| subjects affected / exposed                    | 0 / 8 (0.00%) | 0 / 27 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all)                              | 0             | 0              | 0              |
| Neutrophil Count Decreased                     |               |                |                |
| subjects affected / exposed                    | 0 / 8 (0.00%) | 0 / 27 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all)                              | 0             | 0              | 0              |
| Injury, poisoning and procedural complications |               |                |                |
| Head Injury                                    |               |                |                |
| subjects affected / exposed                    | 0 / 8 (0.00%) | 0 / 27 (0.00%) | 1 / 17 (5.88%) |
| occurrences (all)                              | 0             | 0              | 1              |
| Skin Wound                                     |               |                |                |

|  |                     |                       |                     |
|--|---------------------|-----------------------|---------------------|
| subjects affected / exposed<br>occurrences (all)   | 0 / 8 (0.00%)<br>0  | 0 / 27 (0.00%)<br>0   | 1 / 17 (5.88%)<br>1 |
| Skin Laceration<br>subjects affected / exposed<br>occurrences (all)                                    | 0 / 8 (0.00%)<br>0  | 1 / 27 (3.70%)<br>1   | 1 / 17 (5.88%)<br>1 |
| Ligament Sprain<br>subjects affected / exposed<br>occurrences (all)                                    | 0 / 8 (0.00%)<br>0  | 0 / 27 (0.00%)<br>0   | 0 / 17 (0.00%)<br>0 |
| Cardiac disorders<br>Tachycardia<br>subjects affected / exposed<br>occurrences (all)                   | 0 / 8 (0.00%)<br>0  | 0 / 27 (0.00%)<br>0   | 0 / 17 (0.00%)<br>0 |
| Sinus Tachycardia<br>subjects affected / exposed<br>occurrences (all)                                  | 0 / 8 (0.00%)<br>0  | 0 / 27 (0.00%)<br>0   | 0 / 17 (0.00%)<br>0 |
| Palpitations<br>subjects affected / exposed<br>occurrences (all)                                       | 0 / 8 (0.00%)<br>0  | 0 / 27 (0.00%)<br>0   | 0 / 17 (0.00%)<br>0 |
| Nervous system disorders<br>Amnestic Disorder<br>subjects affected / exposed<br>occurrences (all)      | 1 / 8 (12.50%)<br>1 | 0 / 27 (0.00%)<br>0   | 0 / 17 (0.00%)<br>0 |
| Neuropathy Peripheral<br>subjects affected / exposed<br>occurrences (all)                              | 0 / 8 (0.00%)<br>0  | 0 / 27 (0.00%)<br>0   | 1 / 17 (5.88%)<br>1 |
| Headache<br>subjects affected / exposed<br>occurrences (all)   | 3 / 8 (37.50%)<br>3 | 5 / 27 (18.52%)<br>10 | 1 / 17 (5.88%)<br>2 |
| Dizziness Postural<br>subjects affected / exposed<br>occurrences (all)                                 | 0 / 8 (0.00%)<br>0  | 0 / 27 (0.00%)<br>0   | 0 / 17 (0.00%)<br>0 |
| Blood and lymphatic system disorders<br>Leukopenia<br>subjects affected / exposed<br>occurrences (all) | 1 / 8 (12.50%)<br>1 | 0 / 27 (0.00%)<br>0   | 0 / 17 (0.00%)<br>0 |
| Anaemia  |                     |                       |                     |

|  |                     |                     |                     |
|--|---------------------|---------------------|---------------------|
| subjects affected / exposed<br>occurrences (all)   | 1 / 8 (12.50%)<br>1 | 0 / 27 (0.00%)<br>0 | 1 / 17 (5.88%)<br>1 |
| Neutropenia<br>subjects affected / exposed<br>occurrences (all)  | 1 / 8 (12.50%)<br>1 | 0 / 27 (0.00%)<br>0 | 0 / 17 (0.00%)<br>0 |
| Thrombocytopenia<br>subjects affected / exposed<br>occurrences (all)                                   | 0 / 8 (0.00%)<br>0  | 0 / 27 (0.00%)<br>0 | 0 / 17 (0.00%)<br>0 |
| Ear and labyrinth disorders<br>Ear Pain<br>subjects affected / exposed<br>occurrences (all)            | 0 / 8 (0.00%)<br>0  | 0 / 27 (0.00%)<br>0 | 0 / 17 (0.00%)<br>0 |
| Eye disorders<br>Cataract<br>subjects affected / exposed<br>occurrences (all)                          | 0 / 8 (0.00%)<br>0  | 0 / 27 (0.00%)<br>0 | 0 / 17 (0.00%)<br>0 |
| Conjunctival Hyperaemia<br>subjects affected / exposed<br>occurrences (all)                            | 0 / 8 (0.00%)<br>0  | 0 / 27 (0.00%)<br>0 | 1 / 17 (5.88%)<br>1 |
| Visual Impairment<br>subjects affected / exposed<br>occurrences (all)                                  | 0 / 8 (0.00%)<br>0  | 0 / 27 (0.00%)<br>0 | 0 / 17 (0.00%)<br>0 |
| Myopia<br>subjects affected / exposed<br>occurrences (all)   | 0 / 8 (0.00%)<br>0  | 0 / 27 (0.00%)<br>0 | 0 / 17 (0.00%)<br>0 |
| Eye Pruritus<br>subjects affected / exposed<br>occurrences (all)                                       | 0 / 8 (0.00%)<br>0  | 1 / 27 (3.70%)<br>1 | 0 / 17 (0.00%)<br>0 |
| Gastrointestinal disorders<br>Abdominal Discomfort<br>subjects affected / exposed<br>occurrences (all) | 1 / 8 (12.50%)<br>1 | 0 / 27 (0.00%)<br>0 | 0 / 17 (0.00%)<br>0 |
| Aphthous Ulcer<br>subjects affected / exposed<br>occurrences (all)                                     | 0 / 8 (0.00%)<br>0  | 0 / 27 (0.00%)<br>0 | 1 / 17 (5.88%)<br>2 |
| Abdominal Pain Upper   |                     |                     |                     |

|                                  |                |                |                |
|----------------------------------|----------------|----------------|----------------|
| subjects affected / exposed      | 0 / 8 (0.00%)  | 0 / 27 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all)                | 0              | 0              | 0              |
| Abdominal Pain Lower             |                |                |                |
| subjects affected / exposed      | 0 / 8 (0.00%)  | 0 / 27 (0.00%) | 1 / 17 (5.88%) |
| occurrences (all)                | 0              | 0              | 1              |
| Abdominal Pain                   |                |                |                |
| subjects affected / exposed      | 0 / 8 (0.00%)  | 0 / 27 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all)                | 0              | 0              | 0              |
| Abdominal Distension             |                |                |                |
| subjects affected / exposed      | 0 / 8 (0.00%)  | 1 / 27 (3.70%) | 0 / 17 (0.00%) |
| occurrences (all)                | 0              | 1              | 0              |
| Constipation                     |                |                |                |
| subjects affected / exposed      | 0 / 8 (0.00%)  | 1 / 27 (3.70%) | 0 / 17 (0.00%) |
| occurrences (all)                | 0              | 1              | 0              |
| Dental Caries                    |                |                |                |
| subjects affected / exposed      | 1 / 8 (12.50%) | 0 / 27 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all)                | 1              | 0              | 0              |
| Haemorrhoids                     |                |                |                |
| subjects affected / exposed      | 0 / 8 (0.00%)  | 0 / 27 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all)                | 0              | 0              | 0              |
| Gastrooesophageal Reflux Disease |                |                |                |
| subjects affected / exposed      | 0 / 8 (0.00%)  | 0 / 27 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all)                | 0              | 0              | 0              |
| Food Poisoning                   |                |                |                |
| subjects affected / exposed      | 1 / 8 (12.50%) | 0 / 27 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all)                | 1              | 0              | 0              |
| Dyspepsia                        |                |                |                |
| subjects affected / exposed      | 0 / 8 (0.00%)  | 2 / 27 (7.41%) | 0 / 17 (0.00%) |
| occurrences (all)                | 0              | 2              | 0              |
| Diarrhoea                        |                |                |                |
| subjects affected / exposed      | 1 / 8 (12.50%) | 0 / 27 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all)                | 1              | 0              | 0              |
| Large Intestine Polyp            |                |                |                |
| subjects affected / exposed      | 0 / 8 (0.00%)  | 0 / 27 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all)                | 0              | 0              | 0              |
| Nausea                           |                |                |                |

|   |                |                 |                |
|---|----------------|-----------------|----------------|
| subjects affected / exposed                     | 3 / 8 (37.50%) | 4 / 27 (14.81%) | 0 / 17 (0.00%) |
| occurrences (all)                               | 3              | 4               | 0              |
| Mouth Ulceration                                |                |                 |                |
| subjects affected / exposed                     | 0 / 8 (0.00%)  | 0 / 27 (0.00%)  | 1 / 17 (5.88%) |
| occurrences (all)                               | 0              | 0               | 1              |
| Rectal Haemorrhage                              |                |                 |                |
| subjects affected / exposed                     | 0 / 8 (0.00%)  | 0 / 27 (0.00%)  | 0 / 17 (0.00%) |
| occurrences (all)                               | 0              | 0               | 0              |
| Vomiting  |                |                 |                |
| subjects affected / exposed                     | 0 / 8 (0.00%)  | 0 / 27 (0.00%)  | 0 / 17 (0.00%) |
| occurrences (all)                               | 0              | 0               | 0              |
| Toothache                                       |                |                 |                |
| subjects affected / exposed                     | 1 / 8 (12.50%) | 0 / 27 (0.00%)  | 0 / 17 (0.00%) |
| occurrences (all)                               | 1              | 0               | 0              |
| Skin and subcutaneous tissue disorders          |                |                 |                |
| Eczema  |                |                 |                |
| subjects affected / exposed                     | 0 / 8 (0.00%)  | 0 / 27 (0.00%)  | 0 / 17 (0.00%) |
| occurrences (all)                               | 0              | 0               | 0              |
| Rash Maculo-Papular                             |                |                 |                |
| subjects affected / exposed                     | 0 / 8 (0.00%)  | 0 / 27 (0.00%)  | 0 / 17 (0.00%) |
| occurrences (all)                               | 0              | 0               | 0              |
| Skin Irritation                                 |                |                 |                |
| subjects affected / exposed                     | 0 / 8 (0.00%)  | 0 / 27 (0.00%)  | 0 / 17 (0.00%) |
| occurrences (all)                               | 0              | 0               | 0              |
| Alopecia  |                |                 |                |
| subjects affected / exposed                     | 0 / 8 (0.00%)  | 0 / 27 (0.00%)  | 0 / 17 (0.00%) |
| occurrences (all)                               | 0              | 0               | 0              |
| Skin Ulcer                                      |                |                 |                |
| subjects affected / exposed                     | 0 / 8 (0.00%)  | 0 / 27 (0.00%)  | 0 / 17 (0.00%) |
| occurrences (all)                               | 0              | 0               | 0              |
| Renal and urinary disorders                     |                |                 |                |
| Dysuria   |                |                 |                |
| subjects affected / exposed                     | 0 / 8 (0.00%)  | 0 / 27 (0.00%)  | 0 / 17 (0.00%) |
| occurrences (all)                               | 0              | 0               | 0              |
| Musculoskeletal and connective tissue disorders |                |                 |                |



|                                   |                |                |                |
|-----------------------------------|----------------|----------------|----------------|
| Pain in Extremity                 |                |                |                |
| subjects affected / exposed       | 1 / 8 (12.50%) | 0 / 27 (0.00%) | 1 / 17 (5.88%) |
| occurrences (all)                 | 1              | 0              | 1              |
| Muscular Weakness                 |                |                |                |
| subjects affected / exposed       | 0 / 8 (0.00%)  | 1 / 27 (3.70%) | 0 / 17 (0.00%) |
| occurrences (all)                 | 0              | 1              | 0              |
| Muscle Spasms                     |                |                |                |
| subjects affected / exposed       | 0 / 8 (0.00%)  | 1 / 27 (3.70%) | 0 / 17 (0.00%) |
| occurrences (all)                 | 0              | 1              | 0              |
| Limb Mass                         |                |                |                |
| subjects affected / exposed       | 1 / 8 (12.50%) | 0 / 27 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all)                 | 1              | 0              | 0              |
| Back Pain                         |                |                |                |
| subjects affected / exposed       | 1 / 8 (12.50%) | 2 / 27 (7.41%) | 0 / 17 (0.00%) |
| occurrences (all)                 | 1              | 2              | 0              |
| Arthralgia                        |                |                |                |
| subjects affected / exposed       | 0 / 8 (0.00%)  | 0 / 27 (0.00%) | 1 / 17 (5.88%) |
| occurrences (all)                 | 0              | 0              | 1              |
| Myalgia                           |                |                |                |
| subjects affected / exposed       | 0 / 8 (0.00%)  | 1 / 27 (3.70%) | 0 / 17 (0.00%) |
| occurrences (all)                 | 0              | 1              | 0              |
| Infections and infestations       |                |                |                |
| Aspergilloma                      |                |                |                |
| subjects affected / exposed       | 0 / 8 (0.00%)  | 0 / 27 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all)                 | 0              | 0              | 0              |
| Acarodermatitis                   |                |                |                |
| subjects affected / exposed       | 1 / 8 (12.50%) | 0 / 27 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all)                 | 1              | 0              | 0              |
| Lower Respiratory Tract Infection |                |                |                |
| subjects affected / exposed       | 0 / 8 (0.00%)  | 0 / 27 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all)                 | 0              | 0              | 0              |
| Carbuncle                         |                |                |                |
| subjects affected / exposed       | 0 / 8 (0.00%)  | 0 / 27 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all)                 | 0              | 0              | 0              |
| Conjunctivitis                    |                |                |                |

|  |                |                |                 |
|--|----------------|----------------|-----------------|
| subjects affected / exposed                | 0 / 8 (0.00%)  | 1 / 27 (3.70%) | 0 / 17 (0.00%)  |
| occurrences (all)                          | 0              | 1              | 0               |
| Covid-19                                   |                |                |                 |
| subjects affected / exposed                | 2 / 8 (25.00%) | 2 / 27 (7.41%) | 0 / 17 (0.00%)  |
| occurrences (all)                          | 2              | 2              | 0               |
| Hepatitis B                                |                |                |                 |
| subjects affected / exposed                | 0 / 8 (0.00%)  | 0 / 27 (0.00%) | 0 / 17 (0.00%)  |
| occurrences (all)                          | 0              | 0              | 0               |
| Influenza                                  |                |                |                 |
| subjects affected / exposed                | 0 / 8 (0.00%)  | 1 / 27 (3.70%) | 0 / 17 (0.00%)  |
| occurrences (all)                          | 0              | 1              | 0               |
| Lower Respiratory Tract Infection<br>Viral |                |                |                 |
| subjects affected / exposed                | 0 / 8 (0.00%)  | 0 / 27 (0.00%) | 0 / 17 (0.00%)  |
| occurrences (all)                          | 0              | 0              | 0               |
| Nasopharyngitis                            |                |                |                 |
| subjects affected / exposed                | 0 / 8 (0.00%)  | 2 / 27 (7.41%) | 2 / 17 (11.76%) |
| occurrences (all)                          | 0              | 2              | 2               |
| Oral Herpes                                |                |                |                 |
| subjects affected / exposed                | 0 / 8 (0.00%)  | 0 / 27 (0.00%) | 0 / 17 (0.00%)  |
| occurrences (all)                          | 0              | 0              | 0               |
| Paronychia                                 |                |                |                 |
| subjects affected / exposed                | 0 / 8 (0.00%)  | 0 / 27 (0.00%) | 1 / 17 (5.88%)  |
| occurrences (all)                          | 0              | 0              | 1               |
| Periodontitis                              |                |                |                 |
| subjects affected / exposed                | 0 / 8 (0.00%)  | 0 / 27 (0.00%) | 1 / 17 (5.88%)  |
| occurrences (all)                          | 0              | 0              | 1               |
| Respiratory Tract Infection                |                |                |                 |
| subjects affected / exposed                | 1 / 8 (12.50%) | 0 / 27 (0.00%) | 0 / 17 (0.00%)  |
| occurrences (all)                          | 1              | 0              | 0               |
| Urinary Tract Infection                    |                |                |                 |
| subjects affected / exposed                | 0 / 8 (0.00%)  | 0 / 27 (0.00%) | 0 / 17 (0.00%)  |
| occurrences (all)                          | 0              | 0              | 0               |
| Viral Infection                            |                |                |                 |
| subjects affected / exposed                | 0 / 8 (0.00%)  | 0 / 27 (0.00%) | 0 / 17 (0.00%)  |
| occurrences (all)                          | 0              | 0              | 0               |

|  |                     |                     |                     |
|--|---------------------|---------------------|---------------------|
| Respiratory Tract Infection Viral<br>subjects affected / exposed<br>occurrences (all)                        | 1 / 8 (12.50%)<br>1 | 0 / 27 (0.00%)<br>0 | 0 / 17 (0.00%)<br>0 |
| Upper Respiratory Tract Infection<br>subjects affected / exposed<br>occurrences (all)                        | 0 / 8 (0.00%)<br>0  | 1 / 27 (3.70%)<br>1 | 1 / 17 (5.88%)<br>3 |
| Sinusitis<br>subjects affected / exposed<br>occurrences (all)  | 0 / 8 (0.00%)<br>0  | 0 / 27 (0.00%)<br>0 | 1 / 17 (5.88%)<br>1 |
| Rhinitis<br>subjects affected / exposed<br>occurrences (all)   | 0 / 8 (0.00%)<br>0  | 0 / 27 (0.00%)<br>0 | 1 / 17 (5.88%)<br>1 |
| Metabolism and nutrition disorders<br>Decreased Appetite<br>subjects affected / exposed<br>occurrences (all) | 0 / 8 (0.00%)<br>0  | 2 / 27 (7.41%)<br>2 | 0 / 17 (0.00%)<br>0 |
| Iron Deficiency<br>subjects affected / exposed<br>occurrences (all)  | 0 / 8 (0.00%)<br>0  | 0 / 27 (0.00%)<br>0 | 0 / 17 (0.00%)<br>0 |
| Vitamin B12 Deficiency<br>subjects affected / exposed<br>occurrences (all)                                   | 0 / 8 (0.00%)<br>0  | 0 / 27 (0.00%)<br>0 | 1 / 17 (5.88%)<br>1 |

| <b>Non-serious adverse events</b>  | CP: Cohort 2 (Per PA<br>6): JNJ-3989 + NA<br>+ PegIFN-alpha-2a | FU: Cohort 1: JNJ-<br>3989+ JNJ-<br>6379+NA+PegIFN-<br>alpha-2a | FU: Cohort 1: JNJ-<br>3989 + NA +<br>PegIFN-alpha-2a |
|--|--|---|--|
| Total subjects affected by non-serious<br>adverse events<br>subjects affected / exposed  | 13 / 17 (76.47%)   | 15 / 26 (57.69%)  | 5 / 8 (62.50%)                                       |
| Neoplasms benign, malignant and<br>unspecified (incl cysts and polyps)<br>Haemangioma of Liver<br>subjects affected / exposed<br>occurrences (all) | 0 / 17 (0.00%)<br>0  | 0 / 26 (0.00%)<br>0   | 0 / 8 (0.00%)<br>0                                   |
| General disorders and administration<br>site conditions<br>Hyperthermia<br>subjects affected / exposed<br>occurrences (all)<br><br>Fatigue         | 0 / 17 (0.00%)<br>0  | 0 / 26 (0.00%)<br>0   | 0 / 8 (0.00%)<br>0                                   |

|                               |                 |                |                |
|-------------------------------|-----------------|----------------|----------------|
| subjects affected / exposed   | 4 / 17 (23.53%) | 0 / 26 (0.00%) | 1 / 8 (12.50%) |
| occurrences (all)             | 4               | 0              | 1              |
| Chills                        |                 |                |                |
| subjects affected / exposed   | 1 / 17 (5.88%)  | 0 / 26 (0.00%) | 0 / 8 (0.00%)  |
| occurrences (all)             | 1               | 0              | 0              |
| Asthenia                      |                 |                |                |
| subjects affected / exposed   | 1 / 17 (5.88%)  | 0 / 26 (0.00%) | 0 / 8 (0.00%)  |
| occurrences (all)             | 1               | 0              | 0              |
| Injection Site Erythema       |                 |                |                |
| subjects affected / exposed   | 3 / 17 (17.65%) | 0 / 26 (0.00%) | 0 / 8 (0.00%)  |
| occurrences (all)             | 3               | 0              | 0              |
| Injection Site Bruising       |                 |                |                |
| subjects affected / exposed   | 1 / 17 (5.88%)  | 0 / 26 (0.00%) | 0 / 8 (0.00%)  |
| occurrences (all)             | 1               | 0              | 0              |
| Influenza Like Illness        |                 |                |                |
| subjects affected / exposed   | 2 / 17 (11.76%) | 2 / 26 (7.69%) | 0 / 8 (0.00%)  |
| occurrences (all)             | 2               | 2              | 0              |
| Injection Site Pain           |                 |                |                |
| subjects affected / exposed   | 0 / 17 (0.00%)  | 0 / 26 (0.00%) | 0 / 8 (0.00%)  |
| occurrences (all)             | 0               | 0              | 0              |
| Injection Site Pruritus       |                 |                |                |
| subjects affected / exposed   | 1 / 17 (5.88%)  | 0 / 26 (0.00%) | 0 / 8 (0.00%)  |
| occurrences (all)             | 2               | 0              | 0              |
| Injection Site Rash           |                 |                |                |
| subjects affected / exposed   | 0 / 17 (0.00%)  | 0 / 26 (0.00%) | 0 / 8 (0.00%)  |
| occurrences (all)             | 0               | 0              | 0              |
| Injection Site Reaction       |                 |                |                |
| subjects affected / exposed   | 1 / 17 (5.88%)  | 0 / 26 (0.00%) | 0 / 8 (0.00%)  |
| occurrences (all)             | 5               | 0              | 0              |
| Injury Associated with Device |                 |                |                |
| subjects affected / exposed   | 0 / 17 (0.00%)  | 0 / 26 (0.00%) | 0 / 8 (0.00%)  |
| occurrences (all)             | 0               | 0              | 0              |
| Pyrexia                       |                 |                |                |
| subjects affected / exposed   | 3 / 17 (17.65%) | 1 / 26 (3.85%) | 1 / 8 (12.50%) |
| occurrences (all)             | 4               | 2              | 1              |
| Pain                          |                 |                |                |

|   |                      |                     |                    |
|---|----------------------|---------------------|--------------------|
| subjects affected / exposed<br>occurrences (all)  | 2 / 17 (11.76%)<br>2 | 0 / 26 (0.00%)<br>0 | 0 / 8 (0.00%)<br>0 |
| Non-Cardiac Chest Pain<br>subjects affected / exposed<br>occurrences (all)  | 1 / 17 (5.88%)<br>1  | 0 / 26 (0.00%)<br>0 | 0 / 8 (0.00%)<br>0 |
| Temperature Intolerance<br>subjects affected / exposed<br>occurrences (all)   | 0 / 17 (0.00%)<br>0  | 0 / 26 (0.00%)<br>0 | 0 / 8 (0.00%)<br>0 |
| Immune system disorders<br>Seasonal Allergy<br>subjects affected / exposed<br>occurrences (all)                           | 0 / 17 (0.00%)<br>0  | 1 / 26 (3.85%)<br>1 | 0 / 8 (0.00%)<br>0 |
| Mite Allergy<br>subjects affected / exposed<br>occurrences (all)  | 0 / 17 (0.00%)<br>0  | 0 / 26 (0.00%)<br>0 | 0 / 8 (0.00%)<br>0 |
| Food Allergy<br>subjects affected / exposed<br>occurrences (all)  | 0 / 17 (0.00%)<br>0  | 0 / 26 (0.00%)<br>0 | 0 / 8 (0.00%)<br>0 |
| Reproductive system and breast disorders<br>Vaginal Haemorrhage<br>subjects affected / exposed<br>occurrences (all)       | 0 / 17 (0.00%)<br>0  | 0 / 26 (0.00%)<br>0 | 0 / 8 (0.00%)<br>0 |
| Respiratory, thoracic and mediastinal disorders<br>Oropharyngeal Pain<br>subjects affected / exposed<br>occurrences (all) | 0 / 17 (0.00%)<br>0  | 1 / 26 (3.85%)<br>1 | 0 / 8 (0.00%)<br>0 |
| Epistaxis<br>subjects affected / exposed<br>occurrences (all)   | 0 / 17 (0.00%)<br>0  | 0 / 26 (0.00%)<br>0 | 0 / 8 (0.00%)<br>0 |
| Dyspnoea Exertional<br>subjects affected / exposed<br>occurrences (all)   | 1 / 17 (5.88%)<br>1  | 0 / 26 (0.00%)<br>0 | 0 / 8 (0.00%)<br>0 |
| Dry Throat<br>subjects affected / exposed<br>occurrences (all)  | 1 / 17 (5.88%)<br>1  | 0 / 26 (0.00%)<br>0 | 0 / 8 (0.00%)<br>0 |
| Cough   |                      |                     |                    |

|                              |                |                |                |
|------------------------------|----------------|----------------|----------------|
| subjects affected / exposed  | 0 / 17 (0.00%) | 2 / 26 (7.69%) | 1 / 8 (12.50%) |
| occurrences (all)            | 0              | 2              | 1              |
| Allergic Sinusitis           |                |                |                |
| subjects affected / exposed  | 0 / 17 (0.00%) | 0 / 26 (0.00%) | 0 / 8 (0.00%)  |
| occurrences (all)            | 0              | 0              | 0              |
| Dyspnoea                     |                |                |                |
| subjects affected / exposed  | 0 / 17 (0.00%) | 0 / 26 (0.00%) | 0 / 8 (0.00%)  |
| occurrences (all)            | 0              | 0              | 0              |
| Respiratory Tract Congestion |                |                |                |
| subjects affected / exposed  | 1 / 17 (5.88%) | 0 / 26 (0.00%) | 0 / 8 (0.00%)  |
| occurrences (all)            | 1              | 0              | 0              |
| Rhinitis Allergic            |                |                |                |
| subjects affected / exposed  | 0 / 17 (0.00%) | 0 / 26 (0.00%) | 0 / 8 (0.00%)  |
| occurrences (all)            | 0              | 0              | 0              |
| Rhinorrhoea                  |                |                |                |
| subjects affected / exposed  | 0 / 17 (0.00%) | 0 / 26 (0.00%) | 0 / 8 (0.00%)  |
| occurrences (all)            | 0              | 0              | 0              |
| Sinus Congestion             |                |                |                |
| subjects affected / exposed  | 1 / 17 (5.88%) | 0 / 26 (0.00%) | 0 / 8 (0.00%)  |
| occurrences (all)            | 1              | 0              | 0              |
| Productive Cough             |                |                |                |
| subjects affected / exposed  | 1 / 17 (5.88%) | 0 / 26 (0.00%) | 0 / 8 (0.00%)  |
| occurrences (all)            | 1              | 0              | 0              |
| Psychiatric disorders        |                |                |                |
| Insomnia                     |                |                |                |
| subjects affected / exposed  | 0 / 17 (0.00%) | 0 / 26 (0.00%) | 1 / 8 (12.50%) |
| occurrences (all)            | 0              | 0              | 1              |
| Depressed Mood               |                |                |                |
| subjects affected / exposed  | 0 / 17 (0.00%) | 0 / 26 (0.00%) | 1 / 8 (12.50%) |
| occurrences (all)            | 0              | 0              | 1              |
| Apathy                       |                |                |                |
| subjects affected / exposed  | 0 / 17 (0.00%) | 0 / 26 (0.00%) | 0 / 8 (0.00%)  |
| occurrences (all)            | 0              | 0              | 0              |
| Anxiety Disorder             |                |                |                |
| subjects affected / exposed  | 0 / 17 (0.00%) | 0 / 26 (0.00%) | 0 / 8 (0.00%)  |
| occurrences (all)            | 0              | 0              | 0              |

|  |                 |                |                |
|--|-----------------|----------------|----------------|
| Investigations                         |                 |                |                |
| Alanine Aminotransferase Increased     |                 |                |                |
| subjects affected / exposed            | 4 / 17 (23.53%) | 0 / 26 (0.00%) | 0 / 8 (0.00%)  |
| occurrences (all)                      | 6               | 0              | 0              |
| Aspartate Aminotransferase Increased   |                 |                |                |
| subjects affected / exposed            | 2 / 17 (11.76%) | 0 / 26 (0.00%) | 1 / 8 (12.50%) |
| occurrences (all)                      | 2               | 0              | 1              |
| Blood Creatine Phosphokinase Increased |                 |                |                |
| subjects affected / exposed            | 1 / 17 (5.88%)  | 0 / 26 (0.00%) | 0 / 8 (0.00%)  |
| occurrences (all)                      | 1               | 0              | 0              |
| Blood Alkaline Phosphatase Increased   |                 |                |                |
| subjects affected / exposed            | 1 / 17 (5.88%)  | 0 / 26 (0.00%) | 0 / 8 (0.00%)  |
| occurrences (all)                      | 1               | 0              | 0              |
| Blood Glucose Increased                |                 |                |                |
| subjects affected / exposed            | 0 / 17 (0.00%)  | 0 / 26 (0.00%) | 1 / 8 (12.50%) |
| occurrences (all)                      | 0               | 0              | 1              |
| Body Temperature Increased             |                 |                |                |
| subjects affected / exposed            | 0 / 17 (0.00%)  | 0 / 26 (0.00%) | 0 / 8 (0.00%)  |
| occurrences (all)                      | 0               | 0              | 0              |
| Glucose Urine Present                  |                 |                |                |
| subjects affected / exposed            | 0 / 17 (0.00%)  | 0 / 26 (0.00%) | 1 / 8 (12.50%) |
| occurrences (all)                      | 0               | 0              | 3              |
| Liver Scan Abnormal                    |                 |                |                |
| subjects affected / exposed            | 1 / 17 (5.88%)  | 0 / 26 (0.00%) | 0 / 8 (0.00%)  |
| occurrences (all)                      | 1               | 0              | 0              |
| Ultrasound Liver Abnormal              |                 |                |                |
| subjects affected / exposed            | 0 / 17 (0.00%)  | 0 / 26 (0.00%) | 0 / 8 (0.00%)  |
| occurrences (all)                      | 0               | 0              | 0              |
| White Blood Cell Count Decreased       |                 |                |                |
| subjects affected / exposed            | 0 / 17 (0.00%)  | 0 / 26 (0.00%) | 0 / 8 (0.00%)  |
| occurrences (all)                      | 0               | 0              | 0              |
| Weight Decreased                       |                 |                |                |
| subjects affected / exposed            | 0 / 17 (0.00%)  | 0 / 26 (0.00%) | 0 / 8 (0.00%)  |
| occurrences (all)                      | 0               | 0              | 0              |
| Neutrophil Count Decreased             |                 |                |                |

|  |                     |                     |                    |
|--|---------------------|---------------------|--------------------|
| subjects affected / exposed<br>occurrences (all) | 1 / 17 (5.88%)<br>1 | 0 / 26 (0.00%)<br>0 | 0 / 8 (0.00%)<br>0 |
| Injury, poisoning and procedural complications   |                     |                     |                    |
| Head Injury                                      |                     |                     |                    |
| subjects affected / exposed                      | 0 / 17 (0.00%)      | 0 / 26 (0.00%)      | 0 / 8 (0.00%)      |
| occurrences (all)                                | 0                   | 0                   | 0                  |
| Skin Wound                                       |                     |                     |                    |
| subjects affected / exposed                      | 0 / 17 (0.00%)      | 0 / 26 (0.00%)      | 0 / 8 (0.00%)      |
| occurrences (all)                                | 0                   | 0                   | 0                  |
| Skin Laceration                                  |                     |                     |                    |
| subjects affected / exposed                      | 0 / 17 (0.00%)      | 1 / 26 (3.85%)      | 0 / 8 (0.00%)      |
| occurrences (all)                                | 0                   | 1                   | 0                  |
| Ligament Sprain                                  |                     |                     |                    |
| subjects affected / exposed                      | 0 / 17 (0.00%)      | 0 / 26 (0.00%)      | 0 / 8 (0.00%)      |
| occurrences (all)                                | 0                   | 0                   | 0                  |
| Cardiac disorders                                |                     |                     |                    |
| Tachycardia                                      |                     |                     |                    |
| subjects affected / exposed                      | 0 / 17 (0.00%)      | 0 / 26 (0.00%)      | 1 / 8 (12.50%)     |
| occurrences (all)                                | 0                   | 0                   | 1                  |
| Sinus Tachycardia                                |                     |                     |                    |
| subjects affected / exposed                      | 0 / 17 (0.00%)      | 0 / 26 (0.00%)      | 0 / 8 (0.00%)      |
| occurrences (all)                                | 0                   | 0                   | 0                  |
| Palpitations                                     |                     |                     |                    |
| subjects affected / exposed                      | 1 / 17 (5.88%)      | 0 / 26 (0.00%)      | 0 / 8 (0.00%)      |
| occurrences (all)                                | 1                   | 0                   | 0                  |
| Nervous system disorders                         |                     |                     |                    |
| Amnestic Disorder                                |                     |                     |                    |
| subjects affected / exposed                      | 0 / 17 (0.00%)      | 0 / 26 (0.00%)      | 0 / 8 (0.00%)      |
| occurrences (all)                                | 0                   | 0                   | 0                  |
| Neuropathy Peripheral                            |                     |                     |                    |
| subjects affected / exposed                      | 0 / 17 (0.00%)      | 0 / 26 (0.00%)      | 0 / 8 (0.00%)      |
| occurrences (all)                                | 0                   | 0                   | 0                  |
| Headache   |                     |                     |                    |
| subjects affected / exposed                      | 1 / 17 (5.88%)      | 0 / 26 (0.00%)      | 1 / 8 (12.50%)     |
| occurrences (all)                                | 1                   | 0                   | 1                  |
| Dizziness Postural                               |                     |                     |                    |



|  |                     |                     |                    |
|--|---------------------|---------------------|--------------------|
| subjects affected / exposed<br>occurrences (all) | 1 / 17 (5.88%)<br>1 | 0 / 26 (0.00%)<br>0 | 0 / 8 (0.00%)<br>0 |
| Blood and lymphatic system disorders             |                     |                     |                    |
| Leukopenia                                       |                     |                     |                    |
| subjects affected / exposed                      | 0 / 17 (0.00%)      | 2 / 26 (7.69%)      | 0 / 8 (0.00%)      |
| occurrences (all)                                | 0                   | 3                   | 0                  |
| Anaemia  |                     |                     |                    |
| subjects affected / exposed                      | 0 / 17 (0.00%)      | 0 / 26 (0.00%)      | 0 / 8 (0.00%)      |
| occurrences (all)                                | 0                   | 0                   | 0                  |
| Neutropenia                                      |                     |                     |                    |
| subjects affected / exposed                      | 1 / 17 (5.88%)      | 1 / 26 (3.85%)      | 0 / 8 (0.00%)      |
| occurrences (all)                                | 1                   | 1                   | 0                  |
| Thrombocytopenia                                 |                     |                     |                    |
| subjects affected / exposed                      | 1 / 17 (5.88%)      | 0 / 26 (0.00%)      | 0 / 8 (0.00%)      |
| occurrences (all)                                | 1                   | 0                   | 0                  |
| Ear and labyrinth disorders                      |                     |                     |                    |
| Ear Pain   |                     |                     |                    |
| subjects affected / exposed                      | 0 / 17 (0.00%)      | 0 / 26 (0.00%)      | 0 / 8 (0.00%)      |
| occurrences (all)                                | 0                   | 0                   | 0                  |
| Eye disorders                                    |                     |                     |                    |
| Cataract   |                     |                     |                    |
| subjects affected / exposed                      | 1 / 17 (5.88%)      | 0 / 26 (0.00%)      | 0 / 8 (0.00%)      |
| occurrences (all)                                | 2                   | 0                   | 0                  |
| Conjunctival Hyperaemia                          |                     |                     |                    |
| subjects affected / exposed                      | 0 / 17 (0.00%)      | 0 / 26 (0.00%)      | 0 / 8 (0.00%)      |
| occurrences (all)                                | 0                   | 0                   | 0                  |
| Visual Impairment                                |                     |                     |                    |
| subjects affected / exposed                      | 1 / 17 (5.88%)      | 0 / 26 (0.00%)      | 0 / 8 (0.00%)      |
| occurrences (all)                                | 1                   | 0                   | 0                  |
| Myopia   |                     |                     |                    |
| subjects affected / exposed                      | 0 / 17 (0.00%)      | 0 / 26 (0.00%)      | 0 / 8 (0.00%)      |
| occurrences (all)                                | 0                   | 0                   | 0                  |
| Eye Pruritus                                     |                     |                     |                    |
| subjects affected / exposed                      | 0 / 17 (0.00%)      | 0 / 26 (0.00%)      | 0 / 8 (0.00%)      |
| occurrences (all)                                | 0                   | 0                   | 0                  |
| Gastrointestinal disorders                       |                     |                     |                    |

|                                  |                |                |               |
|----------------------------------|----------------|----------------|---------------|
| Abdominal Discomfort             |                |                |               |
| subjects affected / exposed      | 1 / 17 (5.88%) | 0 / 26 (0.00%) | 0 / 8 (0.00%) |
| occurrences (all)                | 1              | 0              | 0             |
| Aphthous Ulcer                   |                |                |               |
| subjects affected / exposed      | 0 / 17 (0.00%) | 0 / 26 (0.00%) | 0 / 8 (0.00%) |
| occurrences (all)                | 0              | 0              | 0             |
| Abdominal Pain Upper             |                |                |               |
| subjects affected / exposed      | 1 / 17 (5.88%) | 1 / 26 (3.85%) | 0 / 8 (0.00%) |
| occurrences (all)                | 1              | 1              | 0             |
| Abdominal Pain Lower             |                |                |               |
| subjects affected / exposed      | 0 / 17 (0.00%) | 0 / 26 (0.00%) | 0 / 8 (0.00%) |
| occurrences (all)                | 0              | 0              | 0             |
| Abdominal Pain                   |                |                |               |
| subjects affected / exposed      | 1 / 17 (5.88%) | 0 / 26 (0.00%) | 0 / 8 (0.00%) |
| occurrences (all)                | 1              | 0              | 0             |
| Abdominal Distension             |                |                |               |
| subjects affected / exposed      | 1 / 17 (5.88%) | 0 / 26 (0.00%) | 0 / 8 (0.00%) |
| occurrences (all)                | 1              | 0              | 0             |
| Constipation                     |                |                |               |
| subjects affected / exposed      | 0 / 17 (0.00%) | 0 / 26 (0.00%) | 0 / 8 (0.00%) |
| occurrences (all)                | 0              | 0              | 0             |
| Dental Caries                    |                |                |               |
| subjects affected / exposed      | 0 / 17 (0.00%) | 0 / 26 (0.00%) | 0 / 8 (0.00%) |
| occurrences (all)                | 0              | 0              | 0             |
| Haemorrhoids                     |                |                |               |
| subjects affected / exposed      | 0 / 17 (0.00%) | 0 / 26 (0.00%) | 0 / 8 (0.00%) |
| occurrences (all)                | 0              | 0              | 0             |
| Gastrooesophageal Reflux Disease |                |                |               |
| subjects affected / exposed      | 1 / 17 (5.88%) | 0 / 26 (0.00%) | 0 / 8 (0.00%) |
| occurrences (all)                | 1              | 0              | 0             |
| Food Poisoning                   |                |                |               |
| subjects affected / exposed      | 0 / 17 (0.00%) | 0 / 26 (0.00%) | 0 / 8 (0.00%) |
| occurrences (all)                | 0              | 0              | 0             |
| Dyspepsia                        |                |                |               |
| subjects affected / exposed      | 1 / 17 (5.88%) | 1 / 26 (3.85%) | 0 / 8 (0.00%) |
| occurrences (all)                | 1              | 1              | 0             |

|  |                |                |                |
|--|----------------|----------------|----------------|
| Diarrhoea                              |                |                |                |
| subjects affected / exposed            | 0 / 17 (0.00%) | 1 / 26 (3.85%) | 0 / 8 (0.00%)  |
| occurrences (all)                      | 0              | 2              | 0              |
| Large Intestine Polyp                  |                |                |                |
| subjects affected / exposed            | 0 / 17 (0.00%) | 0 / 26 (0.00%) | 0 / 8 (0.00%)  |
| occurrences (all)                      | 0              | 0              | 0              |
| Nausea                                 |                |                |                |
| subjects affected / exposed            | 0 / 17 (0.00%) | 0 / 26 (0.00%) | 0 / 8 (0.00%)  |
| occurrences (all)                      | 0              | 0              | 0              |
| Mouth Ulceration                       |                |                |                |
| subjects affected / exposed            | 0 / 17 (0.00%) | 0 / 26 (0.00%) | 0 / 8 (0.00%)  |
| occurrences (all)                      | 0              | 0              | 0              |
| Rectal Haemorrhage                     |                |                |                |
| subjects affected / exposed            | 0 / 17 (0.00%) | 0 / 26 (0.00%) | 0 / 8 (0.00%)  |
| occurrences (all)                      | 0              | 0              | 0              |
| Vomiting                               |                |                |                |
| subjects affected / exposed            | 0 / 17 (0.00%) | 0 / 26 (0.00%) | 0 / 8 (0.00%)  |
| occurrences (all)                      | 0              | 0              | 0              |
| Toothache                              |                |                |                |
| subjects affected / exposed            | 0 / 17 (0.00%) | 0 / 26 (0.00%) | 0 / 8 (0.00%)  |
| occurrences (all)                      | 0              | 0              | 0              |
| Skin and subcutaneous tissue disorders |                |                |                |
| Eczema                                 |                |                |                |
| subjects affected / exposed            | 1 / 17 (5.88%) | 0 / 26 (0.00%) | 0 / 8 (0.00%)  |
| occurrences (all)                      | 1              | 0              | 0              |
| Rash Maculo-Papular                    |                |                |                |
| subjects affected / exposed            | 0 / 17 (0.00%) | 0 / 26 (0.00%) | 0 / 8 (0.00%)  |
| occurrences (all)                      | 0              | 0              | 0              |
| Skin Irritation                        |                |                |                |
| subjects affected / exposed            | 0 / 17 (0.00%) | 0 / 26 (0.00%) | 0 / 8 (0.00%)  |
| occurrences (all)                      | 0              | 0              | 0              |
| Alopecia                               |                |                |                |
| subjects affected / exposed            | 0 / 17 (0.00%) | 1 / 26 (3.85%) | 1 / 8 (12.50%) |
| occurrences (all)                      | 0              | 1              | 1              |
| Skin Ulcer                             |                |                |                |

|  |                     |                     |                     |
|--|---------------------|---------------------|---------------------|
| subjects affected / exposed<br>occurrences (all)   | 1 / 17 (5.88%)<br>1 | 0 / 26 (0.00%)<br>0 | 0 / 8 (0.00%)<br>0  |
| Renal and urinary disorders<br>Dysuria<br>subjects affected / exposed<br>occurrences (all)                               | 0 / 17 (0.00%)<br>0 | 0 / 26 (0.00%)<br>0 | 0 / 8 (0.00%)<br>0  |
| Musculoskeletal and connective tissue disorders<br>Pain in Extremity<br>subjects affected / exposed<br>occurrences (all) | 1 / 17 (5.88%)<br>1 | 0 / 26 (0.00%)<br>0 | 0 / 8 (0.00%)<br>0  |
| Muscular Weakness<br>subjects affected / exposed<br>occurrences (all)  | 0 / 17 (0.00%)<br>0 | 0 / 26 (0.00%)<br>0 | 0 / 8 (0.00%)<br>0  |
| Muscle Spasms<br>subjects affected / exposed<br>occurrences (all)  | 0 / 17 (0.00%)<br>0 | 0 / 26 (0.00%)<br>0 | 1 / 8 (12.50%)<br>1 |
| Limb Mass<br>subjects affected / exposed<br>occurrences (all)  | 0 / 17 (0.00%)<br>0 | 0 / 26 (0.00%)<br>0 | 0 / 8 (0.00%)<br>0  |
| Back Pain<br>subjects affected / exposed<br>occurrences (all)  | 1 / 17 (5.88%)<br>1 | 1 / 26 (3.85%)<br>1 | 0 / 8 (0.00%)<br>0  |
| Arthralgia<br>subjects affected / exposed<br>occurrences (all)   | 1 / 17 (5.88%)<br>1 | 0 / 26 (0.00%)<br>0 | 0 / 8 (0.00%)<br>0  |
| Myalgia<br>subjects affected / exposed<br>occurrences (all)  | 0 / 17 (0.00%)<br>0 | 0 / 26 (0.00%)<br>0 | 0 / 8 (0.00%)<br>0  |
| Infections and infestations<br>Aspergilloma<br>subjects affected / exposed<br>occurrences (all)                          | 0 / 17 (0.00%)<br>0 | 0 / 26 (0.00%)<br>0 | 0 / 8 (0.00%)<br>0  |
| Acarodermatitis<br>subjects affected / exposed<br>occurrences (all)  | 0 / 17 (0.00%)<br>0 | 0 / 26 (0.00%)<br>0 | 0 / 8 (0.00%)<br>0  |
| Lower Respiratory Tract Infection  |                     |                     |                     |

|  |                |                 |                |
|--|----------------|-----------------|----------------|
| subjects affected / exposed                | 1 / 17 (5.88%) | 0 / 26 (0.00%)  | 0 / 8 (0.00%)  |
| occurrences (all)                          | 1              | 0               | 0              |
| Carbuncle                                  |                |                 |                |
| subjects affected / exposed                | 0 / 17 (0.00%) | 0 / 26 (0.00%)  | 0 / 8 (0.00%)  |
| occurrences (all)                          | 0              | 0               | 0              |
| Conjunctivitis                             |                |                 |                |
| subjects affected / exposed                | 1 / 17 (5.88%) | 0 / 26 (0.00%)  | 0 / 8 (0.00%)  |
| occurrences (all)                          | 1              | 0               | 0              |
| Covid-19                                   |                |                 |                |
| subjects affected / exposed                | 0 / 17 (0.00%) | 7 / 26 (26.92%) | 1 / 8 (12.50%) |
| occurrences (all)                          | 0              | 7               | 1              |
| Hepatitis B                                |                |                 |                |
| subjects affected / exposed                | 1 / 17 (5.88%) | 0 / 26 (0.00%)  | 0 / 8 (0.00%)  |
| occurrences (all)                          | 1              | 0               | 0              |
| Influenza                                  |                |                 |                |
| subjects affected / exposed                | 1 / 17 (5.88%) | 0 / 26 (0.00%)  | 0 / 8 (0.00%)  |
| occurrences (all)                          | 1              | 0               | 0              |
| Lower Respiratory Tract Infection<br>Viral |                |                 |                |
| subjects affected / exposed                | 0 / 17 (0.00%) | 0 / 26 (0.00%)  | 0 / 8 (0.00%)  |
| occurrences (all)                          | 0              | 0               | 0              |
| Nasopharyngitis                            |                |                 |                |
| subjects affected / exposed                | 0 / 17 (0.00%) | 4 / 26 (15.38%) | 0 / 8 (0.00%)  |
| occurrences (all)                          | 0              | 5               | 0              |
| Oral Herpes                                |                |                 |                |
| subjects affected / exposed                | 0 / 17 (0.00%) | 0 / 26 (0.00%)  | 0 / 8 (0.00%)  |
| occurrences (all)                          | 0              | 0               | 0              |
| Paronychia                                 |                |                 |                |
| subjects affected / exposed                | 0 / 17 (0.00%) | 0 / 26 (0.00%)  | 0 / 8 (0.00%)  |
| occurrences (all)                          | 0              | 0               | 0              |
| Periodontitis                              |                |                 |                |
| subjects affected / exposed                | 0 / 17 (0.00%) | 0 / 26 (0.00%)  | 0 / 8 (0.00%)  |
| occurrences (all)                          | 0              | 0               | 0              |
| Respiratory Tract Infection                |                |                 |                |
| subjects affected / exposed                | 1 / 17 (5.88%) | 0 / 26 (0.00%)  | 0 / 8 (0.00%)  |
| occurrences (all)                          | 1              | 0               | 0              |

|  |                      |                     |                     |
|--|----------------------|---------------------|---------------------|
| Urinary Tract Infection<br>subjects affected / exposed<br>occurrences (all)                                  | 0 / 17 (0.00%)<br>0  | 0 / 26 (0.00%)<br>0 | 2 / 8 (25.00%)<br>2 |
| Viral Infection<br>subjects affected / exposed<br>occurrences (all)  | 0 / 17 (0.00%)<br>0  | 0 / 26 (0.00%)<br>0 | 1 / 8 (12.50%)<br>1 |
| Respiratory Tract Infection Viral<br>subjects affected / exposed<br>occurrences (all)                        | 0 / 17 (0.00%)<br>0  | 0 / 26 (0.00%)<br>0 | 0 / 8 (0.00%)<br>0  |
| Upper Respiratory Tract Infection<br>subjects affected / exposed<br>occurrences (all)                        | 0 / 17 (0.00%)<br>0  | 0 / 26 (0.00%)<br>0 | 0 / 8 (0.00%)<br>0  |
| Sinusitis<br>subjects affected / exposed<br>occurrences (all)  | 0 / 17 (0.00%)<br>0  | 0 / 26 (0.00%)<br>0 | 0 / 8 (0.00%)<br>0  |
| Rhinitis<br>subjects affected / exposed<br>occurrences (all)   | 1 / 17 (5.88%)<br>1  | 1 / 26 (3.85%)<br>1 | 0 / 8 (0.00%)<br>0  |
| Metabolism and nutrition disorders<br>Decreased Appetite<br>subjects affected / exposed<br>occurrences (all) | 2 / 17 (11.76%)<br>2 | 0 / 26 (0.00%)<br>0 | 0 / 8 (0.00%)<br>0  |
| Iron Deficiency<br>subjects affected / exposed<br>occurrences (all)  | 0 / 17 (0.00%)<br>0  | 0 / 26 (0.00%)<br>0 | 1 / 8 (12.50%)<br>1 |
| Vitamin B12 Deficiency<br>subjects affected / exposed<br>occurrences (all)                                   | 0 / 17 (0.00%)<br>0  | 0 / 26 (0.00%)<br>0 | 0 / 8 (0.00%)<br>0  |

|   |  |  |   |
|---|--|--|---|
| <b>Non-serious adverse events</b>   | CP: Cohort 1(Prior PA 5): JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a | IP: Cohort 2 - Per PA 6: JNJ-3989 + NA + PegIFN-alpha-2a | CP: Cohort 1(Per PA 5): JNJ-3989+NA+PegIFN-alpha-2a |
| Total subjects affected by non-serious adverse events<br>subjects affected / exposed        | 21 / 25 (84.00%)   | 15 / 19 (78.95%)   | 7 / 7 (100.00%)                                     |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps)<br>Haemangioma of Liver |  |  |   |

|  |                 |                 |                |
|--|-----------------|-----------------|----------------|
| subjects affected / exposed                          | 0 / 25 (0.00%)  | 1 / 19 (5.26%)  | 0 / 7 (0.00%)  |
| occurrences (all)                                    | 0               | 1               | 0              |
| General disorders and administration site conditions |                 |                 |                |
| Hyperthermia   |                 |                 |                |
| subjects affected / exposed                          | 2 / 25 (8.00%)  | 0 / 19 (0.00%)  | 1 / 7 (14.29%) |
| occurrences (all)                                    | 2               | 0               | 1              |
| Fatigue  |                 |                 |                |
| subjects affected / exposed                          | 5 / 25 (20.00%) | 2 / 19 (10.53%) | 2 / 7 (28.57%) |
| occurrences (all)                                    | 5               | 2               | 2              |
| Chills   |                 |                 |                |
| subjects affected / exposed                          | 2 / 25 (8.00%)  | 0 / 19 (0.00%)  | 0 / 7 (0.00%)  |
| occurrences (all)                                    | 2               | 0               | 0              |
| Asthenia   |                 |                 |                |
| subjects affected / exposed                          | 1 / 25 (4.00%)  | 0 / 19 (0.00%)  | 0 / 7 (0.00%)  |
| occurrences (all)                                    | 2               | 0               | 0              |
| Injection Site Erythema                              |                 |                 |                |
| subjects affected / exposed                          | 3 / 25 (12.00%) | 1 / 19 (5.26%)  | 1 / 7 (14.29%) |
| occurrences (all)                                    | 13              | 1               | 1              |
| Injection Site Bruising                              |                 |                 |                |
| subjects affected / exposed                          | 0 / 25 (0.00%)  | 1 / 19 (5.26%)  | 0 / 7 (0.00%)  |
| occurrences (all)                                    | 0               | 1               | 0              |
| Influenza Like Illness                               |                 |                 |                |
| subjects affected / exposed                          | 4 / 25 (16.00%) | 0 / 19 (0.00%)  | 1 / 7 (14.29%) |
| occurrences (all)                                    | 6               | 0               | 1              |
| Injection Site Pain                                  |                 |                 |                |
| subjects affected / exposed                          | 1 / 25 (4.00%)  | 0 / 19 (0.00%)  | 0 / 7 (0.00%)  |
| occurrences (all)                                    | 1               | 0               | 0              |
| Injection Site Pruritus                              |                 |                 |                |
| subjects affected / exposed                          | 0 / 25 (0.00%)  | 0 / 19 (0.00%)  | 0 / 7 (0.00%)  |
| occurrences (all)                                    | 0               | 0               | 0              |
| Injection Site Rash                                  |                 |                 |                |
| subjects affected / exposed                          | 1 / 25 (4.00%)  | 0 / 19 (0.00%)  | 1 / 7 (14.29%) |
| occurrences (all)                                    | 3               | 0               | 1              |
| Injection Site Reaction                              |                 |                 |                |

|   |                      |                     |                     |
|---|----------------------|---------------------|---------------------|
| subjects affected / exposed<br>occurrences (all)  | 2 / 25 (8.00%)<br>2  | 0 / 19 (0.00%)<br>0 | 0 / 7 (0.00%)<br>0  |
| Injury Associated with Device<br>subjects affected / exposed<br>occurrences (all)   | 0 / 25 (0.00%)<br>0  | 0 / 19 (0.00%)<br>0 | 1 / 7 (14.29%)<br>1 |
| Pyrexia<br>subjects affected / exposed<br>occurrences (all)   | 3 / 25 (12.00%)<br>3 | 1 / 19 (5.26%)<br>1 | 0 / 7 (0.00%)<br>0  |
| Pain<br>subjects affected / exposed<br>occurrences (all)  | 0 / 25 (0.00%)<br>0  | 0 / 19 (0.00%)<br>0 | 0 / 7 (0.00%)<br>0  |
| Non-Cardiac Chest Pain<br>subjects affected / exposed<br>occurrences (all)  | 1 / 25 (4.00%)<br>1  | 0 / 19 (0.00%)<br>0 | 0 / 7 (0.00%)<br>0  |
| Temperature Intolerance<br>subjects affected / exposed<br>occurrences (all)   | 0 / 25 (0.00%)<br>0  | 0 / 19 (0.00%)<br>0 | 1 / 7 (14.29%)<br>1 |
| Immune system disorders<br>Seasonal Allergy<br>subjects affected / exposed<br>occurrences (all)                           | 0 / 25 (0.00%)<br>0  | 0 / 19 (0.00%)<br>0 | 0 / 7 (0.00%)<br>0  |
| Mite Allergy<br>subjects affected / exposed<br>occurrences (all)  | 0 / 25 (0.00%)<br>0  | 0 / 19 (0.00%)<br>0 | 0 / 7 (0.00%)<br>0  |
| Food Allergy<br>subjects affected / exposed<br>occurrences (all)  | 0 / 25 (0.00%)<br>0  | 0 / 19 (0.00%)<br>0 | 0 / 7 (0.00%)<br>0  |
| Reproductive system and breast disorders<br>Vaginal Haemorrhage<br>subjects affected / exposed<br>occurrences (all)       | 0 / 25 (0.00%)<br>0  | 1 / 19 (5.26%)<br>1 | 0 / 7 (0.00%)<br>0  |
| Respiratory, thoracic and mediastinal disorders<br>Oropharyngeal Pain<br>subjects affected / exposed<br>occurrences (all) | 0 / 25 (0.00%)<br>0  | 1 / 19 (5.26%)<br>1 | 0 / 7 (0.00%)<br>0  |
| Epistaxis   |                      |                     |                     |



|                              |                |                 |                |
|------------------------------|----------------|-----------------|----------------|
| subjects affected / exposed  | 0 / 25 (0.00%) | 0 / 19 (0.00%)  | 0 / 7 (0.00%)  |
| occurrences (all)            | 0              | 0               | 0              |
| Dyspnoea Exertional          |                |                 |                |
| subjects affected / exposed  | 0 / 25 (0.00%) | 0 / 19 (0.00%)  | 1 / 7 (14.29%) |
| occurrences (all)            | 0              | 0               | 1              |
| Dry Throat                   |                |                 |                |
| subjects affected / exposed  | 0 / 25 (0.00%) | 0 / 19 (0.00%)  | 0 / 7 (0.00%)  |
| occurrences (all)            | 0              | 0               | 0              |
| Cough                        |                |                 |                |
| subjects affected / exposed  | 0 / 25 (0.00%) | 2 / 19 (10.53%) | 1 / 7 (14.29%) |
| occurrences (all)            | 0              | 2               | 1              |
| Allergic Sinusitis           |                |                 |                |
| subjects affected / exposed  | 0 / 25 (0.00%) | 1 / 19 (5.26%)  | 0 / 7 (0.00%)  |
| occurrences (all)            | 0              | 1               | 0              |
| Dyspnoea                     |                |                 |                |
| subjects affected / exposed  | 0 / 25 (0.00%) | 1 / 19 (5.26%)  | 0 / 7 (0.00%)  |
| occurrences (all)            | 0              | 1               | 0              |
| Respiratory Tract Congestion |                |                 |                |
| subjects affected / exposed  | 0 / 25 (0.00%) | 0 / 19 (0.00%)  | 0 / 7 (0.00%)  |
| occurrences (all)            | 0              | 0               | 0              |
| Rhinitis Allergic            |                |                 |                |
| subjects affected / exposed  | 0 / 25 (0.00%) | 0 / 19 (0.00%)  | 0 / 7 (0.00%)  |
| occurrences (all)            | 0              | 0               | 0              |
| Rhinorrhoea                  |                |                 |                |
| subjects affected / exposed  | 0 / 25 (0.00%) | 1 / 19 (5.26%)  | 0 / 7 (0.00%)  |
| occurrences (all)            | 0              | 1               | 0              |
| Sinus Congestion             |                |                 |                |
| subjects affected / exposed  | 0 / 25 (0.00%) | 0 / 19 (0.00%)  | 0 / 7 (0.00%)  |
| occurrences (all)            | 0              | 0               | 0              |
| Productive Cough             |                |                 |                |
| subjects affected / exposed  | 0 / 25 (0.00%) | 0 / 19 (0.00%)  | 0 / 7 (0.00%)  |
| occurrences (all)            | 0              | 0               | 0              |
| Psychiatric disorders        |                |                 |                |
| Insomnia                     |                |                 |                |
| subjects affected / exposed  | 1 / 25 (4.00%) | 0 / 19 (0.00%)  | 0 / 7 (0.00%)  |
| occurrences (all)            | 1              | 0               | 0              |

|  |                     |                     |                     |
|--|---------------------|---------------------|---------------------|
| Depressed Mood<br>subjects affected / exposed<br>occurrences (all)                         | 0 / 25 (0.00%)<br>0 | 0 / 19 (0.00%)<br>0 | 0 / 7 (0.00%)<br>0  |
| Apathy<br>subjects affected / exposed<br>occurrences (all)                                 | 0 / 25 (0.00%)<br>0 | 0 / 19 (0.00%)<br>0 | 0 / 7 (0.00%)<br>0  |
| Anxiety Disorder<br>subjects affected / exposed<br>occurrences (all)                       | 0 / 25 (0.00%)<br>0 | 1 / 19 (5.26%)<br>1 | 0 / 7 (0.00%)<br>0  |
| Investigations   |                     |                     |                     |
| Alanine Aminotransferase Increased<br>subjects affected / exposed<br>occurrences (all)     | 2 / 25 (8.00%)<br>2 | 1 / 19 (5.26%)<br>3 | 0 / 7 (0.00%)<br>0  |
| Aspartate Aminotransferase Increased<br>subjects affected / exposed<br>occurrences (all)   | 0 / 25 (0.00%)<br>0 | 0 / 19 (0.00%)<br>0 | 1 / 7 (14.29%)<br>1 |
| Blood Creatine Phosphokinase Increased<br>subjects affected / exposed<br>occurrences (all) | 0 / 25 (0.00%)<br>0 | 0 / 19 (0.00%)<br>0 | 0 / 7 (0.00%)<br>0  |
| Blood Alkaline Phosphatase Increased<br>subjects affected / exposed<br>occurrences (all)   | 0 / 25 (0.00%)<br>0 | 0 / 19 (0.00%)<br>0 | 0 / 7 (0.00%)<br>0  |
| Blood Glucose Increased<br>subjects affected / exposed<br>occurrences (all)                | 0 / 25 (0.00%)<br>0 | 0 / 19 (0.00%)<br>0 | 0 / 7 (0.00%)<br>0  |
| Body Temperature Increased<br>subjects affected / exposed<br>occurrences (all)             | 2 / 25 (8.00%)<br>2 | 0 / 19 (0.00%)<br>0 | 0 / 7 (0.00%)<br>0  |
| Glucose Urine Present<br>subjects affected / exposed<br>occurrences (all)                  | 0 / 25 (0.00%)<br>0 | 0 / 19 (0.00%)<br>0 | 0 / 7 (0.00%)<br>0  |
| Liver Scan Abnormal<br>subjects affected / exposed<br>occurrences (all)                    | 0 / 25 (0.00%)<br>0 | 0 / 19 (0.00%)<br>0 | 0 / 7 (0.00%)<br>0  |
| Ultrasound Liver Abnormal  |                     |                     |                     |

|   |                     |                     |                     |
|---|---------------------|---------------------|---------------------|
| subjects affected / exposed<br>occurrences (all)  | 0 / 25 (0.00%)<br>0 | 0 / 19 (0.00%)<br>0 | 0 / 7 (0.00%)<br>0  |
| White Blood Cell Count Decreased<br>subjects affected / exposed<br>occurrences (all)                              | 2 / 25 (8.00%)<br>2 | 0 / 19 (0.00%)<br>0 | 0 / 7 (0.00%)<br>0  |
| Weight Decreased<br>subjects affected / exposed<br>occurrences (all)  | 1 / 25 (4.00%)<br>1 | 1 / 19 (5.26%)<br>1 | 0 / 7 (0.00%)<br>0  |
| Neutrophil Count Decreased<br>subjects affected / exposed<br>occurrences (all)                                    | 2 / 25 (8.00%)<br>2 | 0 / 19 (0.00%)<br>0 | 0 / 7 (0.00%)<br>0  |
| Injury, poisoning and procedural complications<br>Head Injury<br>subjects affected / exposed<br>occurrences (all) | 0 / 25 (0.00%)<br>0 | 0 / 19 (0.00%)<br>0 | 0 / 7 (0.00%)<br>0  |
| Skin Wound<br>subjects affected / exposed<br>occurrences (all)  | 0 / 25 (0.00%)<br>0 | 0 / 19 (0.00%)<br>0 | 0 / 7 (0.00%)<br>0  |
| Skin Laceration<br>subjects affected / exposed<br>occurrences (all)   | 0 / 25 (0.00%)<br>0 | 0 / 19 (0.00%)<br>0 | 0 / 7 (0.00%)<br>0  |
| Ligament Sprain<br>subjects affected / exposed<br>occurrences (all)   | 0 / 25 (0.00%)<br>0 | 1 / 19 (5.26%)<br>1 | 0 / 7 (0.00%)<br>0  |
| Cardiac disorders<br>Tachycardia<br>subjects affected / exposed<br>occurrences (all)                              | 0 / 25 (0.00%)<br>0 | 0 / 19 (0.00%)<br>0 | 0 / 7 (0.00%)<br>0  |
| Sinus Tachycardia<br>subjects affected / exposed<br>occurrences (all)   | 0 / 25 (0.00%)<br>0 | 0 / 19 (0.00%)<br>0 | 1 / 7 (14.29%)<br>1 |
| Palpitations<br>subjects affected / exposed<br>occurrences (all)  | 0 / 25 (0.00%)<br>0 | 0 / 19 (0.00%)<br>0 | 0 / 7 (0.00%)<br>0  |
| Nervous system disorders  |                     |                     |                     |

|   |                       |                      |                     |
|---|-----------------------|----------------------|---------------------|
| Amnestic Disorder<br>subjects affected / exposed<br>occurrences (all)       | 0 / 25 (0.00%)<br>0   | 0 / 19 (0.00%)<br>0  | 0 / 7 (0.00%)<br>0  |
| Neuropathy Peripheral<br>subjects affected / exposed<br>occurrences (all)   | 0 / 25 (0.00%)<br>0   | 0 / 19 (0.00%)<br>0  | 0 / 7 (0.00%)<br>0  |
| Headache<br>subjects affected / exposed<br>occurrences (all)                | 5 / 25 (20.00%)<br>6  | 2 / 19 (10.53%)<br>2 | 0 / 7 (0.00%)<br>0  |
| Dizziness Postural<br>subjects affected / exposed<br>occurrences (all)      | 0 / 25 (0.00%)<br>0   | 0 / 19 (0.00%)<br>0  | 0 / 7 (0.00%)<br>0  |
| Blood and lymphatic system disorders  |                       |                      |                     |
| Leukopenia<br>subjects affected / exposed<br>occurrences (all)              | 4 / 25 (16.00%)<br>6  | 0 / 19 (0.00%)<br>0  | 2 / 7 (28.57%)<br>2 |
| Anaemia<br>subjects affected / exposed<br>occurrences (all)                 | 1 / 25 (4.00%)<br>1   | 0 / 19 (0.00%)<br>0  | 0 / 7 (0.00%)<br>0  |
| Neutropenia<br>subjects affected / exposed<br>occurrences (all)             | 7 / 25 (28.00%)<br>12 | 0 / 19 (0.00%)<br>0  | 2 / 7 (28.57%)<br>3 |
| Thrombocytopenia<br>subjects affected / exposed<br>occurrences (all)        | 1 / 25 (4.00%)<br>1   | 0 / 19 (0.00%)<br>0  | 1 / 7 (14.29%)<br>1 |
| Ear and labyrinth disorders   |                       |                      |                     |
| Ear Pain<br>subjects affected / exposed<br>occurrences (all)                | 0 / 25 (0.00%)<br>0   | 1 / 19 (5.26%)<br>1  | 0 / 7 (0.00%)<br>0  |
| Eye disorders   |                       |                      |                     |
| Cataract<br>subjects affected / exposed<br>occurrences (all)                | 0 / 25 (0.00%)<br>0   | 0 / 19 (0.00%)<br>0  | 0 / 7 (0.00%)<br>0  |
| Conjunctival Hyperaemia<br>subjects affected / exposed<br>occurrences (all) | 0 / 25 (0.00%)<br>0   | 0 / 19 (0.00%)<br>0  | 0 / 7 (0.00%)<br>0  |
| Visual Impairment   |                       |                      |                     |

|                             |                |                 |                |
|-----------------------------|----------------|-----------------|----------------|
| subjects affected / exposed | 0 / 25 (0.00%) | 0 / 19 (0.00%)  | 0 / 7 (0.00%)  |
| occurrences (all)           | 0              | 0               | 0              |
| Myopia                      |                |                 |                |
| subjects affected / exposed | 0 / 25 (0.00%) | 0 / 19 (0.00%)  | 1 / 7 (14.29%) |
| occurrences (all)           | 0              | 0               | 1              |
| Eye Pruritus                |                |                 |                |
| subjects affected / exposed | 0 / 25 (0.00%) | 1 / 19 (5.26%)  | 0 / 7 (0.00%)  |
| occurrences (all)           | 0              | 2               | 0              |
| Gastrointestinal disorders  |                |                 |                |
| Abdominal Discomfort        |                |                 |                |
| subjects affected / exposed | 0 / 25 (0.00%) | 0 / 19 (0.00%)  | 0 / 7 (0.00%)  |
| occurrences (all)           | 0              | 0               | 0              |
| Aphthous Ulcer              |                |                 |                |
| subjects affected / exposed | 0 / 25 (0.00%) | 1 / 19 (5.26%)  | 0 / 7 (0.00%)  |
| occurrences (all)           | 0              | 1               | 0              |
| Abdominal Pain Upper        |                |                 |                |
| subjects affected / exposed | 0 / 25 (0.00%) | 2 / 19 (10.53%) | 0 / 7 (0.00%)  |
| occurrences (all)           | 0              | 2               | 0              |
| Abdominal Pain Lower        |                |                 |                |
| subjects affected / exposed | 0 / 25 (0.00%) | 0 / 19 (0.00%)  | 0 / 7 (0.00%)  |
| occurrences (all)           | 0              | 0               | 0              |
| Abdominal Pain              |                |                 |                |
| subjects affected / exposed | 1 / 25 (4.00%) | 2 / 19 (10.53%) | 0 / 7 (0.00%)  |
| occurrences (all)           | 1              | 2               | 0              |
| Abdominal Distension        |                |                 |                |
| subjects affected / exposed | 0 / 25 (0.00%) | 1 / 19 (5.26%)  | 0 / 7 (0.00%)  |
| occurrences (all)           | 0              | 2               | 0              |
| Constipation                |                |                 |                |
| subjects affected / exposed | 0 / 25 (0.00%) | 1 / 19 (5.26%)  | 0 / 7 (0.00%)  |
| occurrences (all)           | 0              | 1               | 0              |
| Dental Caries               |                |                 |                |
| subjects affected / exposed | 1 / 25 (4.00%) | 0 / 19 (0.00%)  | 0 / 7 (0.00%)  |
| occurrences (all)           | 1              | 0               | 0              |
| Haemorrhoids                |                |                 |                |
| subjects affected / exposed | 0 / 25 (0.00%) | 1 / 19 (5.26%)  | 0 / 7 (0.00%)  |
| occurrences (all)           | 0              | 1               | 0              |

|  |                     |                      |                    |
|--|---------------------|----------------------|--------------------|
| Gastrooesophageal Reflux Disease<br>subjects affected / exposed<br>occurrences (all)                 | 0 / 25 (0.00%)<br>0 | 2 / 19 (10.53%)<br>2 | 0 / 7 (0.00%)<br>0 |
| Food Poisoning<br>subjects affected / exposed<br>occurrences (all)                                   | 0 / 25 (0.00%)<br>0 | 0 / 19 (0.00%)<br>0  | 0 / 7 (0.00%)<br>0 |
| Dyspepsia<br>subjects affected / exposed<br>occurrences (all)  | 0 / 25 (0.00%)<br>0 | 0 / 19 (0.00%)<br>0  | 0 / 7 (0.00%)<br>0 |
| Diarrhoea<br>subjects affected / exposed<br>occurrences (all)  | 2 / 25 (8.00%)<br>2 | 1 / 19 (5.26%)<br>1  | 0 / 7 (0.00%)<br>0 |
| Large Intestine Polyp<br>subjects affected / exposed<br>occurrences (all)                            | 0 / 25 (0.00%)<br>0 | 1 / 19 (5.26%)<br>1  | 0 / 7 (0.00%)<br>0 |
| Nausea<br>subjects affected / exposed<br>occurrences (all)   | 0 / 25 (0.00%)<br>0 | 2 / 19 (10.53%)<br>2 | 0 / 7 (0.00%)<br>0 |
| Mouth Ulceration<br>subjects affected / exposed<br>occurrences (all)                                 | 0 / 25 (0.00%)<br>0 | 0 / 19 (0.00%)<br>0  | 0 / 7 (0.00%)<br>0 |
| Rectal Haemorrhage<br>subjects affected / exposed<br>occurrences (all)                               | 0 / 25 (0.00%)<br>0 | 1 / 19 (5.26%)<br>1  | 0 / 7 (0.00%)<br>0 |
| Vomiting<br>subjects affected / exposed<br>occurrences (all)   | 0 / 25 (0.00%)<br>0 | 1 / 19 (5.26%)<br>1  | 0 / 7 (0.00%)<br>0 |
| Toothache<br>subjects affected / exposed<br>occurrences (all)  | 0 / 25 (0.00%)<br>0 | 1 / 19 (5.26%)<br>1  | 0 / 7 (0.00%)<br>0 |
| Skin and subcutaneous tissue disorders<br>Eczema<br>subjects affected / exposed<br>occurrences (all) | 0 / 25 (0.00%)<br>0 | 1 / 19 (5.26%)<br>1  | 0 / 7 (0.00%)<br>0 |
| Rash Maculo-Papular  |                     |                      |                    |

|  |                      |                      |                     |
|--|----------------------|----------------------|---------------------|
| subjects affected / exposed<br>occurrences (all)   | 0 / 25 (0.00%)<br>0  | 0 / 19 (0.00%)<br>0  | 1 / 7 (14.29%)<br>1 |
| Skin Irritation<br>subjects affected / exposed<br>occurrences (all)  | 0 / 25 (0.00%)<br>0  | 1 / 19 (5.26%)<br>1  | 0 / 7 (0.00%)<br>0  |
| Alopecia<br>subjects affected / exposed<br>occurrences (all)   | 0 / 25 (0.00%)<br>0  | 0 / 19 (0.00%)<br>0  | 0 / 7 (0.00%)<br>0  |
| Skin Ulcer<br>subjects affected / exposed<br>occurrences (all)   | 0 / 25 (0.00%)<br>0  | 0 / 19 (0.00%)<br>0  | 0 / 7 (0.00%)<br>0  |
| Renal and urinary disorders<br>Dysuria<br>subjects affected / exposed<br>occurrences (all)                               | 0 / 25 (0.00%)<br>0  | 1 / 19 (5.26%)<br>1  | 0 / 7 (0.00%)<br>0  |
| Musculoskeletal and connective tissue disorders<br>Pain in Extremity<br>subjects affected / exposed<br>occurrences (all) | 0 / 25 (0.00%)<br>0  | 1 / 19 (5.26%)<br>1  | 2 / 7 (28.57%)<br>2 |
| Muscular Weakness<br>subjects affected / exposed<br>occurrences (all)  | 0 / 25 (0.00%)<br>0  | 0 / 19 (0.00%)<br>0  | 1 / 7 (14.29%)<br>1 |
| Muscle Spasms<br>subjects affected / exposed<br>occurrences (all)  | 0 / 25 (0.00%)<br>0  | 0 / 19 (0.00%)<br>0  | 0 / 7 (0.00%)<br>0  |
| Limb Mass<br>subjects affected / exposed<br>occurrences (all)  | 0 / 25 (0.00%)<br>0  | 0 / 19 (0.00%)<br>0  | 0 / 7 (0.00%)<br>0  |
| Back Pain<br>subjects affected / exposed<br>occurrences (all)  | 0 / 25 (0.00%)<br>0  | 2 / 19 (10.53%)<br>2 | 0 / 7 (0.00%)<br>0  |
| Arthralgia<br>subjects affected / exposed<br>occurrences (all)   | 1 / 25 (4.00%)<br>13 | 1 / 19 (5.26%)<br>1  | 0 / 7 (0.00%)<br>0  |
| Myalgia  |                      |                      |                     |

|  |                     |                     |                    |
|--|---------------------|---------------------|--------------------|
| subjects affected / exposed<br>occurrences (all) | 2 / 25 (8.00%)<br>3 | 1 / 19 (5.26%)<br>1 | 0 / 7 (0.00%)<br>0 |
| Infections and infestations                      |                     |                     |                    |
| Aspergilloma                                     |                     |                     |                    |
| subjects affected / exposed                      | 0 / 25 (0.00%)      | 1 / 19 (5.26%)      | 0 / 7 (0.00%)      |
| occurrences (all)                                | 0                   | 1                   | 0                  |
| Acarodermatitis                                  |                     |                     |                    |
| subjects affected / exposed                      | 0 / 25 (0.00%)      | 0 / 19 (0.00%)      | 0 / 7 (0.00%)      |
| occurrences (all)                                | 0                   | 0                   | 0                  |
| Lower Respiratory Tract Infection                |                     |                     |                    |
| subjects affected / exposed                      | 0 / 25 (0.00%)      | 0 / 19 (0.00%)      | 0 / 7 (0.00%)      |
| occurrences (all)                                | 0                   | 0                   | 0                  |
| Carbuncle  |                     |                     |                    |
| subjects affected / exposed                      | 0 / 25 (0.00%)      | 1 / 19 (5.26%)      | 0 / 7 (0.00%)      |
| occurrences (all)                                | 0                   | 1                   | 0                  |
| Conjunctivitis                                   |                     |                     |                    |
| subjects affected / exposed                      | 0 / 25 (0.00%)      | 1 / 19 (5.26%)      | 1 / 7 (14.29%)     |
| occurrences (all)                                | 0                   | 1                   | 1                  |
| Covid-19   |                     |                     |                    |
| subjects affected / exposed                      | 3 / 25 (12.00%)     | 4 / 19 (21.05%)     | 0 / 7 (0.00%)      |
| occurrences (all)                                | 3                   | 4                   | 0                  |
| Hepatitis B                                      |                     |                     |                    |
| subjects affected / exposed                      | 0 / 25 (0.00%)      | 0 / 19 (0.00%)      | 0 / 7 (0.00%)      |
| occurrences (all)                                | 0                   | 0                   | 0                  |
| Influenza  |                     |                     |                    |
| subjects affected / exposed                      | 0 / 25 (0.00%)      | 1 / 19 (5.26%)      | 0 / 7 (0.00%)      |
| occurrences (all)                                | 0                   | 1                   | 0                  |
| Lower Respiratory Tract Infection<br>Viral       |                     |                     |                    |
| subjects affected / exposed                      | 0 / 25 (0.00%)      | 1 / 19 (5.26%)      | 0 / 7 (0.00%)      |
| occurrences (all)                                | 0                   | 1                   | 0                  |
| Nasopharyngitis                                  |                     |                     |                    |
| subjects affected / exposed                      | 0 / 25 (0.00%)      | 0 / 19 (0.00%)      | 0 / 7 (0.00%)      |
| occurrences (all)                                | 0                   | 0                   | 0                  |
| Oral Herpes                                      |                     |                     |                    |



|                                    |                |                 |                |
|------------------------------------|----------------|-----------------|----------------|
| subjects affected / exposed        | 0 / 25 (0.00%) | 1 / 19 (5.26%)  | 0 / 7 (0.00%)  |
| occurrences (all)                  | 0              | 1               | 0              |
| Paronychia                         |                |                 |                |
| subjects affected / exposed        | 0 / 25 (0.00%) | 0 / 19 (0.00%)  | 0 / 7 (0.00%)  |
| occurrences (all)                  | 0              | 0               | 0              |
| Periodontitis                      |                |                 |                |
| subjects affected / exposed        | 0 / 25 (0.00%) | 0 / 19 (0.00%)  | 0 / 7 (0.00%)  |
| occurrences (all)                  | 0              | 0               | 0              |
| Respiratory Tract Infection        |                |                 |                |
| subjects affected / exposed        | 0 / 25 (0.00%) | 0 / 19 (0.00%)  | 0 / 7 (0.00%)  |
| occurrences (all)                  | 0              | 0               | 0              |
| Urinary Tract Infection            |                |                 |                |
| subjects affected / exposed        | 0 / 25 (0.00%) | 1 / 19 (5.26%)  | 0 / 7 (0.00%)  |
| occurrences (all)                  | 0              | 1               | 0              |
| Viral Infection                    |                |                 |                |
| subjects affected / exposed        | 0 / 25 (0.00%) | 0 / 19 (0.00%)  | 0 / 7 (0.00%)  |
| occurrences (all)                  | 0              | 0               | 0              |
| Respiratory Tract Infection Viral  |                |                 |                |
| subjects affected / exposed        | 0 / 25 (0.00%) | 0 / 19 (0.00%)  | 0 / 7 (0.00%)  |
| occurrences (all)                  | 0              | 0               | 0              |
| Upper Respiratory Tract Infection  |                |                 |                |
| subjects affected / exposed        | 0 / 25 (0.00%) | 2 / 19 (10.53%) | 0 / 7 (0.00%)  |
| occurrences (all)                  | 0              | 3               | 0              |
| Sinusitis                          |                |                 |                |
| subjects affected / exposed        | 0 / 25 (0.00%) | 0 / 19 (0.00%)  | 0 / 7 (0.00%)  |
| occurrences (all)                  | 0              | 0               | 0              |
| Rhinitis                           |                |                 |                |
| subjects affected / exposed        | 0 / 25 (0.00%) | 1 / 19 (5.26%)  | 1 / 7 (14.29%) |
| occurrences (all)                  | 0              | 1               | 1              |
| Metabolism and nutrition disorders |                |                 |                |
| Decreased Appetite                 |                |                 |                |
| subjects affected / exposed        | 1 / 25 (4.00%) | 0 / 19 (0.00%)  | 0 / 7 (0.00%)  |
| occurrences (all)                  | 1              | 0               | 0              |
| Iron Deficiency                    |                |                 |                |
| subjects affected / exposed        | 0 / 25 (0.00%) | 0 / 19 (0.00%)  | 0 / 7 (0.00%)  |
| occurrences (all)                  | 0              | 0               | 0              |

|  |                     |                     |                    |
|--|---------------------|---------------------|--------------------|
| Vitamin B12 Deficiency<br>subjects affected / exposed<br>occurrences (all) | 0 / 25 (0.00%)<br>0 | 0 / 19 (0.00%)<br>0 | 0 / 7 (0.00%)<br>0 |
|--|---------------------|---------------------|--------------------|

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date              | Amendment  |
|-------------------|--|
| 30 July 2021      | Amendment 5: The purpose for this amendment was a change in study treatment regimens, based on the availability of preliminary 48-week treatment data from the Phase 2b study REEF-1 (73763989HPB2001), and new data presented during the European Association for the Study of the Liver (EASL) conference of 2021 showing that HBsAg declines with siRNA treatment can be increased when combined with PegIFN. |
| 30 September 2021 | Amendment 6: The purpose for this amendment was to remove JNJ-6379 as study intervention, to add a new nucleos(t)ide analog (NA) re-treatment criterion for subjects who discontinued NA treatment during follow-up, and to include more frequent monitoring for subjects who discontinued NA treatment during follow-up.  |
| 25 November 2021  | Amendment 7: The purpose of amendment was to update the criteria for post-treatment monitoring and for nucleos(t)ide analog (NA) re-treatment for participants who discontinued NA treatment during follow-up.   |

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported